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ABSTRACT 
 
The overall objective of this PhD project was to develop and validate methods for advancing the 
applications of two techniques, next-generation sequencing (NGS) and motif grafting, in 
synthetic antibody discovery. In the first part of this project, we developed an NGS-assisted 
antibody discovery platform by integrating phage-displayed single-framework synthetic antigen-
binding fragment (Fab) libraries with Ion Torrent sequencing. We constructed a new single-
framework synthetic Fab library containing 8.5 billion unique Fab clones, and validated its 
functionality by generating high affinity Fabs against Notch and Jagged receptors. We developed 
a rapid and simple method to link and sequence all diversified complementarity-determining 
regions (CDRs) in phage Fab pools without losing the CDR pairing information. We identified 
and reconstructed low-frequency rare Fab clones from NGS information in a reliable and high-
throughput manner. In some cases, reconstructed rare clones (frequency ~0.1%) showed higher 
affinity and better specificity than high-frequency top clones isolated by Sanger sequencing, 
highlighting the importance of NGS in synthetic antibody discovery. In the second part of this 
project, we employed motif grafting to semi-rationally design phage-displayed synthetic Fab 
libraries that are biased towards interacting with a specific site on a receptor. We used structural 
information on the epidermal growth factor receptor (EGFR) homo-dimerization interaction to 
design a structure-guided Fab library that was biased towards interacting with domain II of 
EGFR. We used this structure-guided Fab library to obtain Fabs against the EGFR extracellular 
domain. For comparison, we used a naïve synthetic Fab library to generate an anti-EGFR Fab 
whose binding overlapped with the Fab isolated from the structure-guided Fab library. Both Fabs 
possessed low-nM binding values for recombinant and cell-surface EGFR and inhibited EGF-
mediated EGFR activation. Epitope mapping showed that domain II is partially responsible for 
the interaction of Fabs with EGFR. Further, both Fabs target unique epitopes that are different 
from previously validated epitopes on EGFR. In total, this PhD project resulted in novel methods 
for discovering synthetic antibodies using NGS and motif grafting techniques, three functional 
Fab libraries and numerous high-affinity Fabs against Notch, Jagged and EGF receptors. 
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1. INTRODUCTION 
The biologics market encompasses a large variety of products including recombinant 
proteins, vaccines, blood products, gene and cellular therapies, etc. Monoclonal antibodies 
represent the most important class of protein therapeutics in the biologics market (Frenzel et al., 
2016). Global sales revenue of antibody-based products such as monoclonal antibodies, antibody 
fragments, Fc-fusion proteins and antibody-drug conjugates was estimated to be $75 billion in 
2013, accounting for ~50% of the total sales of all biologics. The global market for antibody-
based products is valued at $94 billion in 2017 and is expected to reach nearly $125 billion by 
2020 (Ecker et al., 2015).  
The clinical development of monoclonal antibodies started in the early 1980s, and the 
first therapeutic monoclonal antibody, Muromonab-OKT3, was approved in 1986 (Emmons and 
Hunsicker, 1987; Ecker et al., 2015). As of March 2017, 63 antibody-based products have been 
approved by the Food and Drug Administration (FDA) or European Medicines Agency (EMA) 
(www.antibodysociety.org). Six therapeutic monoclonal antibodies were granted first marketing 
approvals in 2016 by FDA or EMA. As of December 2016, over 230 antibody-based products 
are in phase II clinical studies, 52 antibody-based products are in phase III clinical studies for 
cancer (20 products) or non-cancer indications (32 products), and 9 antibody-based products (8 
monoclonal antibodies and 1 antibody-drug conjugate) are under regulatory review by FDA or 
EMA (Reichert, 2017).  
Antibody-based molecules have evolved to become a highly-established class of 
therapeutics, fueled by progress in target discovery and validation, advances in antibody 
isolation, engineering and production, and successes in clinical development and 
commercialization (Scott et al., 2012; Freise and Wu, 2015). Also, antibody-based molecules 
possess favorable biochemical, biophysical, biological, pharmacological and clinical properties 
for drug development, and have a higher probability of success in acquiring regulatory approval 
than other drug formats (Aggarwal, 2009; Nelson et al., 2010; Chan and Carter, 2010; Scott et 
al., 2012). While the hybridoma technology laid the foundation for modern day antibody 
therapeutics, the emergence of phage and other display technologies revolutionized the discovery 
and optimization of antibody-based molecules. A detailed knowledge on structural, functional 
and pharmacological properties of antibodies allowed researchers to rationally re-engineer lead 
antibodies for improved stability, potency and safety. The adoption of efficient platform-based
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Table 1.1: Therapeutic antibodies approved in 2016/2017 or in review by EMA or FDA 
	
Table compiled from Reichert, 2017; and www.antibodysociety.org 
 
Table 1.1: Therapeutic antibodies approved in 2016/2017 or in review by EMA or FDA 
Name Target Format Indication EU Status  US Status  
Atezolizumab PD-L1 Humanized 
IgG1 
Bladder cancer Review 2016 
Olaratumab PDGFR! Human IgG1 Soft tissue sarcoma 2016 2016 
Reslizumab IL-5 Humanized 
IgG4 
Asthma 2016 2016 
Ixekizumab IL-17a Humanized 
IgG4 
Psoriasis 2016 2016 
Bezlotoxumab C. difficile 
enterotoxin B 
Human IgG1 Prevention of C. 
difficile infection  
2017 2016 
Obiltoxaximab B. anthracis 
exotoxin 
Chimeric 
IgG1 
Prevention of 
inhalational anthrax 
NA 2016 
Ocrelizumab CD20 Humanized 
IgG1 
Multiple sclerosis Review 2017 
Avelumab PD-L1 Human IgG1 Merkel cell 
carcinoma 
Review 2017 
Dupilumab IL-4R! Human IgG4 Atopic dermatitis Review! 2017 
Brodalumab IL-17R Human IgG2 Psoriasis Review! 2017 
Xilonix IL-1! Human IgG1 Advanced colorectal 
cancer 
Review! NA 
Inotuzumab 
ozogamicin 
CD22 Humanized 
IgG4 ADC 
Hematological 
malignancy 
Review! NA 
Sirukumab IL-6 Human IgG1 Rheumatoid arthritis Review! Review!
Sarilumab IL-6R Human IgG1 Rheumatoid arthritis Review! Review!
Guselkumab IL-23  Human IgG1 Plaque psoriasis Review! Review!
Romosozumab Sclerostin Humanized 
IgG2 
Osteoporosis (post-
menopause)  
NA Review!
Durvalumab PD-L1 Human IgG1 Bladder cancer NA Review!
Burosumab FGF23 Human IgG1 X-linked 
hypophosphatemia 
Review NA 
Benralizumab IL-5R! Humanized 
IgG1 
Asthma Review NA 
Tildrakizumab IL-23  Humanized 
IgG1 
Plaque psoriasis Review NA 
Caplacizumab Von- 
Willebrand 
factor 
Humanized 
nanobody 
Acquired thrombotic 
thrombocytopenic 
purpura 
Review NA 
 
 
Table compiled from Reic ; and www.antibodysociety.org 
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approaches in antibody bioprocessing and generation of highly productive cell lines for antibody 
expression enabled large-scale production of antibodies, increased purification yields and 
decreased cost of goods (Nelson et al., 2010; Dübel and Reichert, 2014). 
The continued growth and interest in the development of antibody-based products is also 
fueled by the modularity and versatility of antibodies. Their modular nature resulted in small-
sized antibody fragments for developing diagnostic-imaging products, bi-specific antibodies for 
developing T-cell redirecting therapeutics, and artificial immune-receptors for developing 
chimeric antigen receptor (CAR) T-cell therapies. The ability to attach various cytotoxic 
moieties to the antibody framework led to the development of next-generation antibody 
therapeutics such as antibody-drug conjugates (ADC), antibody-radionuclide conjugates and 
antibody-cytokine fusions (Chames et al., 2009; Weiner, 2015). 
The successful development of therapeutic monoclonal antibodies starts with the 
generation of lead antibodies using hybridoma, transgenic mice or display technologies. Next, 
lead antibodies are optimized in terms of affinity, specificity, action mechanisms, 
immunogenicity, effector function, and serum half-life. Antibodies exhibiting desired 
biochemical and biological properties are then assessed and improved in terms of stability, 
homogeneity, formulation interactions, pharmacokinetics, safety and efficacy. Antibodies 
exhibiting favorable production and pharmacological characteristics successfully enter advanced 
preclinical studies (Shih, 2012; Chiu and Gilliland, 2016). In this PhD project, we describe novel 
strategies for obtaining lead antibodies from synthetic antibody libraries using the phage display 
technology. We also describe the generation, isolation, optimization and characterization of 
synthetic antibody leads against Notch, Jagged and EGF receptors. 
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2. LITERATURE REVIEW 
2.1 Introduction to Antibodies 
2.1.1 Components of the Human Immune System 
The immune system of vertebrates has evolved a complex network of proteins, 
specialized cells, tissues and organs to protect us from pathogens. The two main functions of the 
immune system are antigen recognition and eradication of the source of antigen. The immune 
system is classified into two main areas: the innate immune system and the adaptive immune 
system. The innate immune system acts as a first line of defense against pathogens and allows a 
rapid response to invasion. It has three main components: (1) anatomical barriers including 
physical (skin and hair), chemical (body fluids) and biological (probiotics) barriers; (2) cell-
mediated immunity conferred by leukocytes; and (3) humoral immunity conferred by 
complement proteins. Leukocytes consist of many cell types including macrophages, neutrophils, 
eosinophils, basophils, dendritic cells, natural killer cells, mast cells and platelets. Each cell type 
is specialized to respond, recognize, kill, recruit and activate a certain set of cells. The 
complement system is a group of about 20 serum proteins that can fulfill a range of immune 
effector functions (Male et al., 2006; Delves et al., 2017).  
Often, innate immunity is not sufficient for clearing pathogens, and the adaptive immune 
system is brought into action. In contrast to the innate immune system that senses common 
molecular patterns in pathogens, the adaptive immune system employs a very large repertoire of 
genetically programmable recognition proteins for sensing antigens. The use of tunable antigen 
receptors provides three key advantages: flexibility, specificity and immunological memory. The 
adaptive immune response is mediated by lymphocytes, which includes T cells and B cells. T 
cells develop in the thymus and comprise the cell-mediated arm of the adaptive immune system. 
There are three types of T cells: cytolytic T cells, helper T cells and regulatory T cells. T cell 
responses require processing and proper presentation of the antigen by major histocompatibility 
complexes (MHCs) on the surface of antigen-presenting cells (APCs). B cells develop in the 
bone marrow and comprise the humoral arm of the adaptive immune system. B cells recognize 
and bind antigens present in serum, tissue fluids or on cell membranes. Upon antigen recognition 
and activation, B cells differentiate into plasma cells, which secrete large amounts of soluble 
glycoproteins known as antibodies. Cytolytic T cells and antibodies use different mechanisms to 
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eliminate pathogens. The innate and adaptive arms of the immune system interact and correlate 
with each other using APCs (macrophages, dendritic cells and B cells) (Male et al., 2006; Delves 
et al., 2017).  
2.1.2 Structure and Function of Antibodies 
Antibodies, also known as immunoglobulins are glycoproteins that belong to the 
immunoglobulin superfamily. They constitute most of the gamma globulin component of blood 
proteins. They are expressed as cell-surface receptors on B cells or as soluble proteins present in 
serum and tissue fluids. The basic structural unit of an immunoglobulin consists of two identical 
heavy chains (~50 kDa each) and two identical light chains (~25 kDa each), which are held 
together by disulfide bridges and non-covalent interactions. There are five different heavy chains 
(γ, α, µ, δ, є) and two different light chains (κ, λ). The type of the heavy chain determines the 
class of the antibody. The five distinct classes of immunoglobulin molecules are IgG, IgA, IgM, 
IgD and IgE. The IgG class is subdivided into four subclasses (IgG1, IgG2, IgG3 and IgG4), and 
the IgA class is subdivided into two subclasses (IgA1 and IgA2). In total, nine different antibody 
isotypes are present in all normal individuals (Male et al., 2006; Delves et al., 2017).  
IgG accounts for 70-75% of the total serum immunoglobulin pool, and provides the 
majority of antibody-based immunity against invading pathogens. It is the only antibody class 
capable of crossing the placenta and give passive immunity to the fetus. IgA accounts for 15-
20% of the total serum immunoglobulin pool. It is predominantly found in mucosal areas, saliva, 
tears and breast milk, and prevents colonization by pathogens. IgM accounts for 10% of the total 
serum immunoglobulin pool, and helps to eliminate pathogens in the early stages of antibody-
based immunity (before there is sufficient IgG secretion). IgM is also expressed as cell-surface 
receptors on B-cells. IgD accounts for less than 1% of the total serum immunoglobulin pool, and 
functions mainly as a cell-surface antigen receptor on naïve B cells. IgE levels are very low in 
the serum (< 0.05 µg/mL), and it protects against allergens by activating basophils and mast cells 
(Male et al., 2006; Delves et al., 2017). 
The overall structure of an antibody depends on its class and subclass; nevertheless, there 
are many common structural features among antibodies. Both light and heavy chains are folded 
into discrete immunoglobulin domains (~100 amino acids each). These domains have a 
characteristic immunoglobulin fold in which two beta sheets create a sandwich shape, which are 
held together by conserved disulfide bridges and non-covalent interactions. The N-terminal 
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Figure 2.1: Crystal structure of Immunoglobulin G (IgG). (A) IgG molecule is a hetero-
tetramer of two light chains (magenta) and two heavy chains (blue). The light chain consists of a 
variable light domain (VL) and a constant light domain (CL) whereas the heavy chain consists of 
a variable heavy domain (VH) and three constant heavy domains (CH1, CH2 and CH3). The IgG 
molecule is held together by multiple disulfide bonds and non-covalent interactions. (B) The 
antigen-binding site is contained within the non-glycosylated antigen-binding fragment (Fab) 
heterodimer. The Fab includes the variable fragment (Fv), which consists of the variable 
domains of the light (VL) and heavy chain (VH) and can be produced as a single-chain variable 
fragment (scFv). Antigen recognition is primarily mediated by six hyper-variable loops or 
complementarity-determining regions (CDRs). Three light chain CDRs (L1, L2 and L3) are 
colored in green and three heavy chain CDRs (H1, H2 and H3) are colored in red. (C) The Fc 
portion is homo-dimeric and is glycosylated at the conserved Asn297 position located in CH2. 
The Fc segment is responsible for binding to Fc receptors (FcγR), neo-natal Fc receptors (FcRn), 
Complement protein (C1q) and Protein A/G. Cartoon representations of IgG, Fab and Fc 
molecules are derived from PDB entry 1IGT. 
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domains of light and heavy chains contain diverse stretches of amino acids known as 
hypervariable regions, therefore designated as variable domains. Sequences of other light and 
heavy chain domains are conserved within their own classes, therefore designated as constant 
domains. The light chain of antibodies contains two domains: one variable light domain (VL) 
followed by one constant light domain (CL). The heavy chain of IgG, IgA, IgD contains four 
successive domains: one variable heavy domain (VH) and three constant heavy domains (CH1, 
CH2 and CH3). The heavy chain of IgM and IgE contains an additional constant domain (CH4) at 
its C-terminus. The basic functional unit of each antibody is an immunoglobulin monomer (one 
Ig unit) composed of two light and two heavy chains. Secreted antibodies can also be dimeric 
with two Ig units as with IgA or pentameric with five Ig units as with IgM (Male et al., 2006; 
Delves et al., 2017).  
In the case of IgG, the molecule is ‘Y’ shaped, and both arms of the Y are flexible due to 
the presence of an unstructured hinge region between CH1 and CH2. Proteolysis of IgG at the 
hinge region gives rise to three functional fragments: two antigen-binding fragments (Fabs) and 
one crystallizable fragment (Fc). Each Fab is a heterodimer of a light chain (VL-CL) associated 
with the VH-CH1 domains of a heavy chain. The Fc segment is a homodimer of two CH2-CH3 
domains, and is glycosylated at the conserved Asn297 position located in CH2. The hypervariable 
regions, also known as complementarity-determining regions (CDRs), form the antigen-binding 
site in the Fab fragment. The VL domain contains three CDRs (CDRL1, CDRL2 and CDRL3) 
and the VH domain contains three CDRs (CDRH1, CDRH2 and CDRH3). The CDRs and 
selected framework residues on variable domains are responsible for interactions with antigens 
and dictate essential properties such as binding affinity and target specificity. The Fc region is 
responsible for connecting antigen-antibody binding to antibody effector functions. Two 
important antibody effector functions are antibody-mediated cellular cytotoxicity (ADCC) and 
complement-dependent cytotoxicity (CDC). ADCC is the lysis of antibody-coated target cells by 
immune effector cells such as NK cells, macrophages and neutrophils that express cell-surface 
Fc receptors. ADCC is initiated by the binding of the Fc region of antibodies on target cells to Fc 
receptors on immune effector cells. In CDC, the Fc region interacts with the serum C1q protein 
and initiates the complement system, which eventually leads to the lysis of antibody-coated 
target cells. The Fc-C1q interaction also labels the antibody-coated target cells for destruction by 
phagocytosis, a process known as opsonization (Male et al., 2006; Delves et al., 2017). 
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Figure 2.2: General mechanisms of action of therapeutic antibodies. (A) The Fab portion of 
antibodies can inhibit receptor activation by blocking the binding of an activating ligand to the 
target receptor and/or by inhibiting the dimerization of cell-surface receptors. Inhibition of 
receptor activation can cross-link receptors and induce apoptotic signaling. (B) The Fc portion of 
antibodies can mediate antibody-dependent cytotoxicity (ADCC) by binding to immune effector 
cells such as natural killer cells (NK cells), monocytes, granulocytes and neutrophils, which 
express Fc receptors (FcγR) and immune-receptor tyrosine-based activation motifs (ITAM). (C) 
The Fc portion of antibodies can mediate complement-dependent cytotoxicity (CDC) by binding 
to the complement-cascade activating protein C1q. Complement activation results in cell death 
through development of the membrane attack complex (MAC). Complement fixation also results 
in opsonization of target cells, which enhances phagocytosis by monocytes and granulocytes. 
Figure 2.2 reprinted with permission from Nature Publishing Group (Weiner, 2015).	
 
2.1.3 The B-Cell Response 
The variable domains of antibodies are formed by somatic recombination of a finite set of 
tandemly arranged variable (V), diversity (D) and joining (J) germline gene segments. This 
process, known as VDJ recombination, also results in the addition and deletion of nucleotides at 
the junctions between ligated germline segments. The VL domain is encoded by VL and JL genes, 
and the VH domain is encoded by VH, DH, and JH genes. The first two light and heavy chain 
CDRs are encoded by the V segment, while the third CDR is the product of V-J regions for 
CDRL3 and V-D-J regions for CDRH3. Following VDJ recombination, a fully assembled
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Figure 2.3: The B-cell response. Normal B cells are generated in the bone marrow and exist as 
IgD+ and IgM+ naïve B cells in peripheral blood. Naïve B cells undergo germinal center 
reaction after encountering a cognate antigen and receiving assistance from T-cells. The 
germinal center reaction occurs within lymph nodes and gives rise to multiple clonal families of 
B cells. The reaction consists of multiple steps: clonal expansion, affinity maturation, class 
switching and differentiation. Affinity maturation involves two processes: somatic 
hypermutation and clonal selection. B cells that survive the germinal center reaction ultimately 
differentiate into plasmablasts, plasma cells and memory B cells. Plasmablasts circulate in the 
blood, migrate to diseased-tissues and secondary lymphoid organs, and secrete antibodies. 
Plasma cells reside in the bone marrow and lamina propria, and secrete antibodies. Memory B 
cells circulate in the blood and differentiate directly into antibody-producing cells upon re-
exposure to their cognate antigen. Figure 2.3 reprinted with permission from Nature Publishing 
Group (Robinson, 2015).  
 
antibody heterodimer (IgD and/or IgM) is expressed on the surface of naïve B cells. When a 
naïve B cell encounters an antigen in the right environment (T-cell help and co-stimulatory 
signals), it goes through multiple stages of development to become an antigen-specific B cell that 
produce antibodies against the antigen. The overall process known as the germinal center 
reaction consists of the following steps: clonal expansion, affinity maturation, class switching 
and differentiation. Stimulation of cell-surface IgD and/or IgM molecules by the antigen leads to 
rapid proliferation of naïve B cells, a process known as clonal expansion. Affinity maturation 
involves two processes: somatic hypermutation and clonal selection. During somatic 
hypermutation, antibody variable regions, primarily CDRs, are mutated 1-2 times per cell 
division. During clonal selection, B cells compete for antigens and growth factors in the germinal 
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center, and B cells expressing high-affinity antibodies are only selected for further expansion and 
survival. Following multiple rounds of affinity maturation, B cells bearing high-affinity 
antibodies for the cognate antigen undergo class-switch recombination to express IgG, IgA or 
IgE isotypes. Class-switched B cells further respond to growth factors and other signals and 
differentiate into antibody-producing plasmablasts, plasma cells and memory B cells. 
Plasmablasts migrate to tissues involved in the disease process and secondary lymphoid organs, 
and secrete antibodies. Plasma cells reside primarily in the bone marrow and secrete antibodies. 
Memory B cells circulate in the blood and differentiate directly into antibody-producing cells 
upon re-exposure to their target antigen (reviewed by Victora and Nussenzweig, 2012; Gitlin et 
al., 2014; Georgiou et al., 2014; Robinson, 2015). 
2.2 Generation of Antibodies 
2.2.1 Hybridoma and Display Technologies 
Antibodies can be generated using hybridoma-based technologies and display 
technologies. Kohler and Milstein first described the classical hybridoma approach in 1975 and 
received a Nobel Prize for their discovery in 1984. This technology requires the fusion of 
immortal myeloma cells with antibody-producing B-lymphocytes from an immunized animal 
(Kohler and Milstein, 1975). The resulting hybrid cell acquires the capacity of indefinite growth 
from the myeloma tumor cell and the capacity to produce a specific antibody from the B-
lymphocyte cell. The hybridoma cell secreting the desired antibody is isolated from the 
population of fused hybrid cells, stabilized by repeated cell cloning, and used to produce fairly 
large quantities of identical antibody for years (Moldenhauer, 2014). The hybridoma technology 
revolutionized both basic and applied sciences by providing monoclonal antibodies that served as 
a key tool for researchers, as tracking and detection reagents in medical laboratories, and also as 
therapeutics in the hands of clinicians (Nelson et al., 2010). From a clinical standpoint, 
hybridoma antibodies are typically derived from murine sources, which bear the potential for 
triggering hypersensitivity reactions and anti-mouse antibodies in humans (Pendley et al., 2003; 
Schmidt et al., 2009). Strategies such as chimerization and humanization have been devised to 
reduce the immunogenicity of monoclonal antibodies (Almagro and Fransson, 2008), and 
transgenic mouse strains have been developed to produce human antibodies instead of mouse 
antibodies (Lonberg, 2008). However, bottlenecks in the immunization process, intense manual 
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liquid handling during generation and characterization of antibodies, and the lack of direct access 
to antibody genes have slowed down antibody development. Further, it is difficult to generate 
antibodies against unstable, toxic and highly conserved targets in animal systems (Sidhu, 2012). 
Fortunately, the advent of in vitro display technologies has enabled generation, 
identification and engineering of fully-human antibodies without the use of animals (Geyer et al., 
2012). Antibody display technologies can be roughly divided into cell-free (phage and ribosome 
display) and cell-based (yeast, bacterial and mammalian cell display) display technologies 
(Harel-Inbar and Benhar, 2012). Though several display systems are available, the basic 
principle behind these methods centers on the coupling of genotype (antibody genes) with 
phenotype (binding to proteins). The availability of numerous display platforms offers different 
ways to generate, manipulate and present antibodies to targets during binding selections (Geyer 
et al., 2012). Phage display is the most robust and well-established of these methods and has 
yielded numerous antibodies for research and clinical applications (Shim, 2016). In antibody 
engineering, phage display is primarily used to isolate antigen-specific antibody fragments from 
Fab or scFv libraries. In contrast to animal immunization, phage display offers precise control 
over selection conditions, for example, presentation of specific conformations of the target or 
addition of competitors to direct selections against epitopes of interest (Sidhu and Fellouse, 
2006; Bradbury et al., 2011). Further, the gene encoding the antibody is cloned simultaneously 
with selection, which provides many advantages for engineering and rapid characterization of 
selected antibodies such as improving the affinity and stability of antibodies, altering the 
specificity of antibodies and sub-cloning antibody genes into alternate expression platforms 
(Michnick and Sidhu, 2008; Geyer et al., 2012). Also, phage display is wholly amenable to 
integration with robotic liquid-handling devices and highly sophisticated equipment for antibody 
selection, production and characterization, which are essential for high-throughput generation of 
antibodies (Miersch and Sidhu, 2012). 
2.2.2 Phage Display of Antibody Fragments 
Although many viruses (including λ, T4 and T7) have been employed for phage display, 
most antibody phage display platforms use M13- E. coli phage-host system because of the 
following reasons: (1) the non-lytic nature of phage infection, (2) high viral titer capacity, (3) 
simultaneous presence of both single- and double-stranded forms of viral DNA, (4) little size 
constraint on inserted DNA and (5) assembly of display proteins in the bacterial periplasm 
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suitable for disulfide bond formation. M13 belongs to the Ff class of filamentous bacteriophages 
(genus Inovirus) that infects a wide variety of gram-negative bacteria. Ff viral particles are 
pencil-shaped; ~900 nm long and ~65 Å in diameter. The single-stranded genome is made up of 
~6400 bases that encodes a total of 11 phage proteins. Six proteins (pI, pII, pIV, pV, pX and 
pXI) are involved in phage DNA replication, phage assembly and secretion, and five proteins 
(pIII, pVI, pVII, pVIII and pIX) form the capsid that encloses the single-stranded phage DNA. 
The phage filament is comprised of ~2700 copies of the major coat protein pVIII, which is 
capped on both ends by ~5 copies of minor coat proteins (pIII and pVI on one end, and pVII and 
pIX on the other end). Filamentous phage infection is a multi-step process; recognition of the 
bacterial cell-surface receptor F-conjugative pilus by the phage pIII protein, followed by pilus 
retraction, binding of the pIII protein to the periplasmic TolA receptor, uncoating of viral DNA 
and its concomitant translocation into the host cell cytoplasm. Inside the host cell, single-
stranded DNA (ssDNA) is converted to a double-stranded replicative form by host polymerases, 
which then undergoes translation to enable synthesis of new viral proteins and rolling-circle 
replication to enable synthesis of progeny ssDNA. Nascent viral coat proteins exist as integral 
membrane proteins in the inner membrane of E. coli. One-hour post-infection, the pV protein 
pre-packages the new ssDNA for viral assembly, packaging and extrusion. Viral assembly and 
export occurs through a membrane pore without host cell lysis (reviewed by Rodi et al., 2005; 
Miersch and Sidhu, 2012; Rodi et al., 2015).  
In 1985, George Smith first demonstrated that functional polypeptides could be displayed 
on the surface of phage particles as fusions to the pIII protein (Smith, 1985). Shortly thereafter, 
several groups showed that Fab or scFv could also be displayed on phage particles and led the 
way for the development of phage-displayed antibody libraries (Huse et al., 1989; Barbas et al., 
1991; McCafferty et al., 1990; Clackson et al., 1991). Since then, phage display is constantly 
being applied to new experimental and practical problems, giving rise to many phage display 
reagents, methods and platforms. Here, we will restrict the discussion to the phage display 
system used is this project. We utilized a phagemid- helper phage system that has been optimized 
for the efficient construction and screening of Fab libraries displayed on M13 phage particles as 
fusions to a truncated pIII protein. Since integration of exogenous display proteins into the viral 
genome hampers phage infectivity, production and stability; historically, phage display platforms 
have utilized a phagemid- helper phage system (Miersch and Sidhu, 2012). The phagemid is a 
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Figure 2.4: M13 phage life cycle. M13 phage particles initiate contact with gram-negative 
bacteria expressing the F conjugative pilus using the pIII coat protein. The pIII protein that 
mediates the infection process is composed of three domains: N1 and N2 domains at the N-
terminus and the CT domain at the C-terminus. During infection, the N2 domain interacts with 
the F-pilus on the host bacterium. The F-pilus retracts and enables binding between the N1 
domain and the TolA receptor in the bacterial periplasm. Through additional interactions, pIII is 
inserted into the bacterial inner membrane, and the CT domain mediates the release of phage 
ssDNA into the bacterial cytoplasm. Phage ssDNA is converted into the dsDNA replicative form 
by bacterial polymerases. This dsDNA form is used for the synthesis of new phage proteins that 
translocate and reside in bacterial inner-membrane in preparation for viral assembly. The dsDNA 
also undergoes rolling circle amplification for the generation of new ssDNA. One-hour post-
infection, the pV protein pre-packages the new ssDNA for viral assembly, packaging and 
extrusion. Viral assembly and export occurs through a membrane pore without host cell lysis. 
Figure 2.4 reprinted with permission from Elsevier (Miersch and Sidhu, 2012).  
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double-stranded plasmid designed to express the exogenous display protein- coat protein fusion 
within the bacterial host. The phagemid used in this work (pHP153) contains a truncated form of 
gIII, an antibiotic resistance marker and double-stranded DNA origin of replication for phagemid 
propagation in E. coli, and an f1 origin of replication for synthesis and packaging of ssDNA (Lee 
et al., 2004A; Fellouse and Sidhu, 2006). The truncated gIII only expresses the C-terminal 
domain of pIII required for anchoring the coat protein into the viral capsid and for the assembly 
of phage particles. The two N-terminal domains (N1 and N2) required for host infection are not 
fused to the Fab protein. Since, the phagemid lacks wild-type pIII and other phage genes, 
functional phage production requires co-infection with helper phage M13KO7 that contains all 
phage genes (Miersch and Sidhu, 2012; Rajan and Sidhu, 2012). M13KO7 contains a point 
mutation (Met40Ile) in gII, which substantially decreases the replication of M13KO7 ssDNA and 
preferentially packages the phagemid DNA into phage particles (Russell et al., 2004).  
We chose to use Fab over other antibody formats because a higher proportion of Fabs in 
the library are stable, functionally folded, well displayed, easily expressed and purified and 
reliably converted into functional bivalent IgG molecules (Ponsel et al., 2011; Miersch and 
Sidhu, 2012; Shim, 2016). The pHP153 phagemid is a bicistronic vector that expresses light and 
heavy chains of Fabs as two open-reading frames under the control of an alkaline phosphatase 
promoter. Truncated gIII is fused to the C-terminus of the Fab heavy chain. The phagemid also 
contains leader sequences at the N-terminus of both chains to export the Fab light chain and the 
Fab heavy chain-truncated pIII fusion via the Secretory pathway. Disulfide bond-mediated 
folding of light and heavy chains occur in the oxidizing environment of the bacterial periplasm. 
Both chains associate non-covalently to form Fab molecules (Fellouse and Sidhu, 2006; Rajan 
and Sidhu, 2012). Following helper phage infection, synthesized phage coat proteins reside in the 
inner membrane of E. coli as integral membrane proteins. The pV protein pre-packages the 
phagemid ssDNA for phage assembly, packaging and extrusion. During phage assembly, if the 
Fab-truncated pIII fusion protein is incorporated into the viral capsid along with other coat 
proteins including wild-type pIII, the resulting phage particle displays Fabs on its surface in 
addition to encapsulating its phagemid ssDNA. If all five copies of pIII in the viral capsid 
contain the wild-type protein, the resulting phage particle does not display any Fabs. Around 
200-300 phage particles are produced per E. coli per doubling time (~1000 per hour) (Miersch 
and Sidhu, 2012; Shim, 2016). The phagemid also supports bivalent display of Fabs to resemble
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Figure 2.5: Phage display of Fabs in the bivalent format. (A) Schematic of the pHP153 
phagemid used for bivalent Fab display. A phosphatase-A (phoA) promoter drives the bicistronic 
expression of light and heavy chain fragments. The light chain contains the VL domain, the CL 
domain and a C-terminus FLAG tag. The heavy chain contains the VH domain, the CH1 domain, 
a dimerization domain and the truncated pIII protein. The N-terminus secretion signals direct the 
light and heavy chains to the bacterial periplasm where they associate to form Fabs. The 
phagemid contains origins of replication for single-stranded DNA (f1 ori) and double-stranded 
DNA (dsDNA ori), and a selection marker (Ampr) that confers resistance to carbenicillin. (B) 
Amino acid sequence of the anti-maltose-binding protein Fab heavy and light chain fragments 
encoded by the template phagemid. Signal sequences are underlined, Fab encoding sequences are 
in bold letters and the truncated PIII protein is in italics. Cysteines that form the inter-chain 
disulfide bond between the heavy and light chains are shown in solid boxes. The dimerization 
domain is shown in a dashed box. The cysteine within the dimerization domain is utilized for 
displaying Fabs in the bivalent format. (C) Schematic of monovalent (Fab) and bivalent (Fab2) 
display arrangements of Fabs on M13 phage particles. The disulfide bond between two heavy 
chain dimerization domains is shown for the bivalent display format. Figure 2.5 reprinted with 
permission from Springer (Adams et al., 2014).	
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the antigen-binding site of an IgG antibody. Bivalent Fab display is achieved by engineering a 
cysteine-containing peptide at the linker region that fuses the C-terminus of Fab CH1 with 
truncated pIII. Disulfide bond formation between two Fab heavy chain-truncated pIII fusion 
proteins joins two Fab molecules at the hinge region (Lee et al., 2004A; Adams et al., 2014). 
2.2.3 Phage-Displayed Antibody Libraries 
Recombinant antibody libraries used in phage display are classified into natural, synthetic 
and semi-synthetic libraries. The fundamental difference between these libraries lies in their 
source of diversity. Natural libraries are derived from donor-derived B-lymphocytes (biological 
diversity), whereas synthetic libraries are assembled from synthetic genes and oligonucleotides 
(chemical diversity). Semi-synthetic libraries incorporate diversity by combining material 
derived from both sources (Ponsel et al., 2011; Shim, 2016).  
Natural repertoires are classified into naïve and immune antibody libraries. They are 
generated using B-cells extracted from unimmunized animals, and animals immunized with an 
antigen of interest, respectively. To construct natural antibody libraries, antibody variable 
regions are amplified from B-cell cDNA by PCR and assembled into a phagemid vector 
(Hoogenboom, 2005). Naïve libraries usually contain a large diversity (up to 1011 members) and 
can be used to generate antibodies against a wide variety of antigens. Since immune libraries are 
generated from immunized donors, library members are predisposed for recognition of certain 
antigens, thus not suitable for the identification of antibodies against a large panel of antigens. 
Immune libraries therefore contain lower sequence diversity (107 members) than naïve libraries 
(Ponsel et al., 2011). Naïve antibody libraries have been used successfully to generate 
therapeutic antibodies such as Adalimumab, Ramucirumab, Belimumab, Raxibacumab and 
Necitumumab (Nixon et al., 2014; Frenzel et al., 2016). There are also a few limitations with 
using natural antibody repertoires. Since light and heavy chain genes are amplified from different 
chromosomal locations, their combinatorial assembly introduces random pairing of heavy and 
light chain variable regions. This results in the reduction of functional antibody diversity in the 
library, and leads to the isolation of antibodies with unusual VH-VL pairs and sub-optimal 
biophysical properties (Benhar, 2007; Finlay and Almagro, 2012). It is difficult to obtain 
antibodies against self-antigens from naïve libraries because such antibodies are often deleted by 
the immune system to prevent autoimmune disorders. The need for immunization restricts the 
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Table 2.1: Phage display-derived monoclonal antibodies approved for therapeutic applications 
or in phase III clinical studies 
	
Table compiled from Frenzel et al., 2016; Shim, 2016; and www.antibodysociety.org 
 
development of fully human immune libraries, and antibodies isolated from animal-derived 
immune libraries provoke immune responses in patients (Ackerman et al., 2011). 
Semi-synthetic libraries represent some of the earliest attempts to generate antibodies 
from libraries constructed using non-natural sources. They are part natural and part synthetic in a 
variety of formats. For example, semi-synthetic libraries can have natural VH and synthetic VL, 
natural frameworks and synthetic CDRs, and synthetic frameworks and natural CDRs 
(Hoogenboom, 2005; Shim, 2016). Synthetic libraries are constructed by in vitro diversification 
Table 2.1: Phage display-derived monoclonal antibodies approved for therapeutic applications 
or in phase III clinical studies 
Name Target Phage library, Format 
Final  
Format Indication Status 
Adalimumab TNF-! Semi-synthetic, 
scFv  
IgG1 Rheumatoid arthritis  
Crohn’s disease 
Psoriatic arthritis 
Plaque psoriasis  
Approved 
2002 
Belimumab B-LyS Naïve, scFv IgG1 Systemic lupus 
erythematosus 
Approved 
2011 
Raxibacumab B. anthrasis  
Antigen 
Naïve, scFv IgG1 Prophylaxis  
Anthrax prevention 
Approved 
2012 
Necitumumab EGFR Naïve, Fab IgG1 Non-small cell lung- 
cancer 
Approved 
2015 
Avelumab PD-L1 Naïve, Fab IgG1 Merkel cell carcinoma Approved 
2017 
Bimagrumab ACVR2B  Synthetic, Fab IgG1 Cachexia 
Sporadic inclusion body 
myocitis 
Phase III 
Briakinumab IL-12/23 Naïve, scFv IgG1 Psoriasis 
Multiple sclerosis 
Crohn’s disease 
Phase III 
Darleukin  Fibronectin Semi-synthetic, 
scFv 
ScFv-
IL2  
Melanoma Phase III 
Gantenerumab Amyloid " Synthetic, Fab IgG1 Alzheimer’s disease Phase III 
Ganitumab IGF1R Naïve, Fab IgG1 Pancreatic cancer Phase III 
Guselkumab IL-23  Synthetic, Fab IgG1 Plaque psoriasis Phase III 
Lanadelumab Kallikrein Naïve, Fab IgG1 Hereditary angioedema Phase III 
Tralokinumab IL-13 Naïve, scFv IgG4 Asthma 
Ulcerative colitis 
Phase III 
 
 
 
Table compiled from Frenzel et al., 2016; Shim, 2016; and www.antibodysociety.org 
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of CDRs within chosen antibody light and heavy chain variable domains. They were developed 
to carefully control the usage of antibody frameworks and the composition of CDR diversity 
(Shim, 2015). Also, chemical synthesis of antibody frameworks enables the incorporation of 
desirable features for subsequent display and characterization, and CDR diversities encoded by 
synthetic oligonucleotides are not limited to the scope of the natural immune system. The use of 
optimal antibody frameworks and tailored CDR diversity makes synthetic antibody libraries 
ideal for therapeutic antibody discovery (Harel-Inbar and Benhar, 2012; Adams and Sidhu, 
2014).  
Synthetic repertoires are classified into multiple- and single-framework synthetic 
antibody libraries (Ponsel et al., 2011). In multiple framework libraries, many antibody 
frameworks are chosen and used for library construction. For example, the HuCAL (Human 
combinatorial antibody library) series of synthetic libraries uses up to seven VH and seven VL 
genes resulting in 49 different VH-VL combinations that augment the antibody variable domain 
diversity. Since framework residues are known to influence CDR conformations, the presence of 
multiple frameworks also enables the engineering of CDRs with a wide variety of canonical 
conformations (Knappik et al., 2000; Rothe et al., 2007; Prassler et al., 2011; Tiller et al., 2013). 
Multiple framework libraries are advantageous in terms of antibody framework diversity and 
CDR conformational diversity, however construction of multiple-framework libraries is very 
expensive, time-consuming and typically undertaken in an industry environment (Shim, 2015).  
The observation that one or two frameworks are often overrepresented after selection from 
multiple-framework synthetic antibody libraries, together with the desire to increase the 
functional diversity of the synthetic antibody library by structure-inspired design led to the 
development of single-framework synthetic antibody libraries (Ponsel et al., 2011). Single-
framework libraries are constructed by targeted diversification of selected CDR residues of a 
single chosen antibody framework (Benhar, 2007). Single-framework libraries offer many 
advantages over multiple-framework libraries. First, libraries can be built on a single, clinically 
validated, human antibody framework that has optimal biophysical and pharmacokinetic 
properties. Second, CDR diversities can be designed based on known structures of the 
framework, which increases the number of stable and functional members in the antibody 
library. Third, design and construction of single-framework libraries are relatively easy and less 
expensive, and they provide valuable information on the fundamentals of antigen-antibody 
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interactions. Fourth, single framework libraries are well suited for high-throughput antibody 
generation pipelines, as the defined nature of the framework enables rapid sequence analysis and 
downstream characterization, and allows facile reformatting between different vector systems for 
affinity maturation and antibody expression (Miersch and Sidhu, 2012; Adams and Sidhu, 2014; 
Shim, 2015).  
Though synthetic antibody libraries offer many advantages, natural repertoires have been 
used extensively for phage display selections, as simple exploitation of natural repertoires is 
considered easier than constructing useful synthetic repertoires. Synthetic antibody libraries are 
built from scratch, and therefore this technology requires detailed and extensive knowledge of 
antibody structure and function and antigen recognition by antibodies. In addition, there is a need 
for highly sophisticated equipment to design and implement the synthetic antibody technology 
(Fellouse and Sidhu, 2005; Fellouse and Sidhu, 2015). Despite these issues, there has been a 
significant progress in the field of synthetic antibody engineering. Many synthetic antibody 
libraries have been constructed and used successfully in antibody discovery programs, and a few 
synthetic antibodies including Bimagrumab, Gantenerumab, Guselkumab and Avelumab have 
entered phase III clinical trials (Nixon et al., 2014; Frenzel et al., 2016). 
The Sidhu lab at the University of Toronto has made major contributions towards the 
development of single-framework synthetic antibody libraries. His group optimized phage 
vectors and antibody frameworks to ensure libraries are well displayed as functional proteins on 
phage surfaces (Sidhu et al., 2000A; Fuh and Sidhu, 2000; Roth et al., 2002; Held and Sidhu, 
2004; Sidhu et al., 2007; Barthelemy et al., 2008). They also developed robust methods for 
construction, screening and characterization of phage-displayed Fab libraries that contain >1010 
members (Sidhu et al, 2000B; Vajdos et al., 2002; Sidhu and Weiss, 2003; Fellouse and Sidhu, 
2006; Pal et al., 2006). Phage-displayed libraries constructed by his group have been used to 
develop antibodies against numerous proteins, providing valuable reagents and potential 
therapeutics (Sidhu et al., 2004; Lee et al., 2004B; Fellouse et al., 2007; Persson et al., 2013; Ma 
et al., 2013). In many cases, they conducted detailed structural and functional studies of 
engineered antibodies to understand the molecular basis for antigen recognition and they used 
this knowledge to further improve antibody function (Fellouse et al., 2006; Sidhu and Koide, 
2007; Birtalan et al., 2008; Fisher et al., 2010;	 Reshetnyak et al., 2013). In addition to providing 
reliable methods, libraries and antibodies, these studies resulted in the accumulation of a large
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Table 2.2: Representative examples of phage-displayed antibody libraries 
 
 
Table 2.2: Representative examples of phage-displayed antibody libraries 
Library name Type, Format Note Lib. size Reference 
CAT-BMV Naïve, scFv Derived from bone 
marrow, PBL and tonsils 
1.4 # 1010 Vaughan et al., 
1996 
CAT-DP47 Naïve, scFv Derived from spleens  1 # 1010 Groves et al., 
2006 
CAT-CS Naïve, scFv Derived from spleen and 
fetal liver 
1.2 # 1011 Lloyd et al., 
2009 
HAL9/10 Naïve, scFv Derived from PBL 1.5 # 1010 Kugler et al., 
2015 
Anti-HIV gp120 Immune, Fab Derived from HIV-
positive patients 
1 # 107 Burton et al., 
1991 
Anti-
acetylcholine 
receptor 
Immune, Fab Derived from 
Myasthenia Gravis 
patients 
1.1 # 106 Graus et al., 
1997 
Anti-HER2 Immune, Fab Derived from colorectal 
cancer patients 
2 # 107 Clark et al., 
1997 
Anti-Ebola virus Immune, Fab Derived from Ebola-
positive patients 
6 # 106 Maruyama et 
al., 1999 
n-CoDeR Semi-synthetic, 
scFv 
Natural CDRs on a 
synthetic framework 
2 # 109 Söderlind et 
al., 2000 
Dyax Semi-synthetic, 
Fab 
Synthetic VH, natural 
CDRH3 and VL 
3.5 # 1010 Hoet et al., 
2005 
HuCAL Synthetic, scFv Multiple frameworks 
TRIM CDR  
2.1 # 109 Knappik et al., 
2000 
HuCAL Gold Synthetic, Fab Multiple frameworks 
TRIM CDR  
1.6 # 1010 Rothe et al., 
2008 
HuCAL 
Platinum 
Synthetic, Fab Multiple frameworks 
TRIM CDR 
4.5 # 1010 Prassler et al., 
2011 
Ylanthia Synthetic, Fab Multiple frameworks 
Slonomics CDR  
1.3 # 1011 Tiller et al., 
2013 
Rajpal lab Synthetic, Fab Multiple frameworks 
Slonomics CDR  
3.6 # 1010 Zhai et al., 
2011 
Library-D Synthetic, Fab Single framework 
Tailored and TRIM CDR 
3 # 1010 Fellouse et al., 
2007 
Library-F Synthetic, Fab Single framework 
Tailored and TRIM CDR 
3 # 1010 Persson et al., 
2013 
Shim lab Synthetic, scFv Single framework 
CDR by array synthesis 
8 # 108 Bai et al., 2015 
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knowledge base relating to antibody structure and function, which can be readily applied to the 
development of improved synthetic antibody libraries. 
2.2.4 Design, Construction and Screening of Synthetic Antibody Libraries 
Synthetic antibody libraries differ in terms of size, framework and CDR composition, and 
method of preparation. The size of an antibody library is commonly described using three terms; 
theoretical, practical and functional diversity. The theoretical diversity is the number of 
combinatorial possibilities encoded by the oligonucleotides used for randomization. The 
practical diversity is the maximum size of the library that can be achieved by the display 
technology. In phage display, the practical diversity is 1010 clones due to limitations in the 
transformation efficiency of E. coli used for library construction. The functional diversity is the 
number of antibody clones that are folded and displayed properly and are capable of binding. In 
a typical antibody library, the theoretical diversity is higher than the practical diversity, and the 
functional diversity is lower than the practical diversity. Synthetic antibody libraries are designed 
and constructed to display sufficient functional diversity for generating antibodies with favorable 
biophysical properties against a broad range of antigens (Reviewed by Ponsel et al., 2011; 
Miersch and Sidhu, 2012). 
Phage-displayed antibody libraries with 1010 members can completely cover the sequence 
space of only six sites randomized with twenty amino acids. With an optimal length for CDRL3 
and CDRH3 loops, the antibody framework that we have chosen contains 63 sites for 
randomization in its six CDRs. Consequently, it is impossible to generate a phage display library 
that fully covers the combinatorial diversity of these sites (~1082). Therefore, while designing 
synthetic antibody libraries, one has to limit the number of CDR positions or the number of 
amino acid types used at a given position without compromising the binding function of 
antibodies (Sidhu and Kossiakoff, 2007; Miersch and Sidhu, 2012). Analysis of antibody 
sequences and structures has revealed the CDR positions and amino acid types that have greater 
effects in antigen binding. The CDRs do not play equal roles in antigen binding, and there is a 
distinct hierarchy among the CDRs in this regard. Heavy chain CDRs dominate over their light 
chain counterparts, and among the heavy chain CDRs, CDRH3 plays the major role in 
determining antibody specificity and affinity (Zemlin et al., 2003; Birtalan et al., 2008; 
Burkovitz and Ofran, 2016). Within CDRs, anchor residues are critical for maintaining the 
canonical conformations of CDR loops, and solvent exposed residues are critical for mediating 
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interactions with the antigen (Chothia et al., 1992). Once the desired CDRs and CDR positions 
are identified, the sequence diversity for each CDR position has to be precisely defined. 
Fortunately, in human antibodies >90% of the sequence diversity for any one CDR position can 
be accounted for in most cases by approximately five to six amino acids (Kabat et al., 1991; 
Ramaraj et al., 2012).  
The Sidhu lab made a major breakthrough in balancing requirements for CDR residue 
coverage with sequence diversity. A series of antibody libraries based on “reduced genetic 
codes”, which employ only a fraction of the natural amino acid types, were constructed and 
screened by phage display to produce high-affinity Fab and scFv molecules (Fellouse et al., 
2004; Sidhu and Kossiakoff, 2007; Gilbreth et al., 2008; Koide and Sidhu, 2009). In the simplest 
case, a binary code of only two amino acids (tyrosine and serine) has been used to construct 
minimalist synthetic antibody libraries that have been used to raise specific Fabs against many 
proteins (Fellouse et al., 2005). Recently, a single-framework synthetic Fab library known as 
library-F was designed and generated in the Sidhu lab, and was used to isolate high-affinity Fabs 
against different classes of antigens. The library diversity was restricted to solvent-exposed 
residues within three heavy chain CDRs and CDRL3. Binary amino acid diversity was added to 
positions within CDRs H1 and H2. Within CDRs L3 and H3, the chemical diversity was 
generated using nine amino acids at each position, which was biased in favor of tyrosine (25%), 
serine (20%) and glycine (20%). Further, length diversity was incorporated into the library by 
allowing different loop lengths for CDRs L3 and H3 (Persson et al., 2013; Hornsby et al., 2015). 
A detailed description of library-F design is included in Section 5.1.2. The commercial 
availability of high-quality synthetic genes and oligonucleotides has played a crucial role in the 
construction of synthetic antibody libraries. In particular, the development of trinucleotide 
phosphoramidite cassette technology and has enabled the synthesis of mutagenic 
oligonucleotides that can encode desired proportions of tailored amino acid diversities at each 
random position (Miersch and Sidhu, 2012; Shim 2016).  
Phage-displayed single-framework synthetic antibody libraries are constructed in three 
major steps. First, the chosen antibody framework is assembled from synthetic gene fragments 
and sub-cloned into a phagemid vector. Second, CDR regions within the template phagemid are 
diversified using mutagenic oligonucleotides. The incorporation of mutagenic oligonucleotides
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Figure 2.6: Library construction by Kunkel mutagenesis. Uracil-containing single-stranded 
DNA form (dU-ssDNA) of the template phagemid is prepared using a dut−/ung− E. coli host 
(CJ236). Phosphorylated mutagenic oligonucleotides (arrows) designed to introduce mutations 
(asterisk) in the CDRs of interest are annealed to the dU-ssDNA template strand. A covalently 
closed, circular, double-stranded DNA (CCC-dsDNA) heteroduplex is synthesized in vitro by T7 
DNA polymerase and T4 DNA ligase in the presence of dNTPs and ATP. The resulting CCC-
dsDNA is then electroporated into a dut+/ung+ E. coli host (SS320) that inactivates the uracil-
containing wild-type strand (dashed circle) leading to the preferential amplification of mutated 
DNA. Figure 2.6 reprinted with permission from Springer (Chen and Sidhu, 2014). 
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 Fig. 2  Library construction by oligonucleotide-directed mutagenesis. The dU-ssDNA of the template DNA is 
prepared from phage particles produced by template phagemid-carrying CJ236 superinfected with M13K07 
helper phage. Phosphorylated synthetic oligonucleotides ( arrows ) designed to introduce mutations ( asterisk ) 
in regions of interest are annealed to the dU-ssDNA template ( dashed circle ) owing to the complementary 
fl anking sequences on both ends of the oligonucleotides. Heteroduplex covalently closed circular, double- 
stranded DNA (CCC-dsDNA) is enzymatically synthesized by T7 DNA polymerase and T4 DNA ligase in the 
presence of dNTPs and ATP. The resulting CCC-dsDNA is then introduced into  E. coli SS320 (or other  dut  +  ung  +  
 E. coli hosts) where the mismatched region  are repaired to ither the wild-type sequence or the mutant 
sequence. The uracil-containing parental strand ( dashed circle ) is degraded in  dut  +  ung  +  host, and the 
Phage Display Synthetic Antibody Libraries 
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into the phagemid vector is typically accomplished using either cassette-based methods with 
restriction enzyme cloning or site-specific annealing to ssDNA followed by whole phagemid 
synthesis. Third, the phagemid library is introduced into E. coli cells by electroporation followed 
by helper-phage infection and library phage production (Miersch and Sidhu, 2012; Fellouse and 
Pal, 2015). In this work, we started with a pHP153 phagemid that contains the Hu4D5-8 Fab 
framework (Persson et al., 2013). To incorporate mutagenic oligonucleotides to the CDR regions 
of the phagemid, we chose to use the classical oligonucleotide-directed mutagenesis method of 
Kunkel et al. (1987). First, uracil-containing template phagemid ssDNA is prepared using a 
dut−/ung− E. coli host. Second, mutagenic oligonucleotides are annealed to the template ssDNA 
to prime the polymerase-dependent in vitro synthesis of complementary DNA strand. The whole 
phagemid vector thus synthesized is ligated to form a covalently closed, circular, double-
stranded DNA (CCC-dsDNA) heteroduplex. Third, CCC-dsDNA is electroporated into a 
dut+/ung+ E. coli host that inactivates the uracil-containing template DNA leading to the 
preferential amplification of mutated DNA (Fellouse and Sidhu, 2006; Adams et al., 2014). 
Kunkel mutagenesis does not require prior assembly of overlapping PCR fragments or restriction 
enzyme sites, enables simultaneous diversification of multiple CDRs in a single mutagenesis 
reaction, and allows using pools of mutagenic oligonucleotides of varying lengths thus 
facilitating the incorporation of length diversity into CDRs (Miersch and Sidhu, 2012). Upon 
electroporation of CCC-dsDNA into E. coli, the phagemid replicates as a dsDNA. Helper phage 
infection initiates ssDNA replication and provides the necessary proteins and viral machinery for 
the production of mature phage particles displaying Fabs encoded in phagemid vectors (Fellouse 
and Sidhu, 2006; Adams et al., 2014).  
Phage display panning is the process of screening phage-displayed libraries for isolating 
binders against a given target. Typically, selections are conducted against purified target proteins 
immobilized onto a solid support. The selection process aims to sequentially enrich the clones of 
the phage-displayed antibody library, which bind to the target of interest as the library undergoes 
successive rounds of selection. At each selection round, negative selections are conducted to 
remove phage clones that bind to undesired regions of the target or any other control proteins. 
Phage pools are then exposed to the immobilized target, non-binding phages are washed away 
and phages retained by the target are eluted and amplified for the next round of selection. After 
each selection round, the enrichment in the selection process is measured by comparing the
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Figure 2.7: Phage display selections of Fabs. Fab libraries are displayed on the surfaces of 
M13 phage particles as fusions to the PIII phage coat protein. Each phage particle displays a 
unique Fab protein and also encapsulates a phagemid that contains the Fab-encoding DNA. The 
phage-displayed Fab library is incubated with the immobilized antigen, and non-binding phages 
are washed away. Antigen-binding phages retained by the immobilized antigen are amplified in 
an E. coli host. The amplified pool is used for additional rounds of selection to eventually obtain 
a phage population that is dominated by antigen-binding clones. At this point, Fab sequences are 
decoded by subjecting the phage pools and/or individual phage clones to DNA sequencing. 
Figure 2.7 reprinted with permission from Nature Publishing Group (Sidhu and Fellouse, 2006). 																								 
phage titers eluted from the target protein and control proteins. After a few rounds of binding 
selection and amplification, target-binding antibody fragments are isolated from the phage pool 
and their identities are decoded using Sanger sequencing (Reviewed by Hoogenboom, 2005; 
Sidhu and Fellouse, 2006; Bradbury et al., 2011; Chan et al., 2014). 
2.3 Novel Strategies for Discovering Antibodies  
2.3.1 Phage Display Challenges and Selection Strategies 
The success of a selection experiment depends on the quality of the phage-displayed 
antibody library, the immobilized target and the phagemid/phage/host system. During library 
design and construction, quality of the antibody library may be affected due to various factors 
such as less-stable antibody frameworks, undesirable framework changes, CDRs designs that 
affect folding and stability of Fabs, inefficient library mutagenesis reactions, and sub-optimal 
phagemid systems that affect phage assembly and Fab display. As a result, the library may not 
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contain sufficient functional diversity to generate antibodies against a broad range of antigens 
(Ponsel et al., 2011; Zhai et al., 2011; Shim 2015). A properly folded and immobilized antigen is 
also critical in determining the success of a selection experiment. Immobilization of proteins on 
plates or tubes may lead to some denaturation thus reducing the proportion of correctly folded 
antigen, result in non-uniform presentation of proteins, disrupt the functional or naïve 
conformation and block access to relevant epitopes on the target (Koide et al., 2009; Miersch and 
Sidhu, 2012; Jara-Acevedo et al., 2016). Finally, antibody selection by phage display is not only 
driven by binding events, but also the amplification phase of panning has a significant effect on 
the enrichment of antibody fragments during successive rounds of selection. The amplification of 
individual clones in the library is not uniform because some phage-displayed antibody fragments 
can influence the infection, propagation and production of M13 and E. coli.  While phagemids, 
antibody libraries and panning protocols have been optimized to minimize the amplification bias, 
an entirely affinity-driven selection is hard to achieve due to the intrinsic limitations of phage 
display that relies on M13 and E. coli biology (Derda et al., 2011; Saggy et al., 2012; Naso et al., 
2014; Shim, 2015).  
Phage display screening of antibody libraries against immobilized targets does not give 
rise to antibody fragments in all selection experiments. Further, antibody fragments obtained 
from a successful selection may not possess favorable biophysical, biochemical, cell biological, 
pharmacological and clinical properties. Therefore, novel strategies are required for increasing 
the success rate of phage display selections and for obtaining useful antibodies with desirable 
properties. We have classified these strategies into six groups: (1) novel library designs; (2) 
target modification; (3) manipulating the selection environment; (4) isolation of rare clones from 
selection outputs; (5) post-selection strategies; and (6) post-clone rescue strategies. Novel library 
designs include either next-generation synthetic antibody libraries with improved biophysical 
properties, favorable production characteristics and reduced immunogenicity (Ponsel et al., 
2011; Tiller et al., 2013) or motif-grafted synthetic antibody libraries that are designed to direct 
the antibody library towards a specific region on a protein (Tiller and Tessier, 2015; Miersch et 
al., 2017). If target immobilization by passive adsorption is unsuccessful, affinity tags can be 
engineered into the target protein for immobilization into magnetic beads. Also, selections can be 
conducted against complex surfaces such as normal and tumorigenic cells, engineered bacterial, 
yeast and mammalian cells, tumor histological samples and proteoliposomes (Miersch and 
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Sidhu, 2012; Jara-Acevedo et al., 2016). In phage display, the selection conditions can be 
tailored or controlled by addition of ligands or competitors, decreasing target concentrations, 
extending washing steps, increasing temperature, including negative selections and competitive 
elution techniques. These strategies increase the chances of obtaining clones with desired 
binding properties including high/low affinity, high/low specificity, thermo-stability, regional or 
conformational specificity and species cross-reactivity (Paduch et al., 2013; Dennis, 2015). The 
use of high-throughput approaches and robotic liquid-handling devices for phage display 
screening can increase the number of unique antibody clones isolated from selection outputs 
(Hornsby et al., 2015). Also, phage pools can be subjected to next-generation sequencing (NGS) 
analysis for identifying and reconstructing low-frequency rare clones from selection outputs 
(D’Angelo et al., 2014). Following one or two rounds of selection, the CDR regions in phage 
pools can be subjected to additional rounds of mutagenesis or sequence diversity can be sub-
cloned into alternate display platforms before resuming further rounds of selection (Ferrara et al., 
2012). Also, NGS analysis of selection pools can provide insight for constructing target-specific 
focused libraries, which can be screened for isolating binders with improved properties (Ravn et 
al., 2010; Mathonet and Ullman, 2013; Koenig et al., 2015). Once an antibody fragment has 
been identified and its sequence decoded, second-generation libraries can be constructed and 
screened for modifying its properties. These libraries, commonly referred to as affinity 
maturation libraries, are constructed by soft randomization of CDRs or by incorporating 
restricted or tailored diversity to CDRs. Knowledge obtained from CDR homology scanning, 
CDR alanine scanning or antibody-antigen structures can be used for designing randomization 
schemes in secondary libraries or for engineering rational mutations into CDRs (Miersch and 
Sidhu, 2012; Marvin and Lowman, 2015). Site-directed mutations can be engineered to Fab or 
Fc framework regions based on previous observations or crystal structures to increase the 
stability or alter the effector function of antibodies (Beck et al., 2010).  
2.3.2 Next-Generation Sequencing in Antibody Discovery 
In a typical antibody selection experiment, once the library is panned against the target, 
antigen-specific antibody fragments must be recovered from phage selection pools. To 
accomplish this, hundreds to thousands of colonies from phage selection outputs are first 
interrogated by binding assays (phage/Fab ELISA) in 96/384 well plates, and then identities of 
ELISA-positive clones are determined by Sanger sequencing (Ravn et al., 2010). In phage 
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display, many binders present in earlier selection rounds do not get enriched and remain at very 
low frequencies in later selection rounds. The iterative nature of panning experiments (rounds of 
binding selection and amplification) often enrich for binders that exhibit certain growth 
advantages in E. coli (Derda et al., 2011; Saggy et al., 2012). The conventional clone recovery 
method (screening followed by sequencing) leads to the repeated identification of the same 
enriched clones that possessed growth-advantage characteristics in E. coli. With this method, it is 
not possible to recover Fab clones that are present at low frequencies in phage pools (termed as 
rare clones). If we were to switch the order of this clone recovery process (sequencing followed 
by screening), we could avoid the repeated identification of growth-advantaged, high frequency 
binders. In addition, this new approach can significantly reduce the amount of work required 
during the upfront screening process, and can help to identify and recover many unique clones 
that are present from high to very-low frequencies in phage pools (Naso et al., 2014; Sasso et al., 
2015; Lopez et al., 2017). 
Sanger sequencing is used to decode the sequences of Fab-encoding phagemids 
recovered from phage pools. It requires the isolation of individual phagemids from phage pools, 
and can only sequence a few hundred clones routinely. Since each selection round in phage 
display gives an output of up to ~106 sequences, only a small fraction of the sequence diversity 
can be sampled by Sanger sequencing. Though Sanger sequencing is sufficient for the typical 
clone recovery process (screening followed by sequencing), the use of next-generation 
sequencing (NGS) becomes necessary if one has to capture and interrogate the entire sequence 
diversity present in phage display selection outcomes. With NGS, entire phage pools can be 
subjected to sequencing (isolation of individual phagemids is not required), and up to ~106
 
– 109
 
individual sequences can be obtained routinely (Fischer, 2011; Glanville et al., 2015). Up to ten 
NGS platforms exist each with its own advantages and preferred applications, with primary 
variables being read length, data quality and quantity, time and cost (Metzger, 2010; Loman et 
al., 2012). Three commonly used NGS platforms in the antibody field include 454 (Roche), 
MiSeq (Illumina) and Ion Torrent (Life Technologies).  
The Fischer lab at Novimmune was the first to use NGS in antibody phage display. The 
Illumina platform was used to sequence the CDRH3 region of a multiple-framework synthetic 
scFv library. NGS analysis was used to assess the quality of the library and to follow changes in 
heavy chain germline usage and CDRH3 length distribution over three rounds of selection. A
	 29	
Table 2.3: Comparison of commonly used next-generation sequencing platforms 
Platform 
Type 
of 
Seq. 
Max 
read 
length 
(bp) 
Throughput Cost (lowest) Accuracy Time 
Type of 
error 
MiSeq 
(Illumina) 
V2/V3 
2×300 600 25×106/lane $1750/lane 
>70% 
reads at 
99.9% 
55h 
Substitution 
2×150 300 16×106/lane $1100/lane 
>80% 
reads at 
99.9% 
24h 
IonTorrent 
(LifeTech)-
318	 1×400 400 5.5×106/chip $749/chip >99% 5h Insertion Deletion 1×200 200 3h 
454 
(Roche)-
GS-FLWX+	 1×700 700 50,000 in 1/8 plate 
$2400/ 
1/8plate 
99.99% 
23h 
Insertion 
Deletion 
1×450 450 $1900/ 1/8plate 10h 
Type of sequencing, maximum read length, number of reads, reagent costs, time taken, error rate 
and types of error for three commonly used NGS platforms. Table modified from Glanville et al., 
2015. 
 
strategy was also developed to rescue rare scFv clones from phage pools using fragment 
assembly (Ravn et al., 2010). The Fischer lab used the same approach to sequence the CDRH3 
region of semi-synthetic scFv libraries, and to rescue rare scFv clones from phage selection 
outputs (Venet et al., 2012; Ravn et al., 2013). The Lerner lab used Roche’s 454 to sequence the 
VH region of a phage selection output originated from a natural scFv library. Three strategies 
were tested for recovering scFv clones based on CDRH3 sequences: fragment assembly, rolling 
circle amplification, and hybridization using biotin probes (Zhang et al., 2011). A few labs have 
used Roche’s 454 to sequence the VH and VL regions of synthetic Fab/scFv libraries, and NGS 
information was used to assess the quality of libraries (Zhai et al., 2011; Tiller et al., 2013; 
Mahon et al., 2013). The Bradbury lab used the Ion Torrent platform to sequence the CDRH3 
region of two different selection outputs originated from a natural scFv library. A rescue strategy 
was also developed to isolate scFv clones from selection outputs using inverse PCR and ligation 
	 30	
(D’Angelo et al., 2014; Spiliotopoulos et al., 2015). Recently, MiSeq (Illumina) was used to 
sequence the CDRH2-CDRH3 region of a selection output originated from a single-framework 
synthetic Fab library (Lopez et al., 2017), and the VH region of selection outputs originated from 
immune scFv libraries (Yang et al., 2017). Both groups used CDRH3 information for analyzing 
the amino acid composition, for monitoring the enrichment of clones during the selection 
process, and for retrieving rare Fab/scFv clones by fragment assembly (Lopez et al., 2017; Yang 
et al., 2017).  
For antibody engineering, a key aspect is to obtain the entire sequence of highly diverse 
VH and VL chains. At present, none of the NGS platforms can provide sufficient read lengths to 
sequence the full-length Fab genes. Roche’s 454 offers the longest read length (700 bp), which is 
only sufficient to cover one of the variable chains (DeKosky et al., 2014). Due to this read-length 
limitation in short-read DNA sequencing platforms, NGS analysis of phage-displayed Fab/scFv 
libraries or selection outputs is usually restricted to CDRH3. It is worth mentioning here that 
CDRH3 is typically the most heavily diversified CDR in Fab/scFv libraries due to its dominant 
role in antigen recognition. CDRH3 sequencing has been used to assess the quality of libraries, 
to monitor the evolution of Fabs during selections and to characterize the changes in CDR length 
or amino acid distribution during selections (Ravn et al., 2010; D’Angelo et al., 2014). 
Reconstruction of rare clones, however, is not the same as sequence identification. To 
reconstruct full length Fab or scFv clones from NGS information, CDRH3 information alone is 
not sufficient, as antibody libraries typically contain two, four or all six diversified CDRs. To 
circumvent this, a few strategies have been tested to rescue Fab/scFv clones from selection 
outputs based only on CDRH3 information. These strategies use both hybridization- and PCR-
based cloning techniques to rescue the entire sequences of Fab/scFv clones (Ravn et al., 2010; 
Zhang et al., 2011; D’Angelo et al., 2014; Lopez et al., 2017; Yang et al., 2017). Gene synthesis 
has also been used to reconstruct scFv clones from NGS information (Lövgren et al., 2016). 
Rescued Fab/scFv clones had been shown to interact with their targets by ELISA or flow 
cytometry (Ravn et al., 2010; D’Angelo et al., 2014; Lopez et al., 2017; Yang et al., 2017). In 
this work, we describe a rapid and simple method for reconstructing rare Fab clones from NGS 
information, and also compare the binding properties of reconstructed rare clones with high-
frequency top clones.  
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2.3.3 Motif-Grafting in Antibody Discovery 
Protein-protein interactions form the molecular basis of most physiological and 
pathological processes. From a structural standpoint, protein-protein interactions can be 
considered as interactions between two epitopes. Epitopes are divided into two categories: linear 
or continuous epitopes and discontinuous epitopes (Van-Regenmortel, 2009). Linear or 
continuous epitopes are formed by a single contiguous stretch of amino acids; however, it must 
be noted that not necessarily each residue in this peptide segment interacts with the partner. The 
peptide segment can exist as a single secondary structure element (β-strands or turns) or with no 
clear secondary structures (patches). Discontinuous epitopes are formed by multiple secondary 
structure elements (α-helixes, β-strands or turns) and complex patches originating from different 
regions of a binding partner (Jubb et al., 2012; Nero et al., 2014; Scott et al., 2016). An antigen-
antibody interaction is essentially a protein-protein interaction, which involves interaction 
between the epitope on the antigen and the antigen-binding region on the antibody. The antigen-
binding region on the antibody is referred to as the “paratope”, which is formed by one to six 
CDR loops and selective framework residues (Sundberg, 2009).  
Motif grafting is one of the key approaches used for rationally designing antibodies based 
solely on the sequence and/or structure of the antigen. Motif grafting relies on engineering 
protein interaction epitopes into CDRs for designing antibodies with desired target specificity by 
mimicking natural protein interactions (Tiller and Tessier, 2015). Many linear peptides or 
discrete motifs have been successfully grafted into CDRs for generating antibodies with 
desirable binding and functional properties (McLane et al., 1995; Moroncini et al., 2004; Simon 
et al., 2005; Kogelberg et al., 2008; Perchiacca et al., 2012; Ladiwala et al., 2012). Recent 
studies have shown that small protein domains can also be grafted into CDRs of certain antibody 
frameworks to obtain fully functional antibodies (Zhang et al., 2013; Zhang et al., 2014; Zhang 
et al., 2015; Liu et al., 2015A; Liu et al., 2016). A few studies have combined motif grafting 
with combinatorial approaches to improve the binding properties of grafted antibodies. Amino 
acids flanking the graft (Barbas et al., 1993; Frederickson et al., 2006; Peng et al., 2015; Lee et 
al., 2015) or amino acids within ungrafted CDRs (van den Beucken et al., 2001; Koerber et al., 
2013) have been optimized using directed evolution to obtain grafted antibody variants with high 
affinity and specificity. These studies highlight the use of motif grafting approaches in rational 
and semi-rational design of synthetic antibodies. 
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The use of antibodies as support scaffolds to mimic protein-protein interactions provides 
many advantages: (1) the antibody framework provides a good platform with respect to stability, 
rigidity, mobility, flexibility, cooperativity and interactivity; (2) CDRs of antibodies show a high 
level of plasticity by exhibiting amino acid, length and conformational diversity, and are able to 
tolerate grafts of any reasonable size or character from a variety of sources; (3) antibodies are 
compatible with combinatorial diversification and selection methods for further optimization of 
binding properties; (4) reliable information on molecular, structural, functional, pharmacological 
and clinical properties of full-length antibodies and antibody fragments is available for design 
and development of epitope mimics; and (5) antibodies can be designed with desirable 
biochemical, biophysical and pharmacokinetic properties and favorable production 
characteristics.  
The antibody paratope is discontinuous; it is composed of multiple CDR loops that are 
spatially brought together by the antibody framework. The interaction of multiple secondary 
structures with the antigen enhances the affinity and specificity of binding. The presence of 
multiple CDRs on a single molecular scaffold enables antibodies to be used as discontinuous 
epitope mimics. In discontinuous epitopes, the shape, conformation and positioning of different 
peptide segments with respect to each other are crucial for mediating an interaction. The exact 
mimicry of these features on antibody CDRs can be extremely difficult (Werkhoven and 
Liskamp, 2013). For this reason, a strategy is proposed in this work for partially resembling 
discontinuous epitopes using antibody CDRs. First, a secondary structure element central for the 
interaction is identified and grafted into CDRH3 of a Fab framework. Second, to compensate for 
other interactions in the protein-protein interface, amino acids within ungrafted CDRs are 
diversified and selected for optimal binding by combinatorial phage display. This approach could 
be used for semi-rationally designing antibody libraries that are biased towards binding to a 
specific region on the protein target for disrupting a discontinuous protein-protein interaction. 
2.4 Background Information about Protein Targets used in this PhD Project 
2.4.1 Notch and Jagged Receptors  
Notch signaling is a highly-conserved pathway that influences multiple cell fate decisions 
including, proliferation, apoptosis, differentiation, migration and angiogenesis in developing and 
adult metazoan organisms. In mammals, Notch signaling is initiated by four Notch receptors 
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(Notch1-4) and five Delta/Serrate/LAG-2 (DSL) ligands (Jagged-1/2 and DLL-1/3/4), all of 
which are modular, type-I single-pass transmembrane proteins. The extracellular region of Notch 
contains a series of epidermal growth factor (EGF)-like repeats that are required for ligand 
binding followed by a negative regulatory region and a hetero-dimerization domain. The 
extracellular region of DSL ligands contains a MNNL domain (module at the N-terminus of 
Notch ligands) followed by a DSL domain and a series of EGF-like repeats like Notch receptors. 
The intracellular region of Notch contains numerous well-defined domains whereas the 
intracellular region is not conserved in DSL ligands (reviewed by Gordon et al., 2008 and 
Espinoza et al., 2013). 		
	
Figure 2.8: Key steps in the Notch signaling pathway: (1) Interaction between a DSL ligand 
on the signal-sending cell and a Notch receptor on the signal-receiving cell; (2) Cleavage of 
Notch at site S2 within the juxtamembrane domain by a metalloprotease of the ADAM family; 
(3) Cleavage of Notch at site S3 within the transmembrane domain by the γ-secretase protein 
complex; (4) Release of intracellular Notch from the membrane and its translocation to the 
nucleus; and (5) Formation of a transcriptional activation complex with CSL and MAM, thus 
inducing the transcription of target genes. (NEC: Notch extracellular; DSL: Delta/Serrate/LAG-
2; ICN: Intracellular Notch; MAM: Mastermind; CSL: C-promoter-binding factor; CBP/p300: 
CREB-binding protein/ E1A binding protein p300). Figure 2.8 reprinted with permission from 
Company of Biologists (Gordon et al., 2008). 	
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The canonical short-range Notch signaling happens between two adjacent cells, with the 
signal-sending cell expressing the DSL ligand and signal-receiving cell expressing the Notch 
receptor. Bi-molecular interaction between the Notch receptor and the DSL ligand at the cell 
surfaces initiates a process called regulated intramembrane proteolysis, in which the Notch 
receptor is cleaved within the extracellular hetero-dimerization domain by a metalloprotease of 
the ADAM family. This DSL-dependent metalloprotease processing renders Notch sensitive to 
the γ-secretase protein complex. γ-Secretase cleaves the Notch receptor within the 
transmembrane region and releases the Notch intracellular domain. The intracellular domain 
translocates into the nucleus where it forms a transcriptional activation complex and regulates 
Notch-responsive genes (reviewed by Gordon et al., 2008 and Wang, 2011).	
In addition to its physiological roles, deregulation of Notch signaling is associated with 
developmental disorders, neurological diseases, solid cancers and hematologic malignancies. 
These pathological conditions result from overexpression or gain/loss-of function mutations 
within Notch and Jagged receptors (Ranganathan et al., 2011). Two kinds of inhibitors have been 
developed to inhibit Notch signaling: small molecules targeting the γ-secretase complex and 
monoclonal antibodies targeting Notch or Jagged ectodomains. Since γ-secretase inhibitors 
inhibit the proteolysis of multiple transmembrane proteins including all four Notch receptors, 
they caused severe toxic side effects in clinical trials. Similar side effects were also observed 
with pan-Notch specific monoclonal antibodies (Takebe et al., 2014). Synthetic antibodies 
targeting the negative-regulatory region of Notch-1 and receptor-binding region of Jagged-1 
bound specifically to Notch and Jagged receptors, respectively. They also exhibited potent and 
selective inhibition of Notch-1 or Jagged-1 signaling in tumor models and showed promising 
results in pre-clinical studies (Wu et al., 2010 and Lafkas et al., 2015). Thus, there is a great 
interest in developing paralogue-specific synthetic antibodies against Notch receptors and DSL 
ligands. 
2.4.2 Epidermal Growth Factor Receptor 
The epidermal growth factor (EGF) family of receptor tyrosine kinases (also known as 
ErbB or HER) plays a well-established role in the growth, differentiation, migration and survival 
of normal adult tissues (Yarden and Sliwkowski, 2001). This family is comprised of four closely 
related receptors including EGFR (ErbB1/HER1), HER2 (EGFR2/ErbB2), HER3 (ErbB3) and 
HER4 (ErbB4), all of which share several structural and functional features including a 4-domain
	 35	
							 	
Figure 2.9: Mechanism of EGF-induced EGFR activation. The extracellular module of EGFR 
contains four domains (I to IV, distal to membrane proximal). Domains I and III form the ligand-
binding site on the receptor. Domain II contains the ‘dimerization arm’. The intracellular module 
of EGFR contains a tyrosine kinase domain and a C-terminal tail. In the absence of EGF, the 
EGFR monomer predominantly exists in an auto-inhibited conformation, where domains II and 
IV form an intramolecular interaction.  In the presence of EGF, EGFR adopts an extended 
conformation, where domain II is exposed for promoting receptor dimerization. EGFR 
dimerization activates the intracellular kinase domain of EGFR, resulting in autophosphorylation 
of the C-terminal tail and initiation of downstream signaling pathways. Figure 2.9 reprinted 
under the terms of the Creative Commons license (Huang et al., 2016).		
 
(I to IV, distal to membrane proximal) modular extracellular region, a single transmembrane 
domain, and intracellular tyrosine kinase and regulatory domains (Ferguson, 2008; Lemmon et 
al., 2014). In the absence of a ligand, EGFR predominantly exists in a tethered conformation in 
which domains II and IV interact and impede ligand binding. Upon ligand binding to domains I 
and III, EGFR adopts an extended conformation in which domain II is exposed for promoting 
receptor dimerization (Ferguson, 2008; Bessman et al., 2014). The domain II dimer interface is 
composed of multiple discontinuous contacts, and a β-hairpin loop in domain II, referred to as 
the dimerization arm has been shown to be crucial for dimerization (Ogiso et al., 2002; Garrett et 
al., 2002; Burgess et al., 2003). Receptor dimerization stabilizes the extended conformation of 
EGFR and triggers phosphorylation events in the cytoplasmic tail of the receptors. These events 
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enable docking of intracellular proteins bearing SH2 domains to phospho-residues, resulting in 
the transmission of signals via the MAPK, PI3K and STAT pathways (Ferguson, 2008; Bessman 
et al., 2014; Huang et al., 2016). 
In addition to their physiological roles, ErbB receptor deregulation and aberrant 
expression are commonly observed features of cancers forming solid tumors (Wang et al., 2011; 
Huang et al., 2012). EGFR overexpression in particular was confirmed to transform normal 
fibroblast cells into tumorigenic cells long ago, and the frequent overexpression of EGFR in 
many cancers and the ensuing correlation with prognosis indicates that EGFR plays a central role 
in oncogenesis, progression and metastasis (Hudziak et al., 1987; Velu et al., 1987). Increased 
EGFR expression in the absence of activating mutations has been confirmed in a wide variety of 
cancers including head and neck, esophageal, lung, colorectal, ovarian, prostate, and breast. 
EGFR overexpression is now known to be a primary driver not only for tumor initiation, but also 
metastasis and invasion, promoting the formation of secondary tumors. Based on the correlation 
between high levels of EGFR expression in solid tumors and disease progression and prognosis, 
EGFR has received substantial attention as an anti-cancer target, which has resulted in the 
development of a host of drugs aimed at inhibiting aberrant EGFR-dependent signals that drive 
tumor development (reviewed by Yewale et al., 2013; Tebbutt et al., 2013; Arteaga and 
Engelman, 2014). 
Currently two classes of anti-EGFR drugs exist and are approved for the treatment of 
cancers: Small molecule tyrosine kinase inhibitors (gefitinib and erlotinib) and monoclonal 
antibodies (cetuximab, panitumumab and nimotuzumab). These drugs have shown promise as 
mono-, combination-, and follow-up therapies in the treatment of colorectal, non-small cell lung, 
pancreatic, and breast cancer as well as squamous cell carcinoma of the head and neck. Although 
patients have derived clinical benefit from small molecule tyrosine kinase inhibitors, monoclonal 
antibody therapies are attractive as antibodies can mediate pleiotropic activities that inhibit 
receptor kinase complex activity and reduce tumor burden by (1) blocking ligand binding and the 
active receptor conformation, (2) inhibition of receptor dimerization, (3) recruitment of immune 
effectors that mediate cell killing, (4) receptor internalization and down-regulation, and (5) 
inhibition of ectodomain proteolysis (reviewed by Peipp et al., 2008; Fauvel and Yasri, 2014; 
Arteaga and Engelman, 2014). 
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One of the main disadvantages of current EGFR-directed therapies is the potential for 
primary resistance (in which individuals initially do not respond to drug) or secondary resistance 
(in which resistance to drug is acquired upon extended exposure to drug), both of which have 
limited the efficacy and utility of anti-EGFR drugs and have resulted in reports of poor 
correlation between EGFR expression and drug responses. Attempts to characterize resistance 
mechanisms have found several likely causes including receptor overexpression and trans-
activation of alternate ErbB receptor family members, as well as mutations in downstream 
effectors of the EGFR pathway including MAPK (BRAF) and PI3K (KRAS, PTEN) pathways, 
which may partially decouple signaling from the receptor (reviewed by Kruser and Wheeler, 
2010; Wheeler et al., 2010; Camidge et al., 2014). Clearly, there is still substantial need for 
novel therapeutics that targets this receptor with unique mechanisms that can help to overcome 
resistance. Synthetic antibodies are ideally suited to this task as they can be designed to target 
unique epitopes and are a well-tolerated, routinely engineered class of biologics.  
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3. OBJECTIVE, HYPOTHESES AND SPECIFIC AIMS 
 
The objective of this PhD project is to develop and validate methods for advancing the 
applications of two techniques, NGS and motif grafting, in synthetic antibody discovery.  
A few strategies have been described to rescue low-frequency Fab/scFv clones from 
phage selection outputs using NGS information. These strategies involve gene synthesis, 
fragment assembly, multi-step PCR reactions and ligation procedures, which are time consuming 
and expensive. These methods are relatively low-throughput compared with the high-throughput 
of NGS and phage display selections. Further, none of these strategies eliminated the use of 
Sanger sequencing during clone rescue or reconstruction. The objective of this NGS project is to 
develop a method for reconstructing rare Fab clones from NGS information, which overcomes 
all of afore-mentioned limitations. We hypothesize that rare Fab clones possessing favorable 
binding properties can be reconstructed from NGS information in a straightforward manner. 
Specific aims for this project include: (1) develop methods for sequencing phage-Fab selection 
outputs and to reconstruct Fabs from NGS information; (2) design, construct and validate a new 
single-framework synthetic Fab library for NGS-assisted selections; and (3) compare binding 
properties of Fabs isolated using conventional and NGS approaches.  
Previous studies have shown that linear peptides, discrete motifs or small domains can be 
grafted into CDRs to design antibodies with desired binding properties. A few studies have 
combined motif grafting with combinatorial approaches to improve the binding properties of 
grafted antibodies. The objective of this motif-grafting project is to test whether structural 
information on discontinuous protein interfaces could be used for semi-rationally designing 
synthetic Fab libraries that are biased towards interacting with a desired site on the target 
receptor. We designed and constructed a structure-guided Fab library by grafting a well-defined 
EGFR interaction motif into CDRH3 and by diversifying few other CDRs of a Fab framework. 
We hypothesize that the structure-guided Fab library can be used for isolating Fabs that 
recognize the native interaction domain in the target receptor. Specific aims for this project 
include: (1) design, construct and screen an EGFR structure-guided synthetic Fab library; (2) test 
the affinity, specificity and activity of anti-EGFR Fabs isolated from the structure-guided and 
naïve synthetic Fab libraries; and (3) characterize the epitopes of anti-EGFR Fabs.  
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4. MATERIALS AND METHODS 
4.1 General Molecular Biology and Microbiology Protocols 
Plasmid DNA was extracted and purified from E. coli using plasmid mini-preparation 
and maxi-preparation kits (Qiagen/Bio-Basic). PCR products and restriction enzyme digested 
plasmids were purified using PCR cleanup kits (Qiagen/Bio-Basic) and gel purification kits 
(Qiagen/Bio-Basic), respectively. Single-stranded DNA was extracted and purified from M13 
phage solution using the Spin M13 kit (Qiagen). Agarose gel electrophoresis and sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) were used to separate DNA and 
proteins based on their molecular weight, respectively. Plasmids were sequenced on a 3500 
Series Genetic Analyzer (Applied Biosystems) using the BigDye Terminator 3.1 Cycle 
Sequencing Kit (Applied Biosystems). 
Bacterial strains were cultured and propagated using standard microbiology procedures. 
2YT broth and 2YT agar were used to cultivate E. coli. The following E. coli strains were used 
in this work: DH10B and MC1061 for general cloning purposes and plasmid amplification, 
CJ236 for dU-ssDNA production, SS320 and SR320 for library generation and phage 
production, XL1 Blue and 5-α F¢Iq for bacteriophage amplification, and BL21 for Fab expression 
and purification. 
Electrocompetent DH10B and MC1061 cells were prepared according to standard 
protocols (Ausubel et al., 1988). To transform DH10B and MC1061 cells, 1 µL of plasmid (50-
150 ng) was mixed with 50 µL of electrocompetent cells, transferred to an electroporation 
cuvette, and the cuvette was subjected to a short electric pulse using a gene pulser (Bio-Rad). 
The cells were recovered immediately, transferred into 1 mL of pre-warmed SOC media and 
incubated for 30 min at 37 °C. The cells were harvested and plated onto 2YT agar plates 
containing the appropriate antibiotic for plasmid selection.  
4.2 Kunkel Mutagenesis 
Kunkel mutagenesis was used to: (1) introduce site-directed mutations into the antibody 
framework or CDRs in the pHP153 phagemid; (2) diversify one or multiple CDRs in the pHP153 
phagemid for generating Fab libraries; (3) create EGFR mutants and domain truncations in the 
EGFR expression plasmid for epitope mapping studies; and (4) delete the framework regions 
between diversified CDRs in phage pools for reducing the NGS amplicon length.  For the first 
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three purposes, we used the conventional mutagenesis approach in which dU-ssDNA is prepared 
in dut−/ung− E. coli, dU-ssDNA is converted to CCC-DNA in vitro, and CCC-dsDNA is 
electroporated into a dut+/ung+ E. coli host. Kunkel mutagenesis (Kunkel et al., 1987) was 
carried out using protocols established by the Sidhu lab (Fellouse and Sidhu, 2006; Tonikian et 
al., 2007; Nelson and Sidhu, 2012). The method used for NGS amplicon preparation is explained 
in Section 4.8.  
To prepare dU-ssDNA, dut−/ung− CJ236 E. coli cells harboring the appropriate phagemid 
were grown, infected with M13KO7 helper phage, and incubated in 2YT media supplemented 
with 100 µg/mL carbenicillin, 25 µg/mL kanamycin, and 0.25 µg/mL uridine for 20 hrs at 37 °C 
with shaking at 200 rpm. Phage particles were precipitated from the culture supernatant, and dU-
ssDNA was extracted and purified from phage particles using the Spin M13 kit (Qiagen). The 
dU-ssDNA template was converted to CCC-dsDNA in three steps: phosphorylation of mutagenic 
oligonucleotides, annealing of the phosphorylated oligonucleotides to dU-ssDNA, and enzymatic 
synthesis of CCC-dsDNA. To phosphorylate mutagenic oligonucleotides, 0.6 µg of each 
oligonucleotide was mixed with 2 µL of 10X TM buffer (0.1 M MgCl2, 0.5 M Tris, pH 7.5), 2 
µL of 10 mM ATP, 1 µL of 100 mM DTT, 2 µL of T4 polynucleotide kinase (10 units/µL, New 
England Biolabs) and H2O to a final volume of 20 µL, and incubated for 1 hr at 37 °C. To anneal 
phosphorylated mutagenic oligonucleotides to dU-ssDNA, 20 µg of dU-ssDNA was mixed with 
25 µL of 10X TM buffer, 20 µL of each phosphorylated oligonucleotide, and H2O to a final 
volume of 250 µL, and incubated at 90 °C for 3 min, 50 °C for 5 min, and 20 °C for 5 min. To 
synthesize CCC-DNA, 250 µL of annealed oligonucleotide/template mixture was mixed with 10 
µL of 10 mM ATP, 15 µL of 100 mM DTT, 10 µL of dNTP mix (25 mM of each nucleotide), 1 
µL of T4 DNA ligase (30 Weiss units/µL, New England Biolabs) and 3 µL of T7 DNA 
polymerase (10 units/µL, New England Biolabs), and incubated overnight at 20 °C. DNA from 
the mutagenesis reaction was purified and desalted using a DNA purification kit (Qiagen), and 
electroporated into dut+/ung+ E. coli cells (DH10B or SR320). If Kunkel mutagenesis was used 
for site-directed mutagenesis of phagemids or plasmids, DNA from the mutagenesis reaction was 
electroporated into DH10B cells, plated as individual colonies, and phagemids/plasmids with 
desired mutations were isolated and verified using Sanger sequencing. If Kunkel mutagenesis 
was used for CDR diversification, DNA from the mutagenesis reaction was electroporated into 
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SR320 cells for phagemid library generation or into M13KO7-infected SR320 cells for library 
phage production. 
4.3 Electroporation of Library DNA and Phage Production 
  SR320 E. coli cells were specially derived for high-efficiency electroporation and large-
scale phage production. Electrocompetent SR320 cells and M13KO7-infected electrocompetent 
SR320 cells were prepared and transformed with library DNA according to established 
procedures (Fellouse and Sidhu, 2006; Tonikian et al., 2007; Nelson and Sidhu, 2012).  The 
following protocol was used to transform M13KO7-infected SR320 cells with library DNA for 
phage library production. Briefly, 350 µL of highly-concentrated electrocompetent cells 
(~3X1011 CFU/mL) was gently mixed with 50 µL of purified library DNA (20 µg) on ice, 
transferred to a cold 0.2 cm gap electroporation cuvette, and electroporated using a BTX ECM-
600 electroporation system with the following settings: 2.5 kV field strength, 125 Ohms 
resistance, and 50 µF capacitance. Electroporated cells were recovered immediately with 2 mL of 
pre-warmed SOC media, transferred into 23 mL of pre-warmed SOC media, and incubated for 
30 min at 37 °C with shaking at 200 rpm. The culture was transferred into 500 mL of 2YT media 
supplemented with 100 µg/mL carbenicillin and 25 µg/mL kanamycin (for phagemid and helper 
phage selection) and incubated overnight at 37 °C with shaking at 200 rpm. Phage particles were 
precipitated from the culture supernatant using 1/5 volume of ice-cold PEG/NaCl solution (20% 
PEG-8000, 2.5 M NaCl), and resuspended in PBS containing 0.5% BSA and 0.05% Tween 
(PBT). The phage solution was centrifuged again to pellet any insoluble matter. The phage 
supernatant was quantified using UV spectrometry (OD268 = 1.0 for a solution of 5×1012 
phage/ml) and stored at -80 °C in the presence of protease inhibitors (2%) and sterile glycerol 
(25%). 
4.4 Library-F Amplification 
An aliquot of library-F phage was obtained from the Sidhu lab at the University of 
Toronto.  To prepare the starter culture, 250 mL of SR320 E. coli cells were grown to mid-log 
phase (OD600 of 0.8) in 2YT media supplemented with 5 µg/mL tetracycline, and incubated with 
1012 library-F phage for 30 min at 37 °C with shaking at 200 rpm. M13KO7 helper phage was 
added to the culture to a final concentration of 1010 PFU/mL and incubated for another 45 min. 
The starter culture was then transferred to 8 L of 2YT media supplemented with 100 µg/mL 
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carbenicillin and 25 µg/mL kanamycin and incubated for 18 hrs at 37 °C with shaking at 200 
rpm. Cultures were pelleted, and phages were precipitated and purified from the culture 
supernatant as described previously. Phage pellets from the final step were resuspended gently in 
8 mL sterile PBS and stored at -80 °C in the presence of protease inhibitors (2%) and sterile 
glycerol (25%). 
4.5 Construction of Synthetic Antibody Libraries 
4.5.1 Library-S 
To create the template phagemid for library-S construction, the pHP153 phagemid 
encoding the anti-maltose binding protein Fab (Persson et al., 2013) was used as the starting 
phagemid (see Appendix 1 for phagemid map). Desired mutations were incorporated into the 
Hu4D5-8 Fab framework and CDRs by Kunkel mutagenesis. In the first round of mutagenesis, 
five oligonucleotides were used to incorporate mutations into the five following regions: 
CDRL1, CDRL2, CDRH1, CDRH2 and FRM3. In the second round of mutagenesis, two 
oligonucleotides were used to incorporate NotI restriction sites into CDRL3 and CDRH3. The 
resulting phagemid was sequence verified and used as the template phagemid for library-S 
mutagenesis. The variable light and heavy chain sequences of the library-S phagemid are 
included in Figure 5.7. To introduce CDR diversity, Kunkel mutagenesis was used to repair the 
NotI sites in the template phagemid and to replace CDRL3 and CDRH3 positions with fixed or 
degenerate codons encoding the amino acid composition shown in Figure 5.6. Custom-designed 
CDRL3 and CDRH3 mutagenic oligonucleotides were purchased from Tri-Link Biotechnologies 
(Appendix 3). CDRL3 was diversified using one oligonucleotide (S-L3-09), whereas CDRH3 
was diversified using 20 oligonucleotides, each encoding a different CDRH3 length. Kunkel 
mutagenesis was performed as described in Section 4.2. Twenty different mutagenesis reactions 
were required for library-S construction, each reaction representing a CDRH3 length. DNA from 
the mutagenesis reaction was purified using the PCR cleanup kit (Qiagen) and 10 µg of purified 
DNA was electroporated into SR320 E. coli cells for the synthesis of double-stranded phagemid 
DNA. The phagemid DNA library was extracted from SR320 cells using the DNA mini-
preparation kit (Qiagen). To remove non-mutated template DNA, 20 µg of the phagemid DNA 
library was digested with NotI (New England Biolabs) according to manufacturer’s instructions. 
DNA from the NotI-digestion reaction was purified using the PCR cleanup kit (Qiagen) and 10 
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µg of purified library DNA was electroporated into M13KO7-infected SR320 E. coli cells for 
phage production (described in Section 4.3). Phages were purified from the culture supernatant, 
resuspended in PBS and stored at -80 °C in the presence of protease inhibitors (2%) and sterile 
glycerol (25%). Phages from 20 sub-libraries were rescued separately and equal number of 
phages from each sub-library (~5´1013 PFU) was mixed together to create the master library.  
4.5.2 The Modified-F long-CDR library 
The template phagemid for constructing the modified F library was derived from the 
pHP153 phagemid encoding the anti-maltose binding protein Fab (Persson et al., 2013). Kunkel 
mutagenesis was used to replace CDRL3, CDRH1, CDRH2 and CDRH3 regions of the 
phagemid with TAA stop codons. The resulting phagemid was sequence verified and used as the 
template phagemid. The modified-F library was constructed and stored using previously 
established protocols (Fellouse and Sidhu, 2006; Rajan and Sidhu, 2012). Kunkel mutagenesis 
was used to simultaneously diversify four CDR regions (L3, H1, H2 and H3) within the template 
phagemid (diversity design explained in Section 5.2.3). CDRs L3, H1 and H2 were diversified 
using library-F mutagenic oligonucleotides. CDRH3 was diversified using 17 JH4-CDRH3 
library-F mutagenic oligonucleotides and 10 JH6-CDRH3 library-S mutagenic oligonucleotides 
(Appendix 4). Eight different mutagenesis reactions were required for constructing the modified-
F library, each reaction representing a set of CDRH3 lengths. DNA from the mutagenesis 
reaction was purified using the PCR cleanup kit (Qiagen) and 10 µg of purified DNA was 
electroporated into M13KO7-infected SR320 E. coli cells for phage production. Phages were 
purified from the culture supernatant, resuspended in PBS and stored at -80 °C in the presence of 
protease inhibitors (2%) and sterile glycerol (25%). Phages from eight sub-libraries were rescued 
separately and equal number of phages from each sub-library (~5´1013 PFU) was mixed together 
to create the master library.  
4.5.3 The EGFR domain II structure-guided Fab library 
The pHP153 phagemid encoding the anti-maltose binding protein Fab (Persson et al., 
2013) was used as the template phagemid for constructing the EGFR domain II structure-guided 
Fab library. A CDRH3 mutagenic oligonucleotide was designed to possess the EGFR 
dimerization loop graft (84 bp) with one additional NNC codon flanking the 3¢ and 5¢	 ends of the 
graft. CDRs L3, H1 and H2 were diversified using library-F mutagenic oligonucleotides 
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(Appendix 5). Kunkel mutagenesis was used to simultaneously diversify four CDR regions (L3, 
H1, H2 and H3) within the template phagemid to encode the amino acid composition shown in 
Figure 5.16. The mutagenesis reaction was electroporated into M13KO7-infected SR320 E. coli 
cells for phage production as described previously (Fellouse and Sidhu, 2006; Rajan and Sidhu, 
2012). Phages were purified from the culture supernatant, resuspended in PBS and stored at -80 
°C in the presence of protease inhibitors (2%) and sterile glycerol (25%). 
4.6 Phage Display Selections  
Solid-phase panning of phage-displayed Fab libraries was conducted according to 
previously established protocols (Fellouse and Sidhu, 2006; Rajan and Sidhu, 2012). 
Recombinant Fc-tag fused human full-length extracellular domains from Notch-1, Notch-2, 
Notch-3, Jagged-1, Jagged-2 and EGFR proteins were purchased from R&D Systems and used 
as selection targets. Phages were precipitated from the frozen master library and resuspended in 
PBS containing 0.5% BSA and 0.05% Tween (PBT). Target and Fc proteins were immobilized 
on Maxisorp plates (Nunc) at 5 µg/mL by overnight incubation at 4 °C. Target wells were 
subsequently blocked with PBS containing 0.5% BSA (PB) for 90 min at RT before washing 
four times with PBS containing 0.05% Tween (PT). Library phage solution (1013 PFU/mL) was 
added to Fc wells and incubated for 90 min at RT to remove phage with affinity for the Fc-tag. 
The depleted library was transferred to target wells and incubated for 2 hrs at RT. The plate was 
washed 8X with PT buffer and phages bound to target wells were eluted with 100 mM HCl. The 
pH of the eluted phage solution was neutralized with 1 M Tris (pH 8), and used to infect 10 
volumes of actively growing XL1-Blue cells in 2YT media supplemented with 5 µg/mL 
tetracycline. Cultures was incubated for 30 min at 37 °C with shaking at 200 rpm. M13KO7 
helper phage was added to the culture to a final concentration of 1010 PFU/mL and incubated for 
another 45 min. Cultures were transferred to 25 volumes of 2YT media supplemented with 100 
µg/mL carbenicillin and 25 µg/mL kanamycin and incubated overnight at 37 °C with shaking at 
200 rpm. Phages were precipitated and purified from the culture supernatant, and used for 
subsequent rounds of selection. Also, before the helper phage addition step, 10 µL of phage-
infected E. coli culture was plated as individual colonies on 2YT-carbenicillin plates for 
determining the titer of the eluted phage, and for isolation and sequencing of phagemid DNA. 
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The enrichment in the selection process is measured by comparing the phage titers eluted from 
the target protein and control proteins. 
4.7 Affinity Maturation of Fab DL06 
To improve the affinity of Fab DL06, an affinity maturation library was first constructed 
by soft-randomization of the CDRH3 graft in the DL06 Fab-encoding phagemid using Kunkel 
mutagenesis. CDRH3 was soft randomized using a mutagenic oligonucleotide in which codons 
encoding for the dimerization loop (excluding Cys240 and Cys267) were replaced with a mixture 
comprising 85% of the wild-type base and 5% of each of the other three bases. DNA from the 
mutagenesis reaction was electroporated into M13KO7-infected SR320 E. coli cells for phage 
production. Phages were purified from the culture supernatant, and used for solid-phase 
selections against immobilized Fc-tagged EGFR-ECD as described in section 4.6. To obtain Fabs 
with improved affinity, concentrations of Fc-tagged EGFR-ECD were decreased in successive 
rounds of selection from 5 to 0.5 µg/mL and single clones were isolated for evaluation by Phage-
ELISA. Fab clones deemed EGFR-specific by phage-ELISA (target to control protein binding 
signal ratio >10) were sequenced and characterized by multi-point ELISA.  
4.8 Ion Torrent Sequencing  
Ion Torrent sequencing was accomplished by the following steps: PCR amplification of 
CDR, emulsion PCR on Ion sphere particles (ISPs) and sequencing enriched ISPs on an Ion 
semiconductor chip (Rothberg et al., 2012). To PCR amplify the CDR of interest; we designed 
primers that hybridize to the fixed framework regions of the phagemid that flank the CDR 
region. The primers contain barcodes for multiplexing purposes and adapter sequences to 
facilitate emulsion PCR (Appendix 6). We amplified the CDR of interest using designed primers, 
checked the purity, concentration and length of PCR products on a 2100 bio-analyzer (Agilent 
Technologies), prepared the template for emulsion PCR by pooling multiple PCR products, 
performed emulsion amplification of the amplicon library on the Ion OneTouch 2 instrument 
(Life Technologies), loaded the enriched ISPs into an Ion Semiconductor chip, and sequenced 
the loaded ISPs on the V2 Ion Personal Genome Machine (PGM) (Thermo-Scientific) according 
to manufacturer’s instructions.  
Ion Torrent sequencing of one diversified CDR was accomplished in three steps. (1) The 
CDR of interest was PCR amplified from phage selection pools using barcoded Forward and 
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reverse primers (Appendix 6). The PCR reaction mix (50 µL) contained 32.5 µL of nuclease-free 
H2O, 10 µL of 5X Phusion High-Fidelity buffer (New England BioLabs), 1 µL of dNTP mix (10 
mM of each nucleotide), 1 µL of phage solution (1012 PFU/mL), 2.5 µL of 10 µM Forward 
primer, 2.5 µL of 10 µM Reverse primer and 0.5 µL of Phusion Hot-Start Flex DNA Polymerase 
(New England BioLabs). The reaction mix was subjected to PCR using the following conditions: 
initial denaturation at 98 °C for 30 sec, 25 amplification cycles each consisting of a denaturing 
step at 98 °C for 10 sec, an annealing step at 56 °C for 10 sec, and an extension step at 72 °C for 
5 sec, and a final extension at 72 °C for 15 sec. (2) PCR amplicons were purified, quantified, 
multiplexed, and subjected to emulsion PCR using the Ion OneTouch template kit. (3) Enriched 
ISPs were loaded on an Ion 314 chip and sequenced using the Ion PGM supplies kit.  
Ion Torrent sequencing of the L3-H3 CDR strip was accomplished in six steps. (1) 
ssDNA was extracted from amplified phage selection outputs (1013 PFU) using the Spin M13 kit. 
(2) 500 ng of ssDNA was subjected to Kunkel mutagenesis for deleting the framework regions 
between diversified CDRs. In the mutagenesis reaction, one oligonucleotide, L3-H3 Seq 
(Appendix 6), was used to link the L3-H3 regions together. Phosphorylation of L3-H3 Seq, 
annealing of L3-H3 Seq to the ssDNA template, and in vitro synthesis of CCC-dsDNA were 
carried out as described in section 4.2. (3) DNA from the mutagenesis reaction was run on an 
agarose gel and the right-sized product (CCC-dsDNA) was excised and purified using a gel-
extraction kit (Qiagen). (4) The L3-H3 CDR strip was PCR amplified from the purified CCC-
dsDNA template using barcoded L3-Fwd and H3-Rev primers (Appendix 6). The PCR reaction 
mix (50 µL) contained 28.5 µL of nuclease-free H2O, 10 µL of 5X Phusion High-Fidelity buffer, 
1 µL of dNTP mix, 5 µL of CCC-dsDNA (50 ng), 2.5 µL of 10 µM L3-Fwd, 2.5 µL of 10 µM 
H3-Rev, and 0.5 µL of Phusion Hot-Start Flex DNA Polymerase. The reaction mix was 
subjected to PCR using the following conditions: initial denaturation at 98 °C for 30 sec, 25 
amplification cycles each consisting of a denaturing step at 98 °C for 10 sec, an annealing step at 
56 °C for 10 sec, and an extension step at 72 °C for 5 sec, and a final extension at 72 °C for 15 
sec. (5) PCR amplicons were purified, quantified, multiplexed and subjected to emulsion PCR 
using the Ion PGM Template OT2 200 kit. (6) Enriched ISPs were loaded on an Ion 314 Chip 
and sequenced using the Ion PGM Sequencing 200 V2 kit. 
Ion Torrent sequencing of the L3-H1-H2-H3 CDR strip was accomplished in six steps. 
(1) ssDNA was extracted from amplified phage selection outputs (1013 PFU) using the Spin M13 
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kit. (2) 500 ng of ssDNA was subjected to Kunkel mutagenesis for deleting the framework 
regions between four diversified CDRs. In the mutagenesis reaction, three oligonucleotides (L3-
H1 Seq, H1-H2 Seq, H2-H3 Seq, were used to link the L3-H1-H2-H3 regions together 
(oligonucleotide sequences in Appendix 6). Phosphorylation of oligonucleotides, annealing of 
oligonucleotides to the ssDNA template, and in vitro synthesis of CCC-dsDNA were carried out 
as described in section 4.2. (3) DNA from the mutagenesis reaction was run on an agarose gel 
and the right-sized product (CCC-dsDNA) was excised and purified using a gel-extraction kit 
(Qiagen). (4) The L3-H1-H2-H3 CDR strip was PCR amplified from 50 ng of purified CCC-
dsDNA using barcoded L3-Fwd and H3-Rev primers (see reaction setup and conditions above). 
(5) PCR amplicons were purified, quantified, multiplexed and subjected to emulsion PCR using 
the Ion PGM Template OT2 400 kit. (6) Enriched ISPs were loaded on an Ion 314 Chip and 
sequenced using the Ion PGM Sequencing 400 kit. 
4. 9 NGS Data Processing and Analysis 
Sequencing flowgrams were base-called, and subsequently adapter regions were removed 
in the Ion Torrent server. Sequences were parsed by barcodes in the Geneious software (Kearse 
et al., 2012) and the following actions were performed on the resulting FASTQ files in the 
Galaxy server (Goecks et al., 2010; Blankenberg et al., 2010): (1) FASTQ quality trimmer (trims 
from 3’ end with a window size of 1 and step size of 1, trimming continues until the base has a 
quality score of 17 or greater); (2) FASTQ quality filter (filters and removes sequences that are 
smaller than the smallest possible CDR or have a combined quality score less than 17); (3) 
FASTQ to FASTA (removes the quality information from the file to allow analysis with 
downstream tools); (4) CDR clip filter (searches for a string of bases following the CDR of 
interest, sequences that contain the clipping sequence are retained, the clipping sequence and the 
three bases that follow it are retained, sequences that do not contain the clipping sequence are 
removed); (5) Translate (sequences are translated to amino acids); (6) FASTA to Tabular (file 
format is converted to allow analysis with downstream tools); (7) Frame-shift filter (searches for 
sequences that contain the four specified amino acids that follow the CDR of interest, sequences 
that do not contain these amino acids are removed); (8) Tabular to FASTA (file format is 
converted to allow analysis with downstream tools); (9) Reverse translate (reverse translates 
amino acids to nucleotides for downstream analysis); (10) Trim CDR clips (searches for and 
trims the sequences that immediately precede and follow the CDR of interest, sequences that do 
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not contain clips are removed); (11) Count sequences (this tool searches for and counts the 
number of template CDR sequences, sequences with stop codons, unique CDRs and determines 
their relative frequencies); and (12) Output Tabular and FASTA files (the Galaxy server outputs 
Tabular and FASTA files for further analysis). Further NGS analyses were conducted using 
Excel (Microsoft), Geneious (Kearse et al., 2012), WebLogo (Crooks et al., 2004), and R (R 
Core Team, 2013) platforms.  
4.10 Expression and Purification of Fabs 
Fab sequences were sub-cloned from the phagemid vector into a modified pCW-LIC Fab 
expression vector (plasmid map in Appendix 2) using standard molecular biology procedures. 
Briefly, Fab sequences were amplified from phagemids by PCR, and ligated into the SacI/XhoI-
digested pCW-LIC vector using Gibson assembly (Gibson et al., 2009). The Fab expression 
plasmid was sequence verified and electroporated into BL21 E. coli cells. Transformed E. coli 
cells were grown to mid-log phase in 2YT media supplemented with 100 µg/mL carbenicillin. 
The starter culture (4 mL) was transferred into 400 mL of Overnight Express Terrific Broth (TB) 
auto-induction medium (EMD Millipore) supplemented with 100 µg/mL carbenicillin and 
incubated for 18 hrs at 25 °C with shaking at 200 rpm. Cells were pelleted by centrifugation, and 
lysed in protein-L binding buffer (20 mM Na2HPO4, 0.15 M NaCl, pH 8) containing 1:100 
dilution of protease inhibitor cocktail (sigma) using a cell disruptor (Constant Systems). Clarified 
supernatant was loaded into a Protein-L column (GE healthcare) and washed with 10 column 
volumes of Protein-L binding buffer (AKTA prime plus). Fabs were eluted with IgG elution 
buffer (Thermo-Scientific) and neutralized with 1 M Tris-HCl (pH 9). Eluted Fabs were dialyzed 
against PBS and stored at -20 °C. Fab purity was verified using 2100 bio-analyzer (Agilent 
Technologies) and Fab concentration was determined by UV-visible spectrometry. 
For high-throughput Fab expression and purification, Fab sequences were sub-cloned 
from the phagemid vector into the pCW-LIC Fab expression vector in 96-well format. To 
eliminate the use of Sanger sequencing, Gibson assembly reactions were directly electroporated 
into BL21 E. coli cells, and three colonies from each reaction were screened for Fab expression 
using bio-layer interferometry in 96-well format. Briefly, single colonies were transferred to 1 
mL of TB auto-induction medium supplemented with 100 µg/mL carbenicillin in 96-well deep 
well boxes, and incubated for 18 hrs at 25 °C and 200 rpm. Cells were pelleted by centrifugation 
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and lysed with 200 µL of B-PER bacterial protein extraction reagent (Pierce). Cells were 
centrifuged again, and 50 µL of the clarified supernatant was transferred to 384-well plates. Fab 
expression was detected using anti-Fab CH1 biosensors and anti-HIS biosensors in the Octet 
RED384 system (ForteBio) according to manufacturer’s instructions. Positive clones were 
transferred into 30 mL of TB auto-induction medium supplemented with 100 µg/mL 
carbenicillin, and incubated for 18 hrs at 25°C with shaking at 200 rpm. Cells were pelleted by 
centrifugation, and lysed in protein-L binding buffer supplemented with protease inhibitors using 
a cell disruptor. Clarified supernatant was incubated with 200 µL of Protein-L resin (GenScript) 
for 1 hr at 4 °C on a nutator. The Protein-L resin was collected by centrifugation and washed 5X 
with Protein-L binding buffer. Fabs were eluted with IgG elution buffer and neutralized with 1 M 
Tris-HCl (pH 9). Eluted Fabs were dialyzed against PBS and stored at -20 °C. Fab purity was 
verified using 2100 bio-analyzer and Fab concentration was determined by UV-visible 
spectrometry.  
For purification of biotinylated Fabs, Fab sequences were sub-cloned into RH2.2 Fab 
expression vector using standard restriction enzyme cloning procedures. The vector contains an 
Avi tag (GGGLNDIFEAQKIEWHE) at the C-terminus of the Fab heavy chain. Expression 
constructs were sequence verified and electroporated into BL21 E. coli cells previously 
transformed with a biotin ligase-encoding plasmid. Single clones were grown to mid-log phase in 
2YT media supplemented with 100 µg/mL carbenicillin and 5 µg/mL chloramphenicol. Fabs 
were expressed in TB auto-induction media supplemented with the same selection antibiotics 
plus 25 mM biotin. Fabs were purified, quantified and stored as described previously.  
4.11 Enzyme-linked immunosorbent assays 
Phage-ELISA was performed to check the binding of phage-displayed Fabs to 
immobilized target proteins. The phagemid-encoding Fab was electroporated into M13KO7-
infected electrocompetent SR320 E. coli cells for phage production. The cells were rescued with 
pre-warmed SOC media and incubated for 30 min at 37 °C. The culture was transferred to 30 mL 
of 2YT media supplemented with 100 µg/mL carbenicillin and 25 µg/mL kanamycin and 
incubated overnight at 37 °C with shaking at 200 rpm. Phages were precipitated from the culture 
supernatant using 6 ml of ice-cold PEG/NaCl solution, resuspended in PBT buffer, and 
quantified using UV spectrometry. 
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To conduct phage-ELISA, target and control proteins were immobilized at 5 µg/mL on 
Maxisorp plates (Nunc) by overnight incubation at 4 °C. The wells were subsequently blocked 
with PB buffer for 90 min at RT before washing four times with PT buffer. Wells were then 
exposed to PBT-diluted phage solution (1012 PFU/mL) for 30 min, washed 8X with PT buffer, 
and then incubated with a 1:3000 dilution of HRP-conjugated anti-M13 antibody (GE healthcare) 
for 30 min at RT. Plates were washed again 6X with PT buffer and 2X with PBS. Wells were 
developed with 3,3¢,5,5¢-tetramethylbenzidine (TMB) substrate for 5 min, and quenched with 
equal volume of 1 M H3PO4. The plates were read at 450 nm using a SpectraMax 340PC plate 
reader (Molecular devices). 
Fab-ELISA was performed to check the binding of purified Fabs to immobilized target 
proteins. Proteins were immobilized at 5 µg/mL on Maxisorp plates (Nunc) by overnight 
incubation at 4 °C. The wells were subsequently blocked with PB buffer for 90 min at RT before 
washing 4X with PT buffer. Wells were then exposed to 100 µL of Fab solution diluted in PT for 
30 min, washed 10X with PT buffer, and then incubated with a 1:3000 dilution of HRP-
conjugated anti-His antibody (Rockland Biosciences) for 30 min at RT. Plates were washed 
again 6X with PT buffer and 2X with PBS. Wells were developed with TMB substrate for 5 min, 
and quenched with equal volume of 1 M H3PO4. The plates were read at 450 nm using a 
SpectraMax 340PC plate reader (Molecular devices). Single-point Fab-ELISA was used to assess 
Fab specificity, and multi-point Fab-ELISA was used to calculate the EC50 for Fab binding to the 
immobilized target. In multi-point Fab ELISA, ABS450 values were obtained for a range of Fab 
concentrations and EC50 was calculated by fitting the data to the one-site specific-binding 
equation in Prism (Graphpad). 
4.12 Analysis of Fab Binding Kinetics 
The ForteBio Octet RED384 system (Pall Corporation) was used to measure the binding 
kinetics between purified Fabs and target proteins. Fabs were immobilized on amine-reactive 
generation-2 biosensors (for KD <5 nM) or anti-Fab CH1 biosensors (for KD >5 nM) according to 
manufacturer’s instructions. Immobilized Fabs were exposed to increasing concentrations of 
target proteins, and association and dissociation rates were measured by the shift in wavelength 
(nm). All reactions were performed at 25 °C in PBS. For each sensor-immobilized Fab, at least 
four different target protein concentrations were used, and KD (equilibrium dissociation constant) 
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was obtained by fitting the data to 1:1 binding model. Data processing and curve fitting were 
performed using the Octet Software (ForteBio). 
4.13 Characterization of Anti-EGFR Fabs and Competition Assays 
Fab-ELISA was used to test the specificity of anti-EGFR Fabs (DL06 and H) against the 
ErbB family receptors. Recombinant Fc-tagged ectodomains of ErbB proteins were immobilized 
on Maxisorp plates at 5 µg/mL by overnight incubation at 4 °C. Wells were blocked, washed and 
incubated with anti-EGFR Fabs (100 nM) for 30 min at RT. Plates were washed and incubated 
with 400 nM of HRP-conjugated anti-FLAG secondary antibody (Sigma) for 30 min at RT. 
Plates were washed, developed and read at 450 nm as described previously. 
To measure relative contributions of diversified CDRs in Fab-DL06 towards EGFR 
binding, we back-mutated sequences of each diversified CDR in Fab-DL06 to the corresponding 
anti-MBP Fab CDR and evaluated the binding of these Fabs to EGFR-ECD by Fab-ELISA. First, 
each diversified CDR in the DL06-encoding RH2.2 Fab expression vector was mutated to anti-
MBP CDR using Kunkel mutagenesis. CDR-mutated Fab-DL06 expression plasmids were 
sequence-verified and electroporated into BL21 E. coli cells. CDR-mutated DL06 Fabs were 
expressed and purified as described previously. To conduct Fab-ELISA, EGFR-ECD was 
immobilized on Maxisorp plates by overnight incubation at 4 °C. Wells were blocked, washed 
and incubated with WT and CDR-mutated DL06 Fabs (250nM) for 30 min at RT. Plates were 
washed and incubated with 400 nM of HRP-conjugated anti-FLAG secondary antibody (Sigma) 
for 30 min at RT. Plates were washed, developed and read at 450 nm as described previously. 
Competitive-ELISA was used to test whether Fab-DL06 and Fab-H compete with each 
other for binding EGFR-ECD. The assay was performed using purified Fabs in both non-
biotinylated and site-specifically biotinylated formats (BT-Fab). EGFR-ECD was immobilized 
on Maxisorp plates by overnight incubation at 4 °C. Wells were blocked, washed and incubated 
with a saturating concentration of Fab-DL06 (50 µg/mL)	 for 30 min, followed by direct addition 
of BT-Fab-H at a sub-saturating concentration (100 ng/mL). The assay was also conducted in the 
opposite configuration in which EGFR-ECD-coated wells were incubated with a saturating Fab-
H concentration (50 µg/mL)	 for 30 min, followed by direct addition of BT-Fab-DL06 at a sub-
saturating concentration (250 ng/mL). Plates were incubated for 30 min, washed, and binding of 
BT-Fab to EGFR-ECD was detected using 0.1 µg/mL of HRP-conjugated streptavidin prepared 
in PBT. Plates were washed, developed and read at 450 nm as described previously. 
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Competitive-ELISA was also used to test whether anti-EGFR mAbs block the binding of 
Fab-DL06 and Fab-H to EGFR-ECD. EGFR-ECD was immobilized on Maxisorp plates, 
blocked, washed and incubated with anti-EGFR antibodies at a saturating concentration (65 nM) 
for 30 min at RT. Anti-EGFR Fabs were added to the wells containing the EGFR-antibody 
complex and incubated for 30 min at RT. Plates were washed and incubated with 400 nM of 
HRP-conjugated anti-FLAG secondary antibody (Sigma) for 30 min at RT. Plates were washed, 
developed and read at 450 nm as described previously. 
Phage-ELISA was used to test whether phage-displayed EGFR domain III binds to anti-
EGFR Fabs and antibodies (Tundidor et al., 2014). To display EGFR domain III on phages, we 
sub-cloned EGFR domain-3 (residues 311-514) into the pHP153 phagemid using Gibson 
assembly (Gibson et al., 2009). Following sequence verification, the EGFR domain III phagemid 
was electroporated into M13KO7-infected SR320 E. coli cells for phage production. Phage was 
precipitated, purified and quantified as described previously. Fabs, antibodies and control 
proteins were immobilized on Maxisorp plates at 5 µg/mL by overnight incubation at 4 °C. The 
wells were blocked, washed and incubated with PBT-diluted EGFR domain III phage solution 
(1012 PFU/mL) for 30 min.  The wells were washed and incubated with a 1:3000 dilution of 
HRP-conjugated anti-M13 antibody for 30 min at RT. Plates were washed, developed and read at 
450 nm as described previously. 
4.14 Flow Cytometry and Epitope Mapping Studies 
Flow cytometry was used: (1) to obtain EC50 values for anti-EGFR Fabs and mAbs 
binding to cell-surface EGFR; (2) to test the influence of EGF and anti-EGFR mAbs on the 
binding of anti-EGFR Fabs to cell-surface EGFR; and (3) to test the binding of anti-EGFR Fabs 
and mAbs to cell-surface EGFR mutants and truncations. Two cell lines were used in this work: 
HEK293F cells transiently transfected with EGFR and A431 cells that endogenously express 
EGFR. HEK293F cells were maintained in suspension in Freestyle 293 expression media at 37 
°C and 5% CO2 with shaking at 125 rpm. A431 cells were maintained as monolayer cultures in 
90% Eagle's minimum essential media with Earle's balanced salt solution (EMEM/EBSS) and 
10% fetal bovine serum (FBS) at 37 °C and 5% CO2. Cells were cultured until 80-90% 
confluent, and passaged every 3-4 days. For overexpressing EGFR in HEK293F cells, we used 
an EGFR plasmid (Addgene) that encodes for full-length human EGFR fused to green 
fluorescent protein (GFP) at its C-terminus (Carter and Sorkin, 1998).  
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To transfect HEK293F cells, 1.5 X 106 cells were transferred from flasks to 10 cm plates 
containing 10 mL Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS, 
and maintained at 37 °C and 5% CO2. On the day prior to transfection, cells were transferred to 
10 mL serum-free DMEM and maintained under the same conditions. For transfection, 10µg of 
plasmid DNA was added to a mixture of 36 µL polyethylenimine (1mg/mL pH 7.5) and 540 µL 
warm optimal-minimal essential medium, and incubated at RT for 30 minutes, before drop-wise 
addition to plates containing HEK293F cells.  Plates were incubated for 24 hrs at 37 °C and 5% 
CO2. Media was changed to DMEM with 10% FBS and expression was allowed to proceed for 
another 24 hrs.  
To obtain EC50 values for anti-EGFR Fabs binding to cell-surface EGFR, EGFR-
expressing HEK293F or A431 cells were split into equal fractions (~2X105 cells) and incubated 
with different concentrations of 100 µL Fab-DL06 or Fab-H prepared in PBS for 1 hr at 4 °C. 
Cells were washed with PBS, and incubated with 100 µL of PE-conjugated anti-FLAG mouse 
secondary antibody (1:5000 dilution, Prozyme) in the dark on ice for 30 min with occasional 
mixing. Flow cytometric analysis of binding was conducted on a MACSQuant VYB flow 
cytometer (Miltenyi-Biotec). A minimum of 103 cell events was acquired for each Fab 
concentration. GFP fluorescence was used to quantify EGFR expression and PE fluorescence 
was used to quantify Fab binding to cells. PE-labeled cells were compared to un-stained control 
cells or cells labeled only with the secondary antibody. The proportion of PE-positive cells was 
determined from the subpopulation of high-GFP expressing cells (~50%) using the FlowJo 
Software. To obtain binding curves and affinity estimates, log [Fab] was plotted vs. %PE-
positive cells and fit using the log [inhibitor] vs. response equation with standard fit in Prism 
(Graphpad). 
To obtain EC50 values for anti-EGFR mAbs binding to cell-surface EGFR, EGFR-
expressing HEK293F cells were split into equal fractions (~2X105 cells) and incubated with 
different concentrations of 100 µL anti-EGFR mAb prepared in PBS for 1 hr at 4 °C. Cells were 
washed with PBS, stained with 100 µL of PE-conjugated goat anti-human IgG secondary 
antibody (1:400 dilution, Beckman Coulter), and analyzed by flow cytometry as described 
previously. 
To test the influence of EGF on anti-EGFR Fabs binding to cell-surface EGFR, EGFR-
expressing HEK293F cells were harvested, incubated with 10 nM EGF for 15 min at 4 °C, split 
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into aliquots of ~5 X 105 cells, and incubated with serial dilutions of either Fab-DL06 or Fab-H 
for 1 hr on ice with occasional gentle swirling. Cells were washed with PBS, stained with the 
PE-conjugated anti-FLAG secondary antibody, and analyzed by flow cytometry as described 
previously.  
To test the influence of anti-EGFR mAbs (CTX and PMB) on Fab-DL06 and Fab-H 
binding to cell-surface EGFR, EGFR-expressing HEK293F cells were harvested, incubated with 
5 nM CTX or PMB for 15 min at 4 °C, split into aliquots of ~5 X 105 cells, and incubated with 
serial dilutions of either Fab-DL06 or Fab-H for 1 hr on ice with occasional gentle swirling. 
Cells were washed with PBS, stained with the PE-conjugated anti-FLAG secondary antibody, 
and analyzed by flow cytometry as described previously.  
To conduct epitope mapping of anti-EGFR Fabs, we generated EGFR mutants by Kunkel 
mutagenesis, and tested the binding of anti-EGFR Fabs to mutant EGFR constructs by flow 
cytometry. The EGFR-GFP plasmid encodes full-length human EGFR comprising the 
extracellular domains (residues 1-622), the transmembrane domain (residues 622-644) and the 
intracellular kinase domain (residues 644-697). WT-EGFR was expressed using this construct 
without any modifications. The presence of f1 origin in the plasmid facilitated the isolation of 
template dU-ssDNA using CJ236 E. coli cells. Mutations were introduced via annealing, 
extension and ligation of phosphorylated mutagenic oligonucleotides on the EGFR-GFP dU-
ssDNA template using Kunkel mutagenesis as described previously (Tonikian et al., 2007; 
Nelson and Sidhu, 2012). The following EGFR mutants were generated: an EGFR double mutant 
(Y251A + R285S), the EGFR dimerization loop deletion mutant (Δ240-267), and the EGFR vIII 
mutant (Δ6-274). The following single and multi-domain constructs were also generated: D1 
(residues 1-162), D2 (residues 163-311), D3 (residues 312-480), D4 (residues 481-614), D1-D2 
(residues 1-311), D2-D3 (residues 163-480), D3-D4 (residues 312-614), D1-D2-D3 (residues 1-
480) and D2-D3-D4 (residues 163-614). EGFR residues 615-1186 (comprising the extracellular 
linker- transmembrane- intracellular linker- kinase domain- C-terminus tail) and the GFP region 
were not manipulated. All new EGFR constructs were sequence verified, amplified in DH10B E. 
coli cells, and used for transfecting HEK293F cells. To test the binding of anti-EGFR Fabs to 
EGFR mutants, cells were split into equal fractions, incubated with different concentrations of 
100 µL anti-EGFR Fab, washed with PBS, stained with the PE-conjugated anti-FLAG secondary 
antibody, and analyzed by flow cytometry. To test the binding of anti-EGFR mAbs to EGFR 
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mutants, cells were split into equal fractions, incubated with different concentrations of 100 µL 
anti-EGFR mAb, washed with PBS, stained with the PE-conjugated goat anti-human IgG 
secondary antibody, and analyzed by flow cytometry.  
4.15 EGFR Signaling Assays 
Western analysis was used to evaluate the effects of anti-EGFR Fabs on EGF-induced 
receptor phosphorylation in A431 cells and MDA-MB-231 cells. A431 cells were cultivated until 
80-90% confluent in 90% RPMI medium supplemented with 10% FBS at 37 °C and 5% CO2. 
MDA-MB-231 cells were cultivated until 80-90% confluent in 90% DMEM medium 
supplemented with 10% FBS at 37 °C and 5% CO2. Growth medium was replaced with pre-
warmed serum-free medium and incubated for 24 hrs. Serum-starved A431 and MDA-MB-231 
cells were pre-treated with various concentrations of Fabs in serum-free media and incubated at 
37 °C for 1 hr. Cells were stimulated with 50 ng/mL EGF for 15 min in the presence of Fabs. 
Cells were washed 2X with cold PBS and collected by scraping with 200 µL of lysis buffer and 
10 µL of protease/phosphatase inhibitors. Cells were sonicated 2X and cell debris was removed 
by centrifugation. A 20 µL aliquot of cleared lysate was mixed with 4X loading buffer, separated 
by electrophoresis on a 4-20% SDS-PAGE gel, and transferred to a PVDF membrane using 
standard methods. Blots were blocked with 5% BSA overnight, and incubated with 1:1000 
dilution of rabbit polyclonal anti-phospho-EGFR Tyr1173 antibody (Cell Signaling) or rabbit 
polyclonal anti-EGFR antibody (Cell Signaling) for 24 hrs. Blots were washed 3X with PT 
buffer, and incubated with a 1:5000 dilution of anti-rabbit-HRP secondary antibody (Santa Cruz) 
for 30 min. Blots were developed with a chemiluminescent substrate (Thermo Scientific) and 
exposed to CL-XPosure radiography film (Thermo Scientific) for 1 min. Intensity of bands were 
quantified using the ImageLab software (Bio-Rad). 
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5. RESULTS AND DISCUSSION 
This chapter is divided into three sections. Section 5.1 is entitled “A platform for high-
throughput reconstruction of synthetic antibody fragments from phage selection outputs”. In this 
section, we describe the design, construction and validation a new single-framework synthetic 
Fab library, named library-S. We developed a method for linking and sequencing all diversified 
CDRs in phage Fab pools by Ion Torrent sequencing. We showed that low-frequency rare clones 
reconstructed from NGS information could possess higher affinity and better specificity than 
high-frequency top clones isolated by Sanger sequencing. Section 5.2 is entitled “Systematic 
generation of synthetic antibody fragments with optimal CDR lengths for Notch-1 recognition”. 
In this section, we tested the potential of two single-framework synthetic Fab libraries to 
generate Fabs with high affinity and specificity for Notch-1. Over the course of Fab generation, 
we also showed that implementing NGS approaches, screening focused diversity libraries, fine-
tuning the library diversity and making small changes to diversity designs can improve the 
success rate of single-framework synthetic Fab libraries. Section 5.3 is entitled “Generation and 
validation of anti-EGFR Fabs from naïve and structure-guided synthetic antibody libraries”. In 
this section, we describe the design and construction of a structure-guided Fab library that was 
biased towards interacting with EGFR domain-II. We isolated two anti-EGFR Fabs, one from the 
structure-guided synthetic Fab library, and one from a previously described naïve synthetic Fab 
library. We characterized both anti-EGFR Fabs in terms of affinity, specificity, activity and 
binding site location. The motif-grafting project described in section 5.3 is a collaboration 
between the Geyer lab at the University of Saskatchewan and the Sidhu lab at the University of 
Toronto. Contributions of other researchers towards this PhD thesis are included in Appendix 7.  
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5.1 A Platform for High-Throughput Reconstruction of Synthetic Antibody Fragments 
from Phage Selection Outputs 
The objective of this section is to develop an NGS-assisted antibody discovery platform 
by integrating phage-displayed single-framework synthetic Fab libraries with Ion Torrent 
sequencing. To accomplish this, we first developed a method for linking and sequencing all 
diversified CDRs in phage Fab pools without losing the CDR pairing information. Second, we 
designed and constructed a new phage-displayed single-framework synthetic Fab library, named 
library-S. Third, we analyzed library-S quality by Ion Torrent sequencing and validated its 
functionality by generating high-affinity Fabs against Jagged-1 and Jagged-2. Fourth, we 
validated the NGS-assisted Fab reconstruction platform by reconstructing and testing low-
frequency rare clones from phage selection outputs. While previous studies chose rare clones for 
rescue based on their relative frequencies in sequencing outputs, we chose rare clones for 
reconstruction from less-frequent CDRH3 lengths. In some cases, reconstructed rare clones 
(frequency ~0.1%) showed higher affinity and better specificity than high-frequency top clones 
isolated by Sanger sequencing. 
5.1.1 Integrating Antibody Phage Display with Ion Torrent Sequencing 
Ion Torrent sequencing consists of three basic steps: (1) PCR amplification of a short 
region of interest, (2) emulsion PCR on proprietary Ion sphere particles (ISPs); and (3) 
sequencing enriched ISPs on an Ion semiconductor chip (Rothberg et al., 2012). Ion Torrent 
chips offer three different read lengths (100, 200 or 400 bp). To sequence a CDR of interest, we 
used 100 bp chips. For example, to amplify CDRH3 from phage pools, we designed primers that 
hybridize to the fixed framework regions of the phagemid that flank the CDRH3 region. We 
introduced barcodes into the forward primer for multiplexing different samples in one run. The 
forward and reverse primers also contained adapter sequences to facilitate emulsion PCR. A 
truncated P1 (trP1) adapter in the reverse primer hybridizes to a complimentary trP1 sequence on 
ISPs, and an A-adapter in the forward primer contains a starting sequence for the synthesis of 
complimentary DNA during emulsion PCR. We amplified the CDR of interest from selection 
outputs using designed primers, performed emulsion amplification of the amplicon library on Ion 
sphere particles (ISPs), and sequenced the enriched ISPs on a 100 bp Ion semi-conductor chip. 
The strategy for sequencing a CDR of interest is illustrated in Figure 5.1. We built a custom
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Figure 5.1: Workflow for CDRH3 Ion Torrent sequencing. The CDRH3 region is PCR 
amplified from phage pools using primers containing barcodes (for multiplexing) and adaptors 
(for emulsion PCR). Amplified DNA is subjected to emulsion PCR for clonal amplification of 
individual DNA molecules on Ion sphere particles (ISPs). Following emulsion PCR, each ISP 
contains up to a million copies of a one short DNA of interest. Enriched ISPs are loaded into an 
Ion semiconductor chip that contains millions of micro-wells. Each well takes up an enriched 
ISP and acts as a pH sensor. The chip is placed on the Ion personal genome machine (Ion PGM), 
which sequentially floods the chip with one nucleotide after another. When a nucleotide 
complements the DNA sequence in a particular well, DNA polymerase incorporates it to the 
growing strand. This results in the release of hydrogen ions and a change in pH of the well. An 
ion sensor detects this pH change and translates the chemical signal into a digital signal. 
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workflow for NGS data processing and analysis (see Section 4.9). In brief, base-called reads 
were parsed by barcodes, quality trimmed and filtered.  Filtered sequences were translated, 
identified, counted and analyzed in terms of length and amino acid distribution. 
Our libraries contain up to four diversified CDRs in a single fixed Fab-4D5 framework 
(Fellouse et al., 2007). The four diversified CDRs are only 200 bp in length combined together, 
which is shorter than the read length offered by the 400 bp Ion semiconductor chip. Therefore, 
we sought to link the diversified CDRs in phage pools next to each other by deleting the 
intervening framework regions, and sequence all four diversified CDRs as a CDR strip (L3-H1-
H2-H3) on a 400 bp chip. Since the template for framework deletion is phage-derived single-
stranded phagemid DNA (ssDNA), we chose to use Kunkel mutagenesis; a method that 
introduces site-directed mutations when ssDNA is converted into double-stranded DNA in vitro 
(Kunkel et al., 1987). The overall strategy for CDR strip generation and sequencing is illustrated 
in Figure 5.2. We generated two kinds of CDR strips using our method, L3-H3 and L3-H1-H2-
H3. Originally, we developed the method to generate L3-H3 strips from a library containing only 
two diversified CDRs (library-S), and to sequence them on a 200 bp chip. As the Ion Torrent 
sequencing technology improved, we extended our method to generate L3-H1-H2-H3 strips from 
a library containing four diversified CDRs (library-F), and to sequence them on a 400 bp chip. 
The oligonucleotides used in the Kunkel reaction are 30 bases long and anneal to the 3’ region of 
one CDR and the 5’ region of the adjacent CDR within the same ssDNA. For example, out of 30 
bases of the L3-H1 primer, 15 bases anneal to the 3’ region of CDRL3 and 15 bases anneal to the 
5’ region of CDRH1. One oligonucleotide was used to bring the L3-H3 regions together, and 
three oligonucleotides were used to bring the L3-H1-H2-H3 regions together. The mutagenesis 
reaction was run on an agarose gel, and the desired product was excised. The gel-purified 
product was then used as a template for PCR amplification of the CDR strip. Quantified, 
multiplexed amplicons were subjected to emulsion PCR and Ion Torrent sequencing.  
To reconstruct Fab clones from CDR strip sequencing information, we cloned desired 
CDR combinations into the Fab-4D5 encoding phagemid by Kunkel mutagenesis (Figure 5.3). A 
Fab-4D5 phagemid whose CDRs have been replaced with NotI sites was used as a template to 
reconstruct Fab clones. Primers were designed to encode for a desired CDR sequence and to 
hybridize to either side of the CDR. Two or four primers were used to reconstruct Fab clones 
from library-S or library-F selections, respectively. Following mutagenesis, the reaction was 
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Figure 5.2: Strategy for CDR strip generation and sequencing. Single-stranded DNA 
(ssDNA) rescued from round-3 phage pools is subjected to Kunkel mutagenesis for deleting the 
intervening framework regions between diversified CDRs. This step links the diversified CDRs 
next to each other (L3-H3 from library-S selections and L3-H1-H2-H3 from library-F selections) 
without losing the CDR pairing information. The right-sized product from the mutagenesis 
reaction is used as a template for PCR amplification of the CDR strip. Quantified, multiplexed 
amplicons are subjected to emulsion PCR and Ion Torrent sequencing. L3-H3 and L3-H1-H2-H3 
strips are sequenced on 200 bp and 400 bp chips, respectively.  
 
transformed into E. coli and positive clones were screened by NotI digestion. It is worth noting 
the differences between Kunkel reactions used in Figures 5.2 and 5.3. The first Kunkel reaction 
was used to link the diversified CDRs together with fixed primer sequences (ssDNA template 
was variable), and the second Kunkel reaction was used to reconstruct Fab phagemids using 
variable primers (ssDNA template was constant for all Fabs). The second one was a very typical
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Figure 5.3: Strategy for reconstructing Fab clones from NGS information. CDR strips (L3-
H3 or L3-H1-H2-H3) generated from round-3 phage pools are subjected to Ion Torrent 
Sequencing. Following NGS analysis, desired CDR combinations are reconstructed by cloning 
CDR-encoding oligonucleotides into the Hu4D5 Fab-encoding template phagemid by Kunkel 
mutagenesis. 
 
Kunkel reaction; uracil-containing ssDNA was used as a template, and the mutagenesis reaction 
was transformed into E. coli to eliminate the undesired wild-type strand. Since ssDNA for the 
first reaction came from phage selection pools, it was not uracil-inserted, and the desired product 
(CCC-dsDNA) from the mutagenesis reaction was isolated by gel purification. 
5.1.2 Design of Synthetic Antibody Libraries F and S 
 We used two single-framework synthetic Fab libraries (F and S) for validating the NGS-
assisted Fab reconstruction platform.	 Library-F is a highly validated Fab library that has been 
used successfully against diverse kinds of targets (Persson et al., 2013; Hornsby et al., 2015; 
Zhong et al., 2015 and Na et al, 2016). It was built on the Hu4D5-8 Fab scaffold derived from 
the anti-Her2 antibody Herceptin. The Hu4D5-8 Fab framework is very stable (Tm 80°C) and is 
used by several approved antibody-based therapeutics (Na et al., 2016). The variable light and 
heavy chain germ lines present in the Hu4D5-8 Fab framework are Vκ1-1 and VH3-23, 
respectively, which are frequently seen in human antibody responses (Lee et al., 2004B).
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Figure 5.4: Library-F design: (A) Variable domains of the Hu4D5-8 Fab framework used for 
library construction. The top-down view of anti-MBP Fab (PDB entry: 3PNW) is shown in 
cartoon representation. Fixed CDRs are colored in pink and diversified CDRs are colored in 
orange. (B) CDR diversity design in library-F. Diversity was restricted to four CDRs (L3, H1, 
H2 and H3). Amino acids allowed at each CDR position are denoted by the single-letter code. X 
denotes any of the following nine amino acids introduced at different proportions: Y (25%), S 
(20%), G (20%), A (10%), F (5%), W (5%), H (5%), P (5%) or V (5%). The lengths of L3 and 
H3 are varied by altering the number of X. Variable (V), Diversity (D) and Joining (J) segments 
in CDRs L3 and H3 are indicated. The Kabat scheme is used for numbering amino acids.  	
Library-F diversity was restricted to three heavy-chain CDRs and CDRL3. In CDRs H1 and H2, 
solvent-accessible positions were randomized with binary degenerate codons that encode equal 
proportions of two amino acids, mostly Tyr and Ser. In CDRs L3 and H3, the central region 
(positions 91-94 encoded by the Vκ gene), and the diversity region (positions 95-99 encoded by 
the DH gene), respectively, were randomized using custom-made codon mixes that encoded pre-
defined proportions of nine amino acids. The joining segment regions within CDRs L3 and H3 
were also softly randomized to resemble the human Jκ4 and JH4 gene segments, respectively. 
The library contains 5 different CDRL3 lengths (from 8 to 12 residues) and 17 different CDRH3 
lengths (from 7 to 23 residues). The theoretical and actual diversities of library-F are ~1028 and 
~1010, respectively. The overall design of library-F is outlined in Figure 5.4.  
Library-S was designed to exist as a simplified and possibly more stable version of 
Library-F. To quickly prepare samples for NGS analysis, and to easily reconstruct Fabs from 
NGS information, we included only two diversified CDRs (L3 and H3) in the Hu4D5-8 Fab 
scaffold whereas library-F contains four diversified CDRs. It is easier and more efficient to link 
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two diversified CDRs together by Kunkel mutagenesis than linking four CDRs. Also, the 
CDRL3-CDRH3 pair from library-S selection outputs can be sequenced on 200 bp chips, and 
reconstruction of rare clones from library-S selections can be accomplished with only two 
oligonucleotides (for two CDRs). To increase the functional diversity of the library, four fixed 
CDRs were designed to preserve the most-frequent ‘canonical’ CDR conformation preferred by 
the Hu4D5 Fab scaffold. The library diversity was engineered within CDRL3 and CDRH3 using 
custom-designed trinucleotide phosphoramidite mixes and biased towards human antibody CDR 
diversities. To compensate for the reduction in CDRH1 and CDRH2 diversities, additional 
length, amino acid and joining-segment (JH) diversities were included within CDRH3. Further, to 
reduce the number of template sequences during library-S construction, we decided to replace 
the template phagemid CDRs with restriction enzyme sites, and to digest the library DNA after 
mutagenesis. NGS analysis of the naïve CDRH3 diversity of library-F indicated that the template 
phagemid used for library construction is retained in ~13% of the population (extended data- 
Figure 5.17B). 
Library-S contains four fixed CDRs (L1, L2, H1 and H2) and two diversified CDRs (L3 
and H3). We aligned 100 Vκ1 variable light chain sequences and 500 VH3 variable heavy chain 
sequences, and used the CDR consensus sequences to fix CDRs L1, L2, H1 and H2 in the 
Hu4D5-8 Fab framework (Figure 5.5). These CDR sequences correspond to the following 
canonical CDR conformations described by Chothia and coworkers (Al-Lazikani et al., 1997): 
L1-2A, L2-1, H1-1 and H2-3A, and the following canonical CDR conformations described by 
North et al in 2011: L1-11-1, L2-8-1, H1-13-1 and H2-10-2. We introduced three point 
mutations (A71R, T73N, and A78L) into the FRM3 region of the Hu4D5-8 Fab framework for 
proper display of H2-3A/ H2-10-2 CDRH2 canonical loop (Carter et al., 1992; Eigenbrot et al., 
1992; Knappik et al., 2000; North et al., 2011; Prassler et al., 2011; Tiller et al., 2013). The use 
of pre-defined CDR conformations in library design has been shown to improve the success rate 
and biophysical properties of synthetic Fab libraries (Rothe et al., 2008; Prassler et al., 2011; 
Tiller et al., 2013).  
Library diversity was included within CDRs L3 and H3. The CDRL3 length was fixed at 
nine amino acids. CDRL3 anchor residues (two at the N-terminus and three at the C-terminus of 
CDRL3) were fixed to favor the L3-9-cis7-1 canonical conformation (North et al., 2011). The 
central region (positions 91-94 encoded by the Vκ gene) was diversified using a custom-made
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Figure 5.5: Sequence logos used for designing fixed CDRs in library-S. Sequence 
conservation within (A) CDRL1, (B) CDRL2, (C) CDRH1, and (D) CDRH2 regions of Vκ1 (n = 
100) and VH3 (n = 500) antibody sequences. Sequence logos were generated using the WebLogo 
server. The Kabat scheme was used for numbering amino acids.  
 
codon mix that encoded pre-defined proportions of thirteen amino acids. The theoretical 
diversity in CDRL3 was 2.9×104. Since CDRH3 plays a dominant role in antigen recognition, 
CDRH3 was designed to contain length, amino acid, conformational, and joining-segment (JH-
region) diversities. 19 different CDRH3 lengths (from 7 to 25 residues) were used in the design. 
Since an increase in JH6 gene usage is observed with increasing CDRH3 lengths during the 
process of human VDJ-recombination (Zemlin et al., 2003; Prassler et al., 2011), a JH6 gene 
segment was incorporated in long CDRH3 sequences (16-25 residues), whereas a JH4 gene 
segment was used for short CDRH3 sequences (7-16 residues). In CDRH3, two different codon 
mixes were used to randomize the diversity region (positions 95-99 encoded by the DH gene). 
For short (7-16 residues) and long (16-25 residues) CDRH3 lengths, custom-made codon mixes 
encoded pre-defined proportions of thirteen and nine amino acids, respectively. To introduce 
CDRH3 conformational diversity, key anchor residues within JH4 or JH6 segments were soft 
randomized to favor both the bulged and non-bulged CDRH3 conformations (North et al., 2011). 
The theoretical diversity in CDRH3 was 2.6×1014. The theoretical diversity of Library-S was 
7.4×1018 members. The overall design of library-S is outlined in Figure 5.6.  
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Figure 5.6: Library-S design. Library-S contains four fixed CDRs (L1, L2, H1, and H2) and 
two diversified CDRs (L3 and H3). Z denotes any of the following thirteen amino acids 
introduced at different proportions: Y (20%), S (20%), G (20%), T (6.5%), A (6.5%), P (6.5%), 
H (3.5%), R (3.5%), E (3.5%), F (2.5%), W (2.5%), V (2.5%) or L (2.5%). X denotes any of the 
following nine amino acids introduced at different proportions: Y (25%), S (20%), G (20%), A 
(10%), F (5%), W (5%), H (5%), P (5%) or V (5%). CDRH3 length is varied by altering the 
number of X and Z. Variable (V), Diversity (D) and Joining (J) segments in CDRs L3 and H3 are 
indicated. The Kabat scheme is used for numbering amino acids.  	
Hu4D5-8 is based on the anti-HER2 mouse monoclonal antibody (Mu4D5). 
Humanization of Mu4D5 VL and VH domains required 24 and 36 amino acid changes, 
respectively. The fully humanized antibody (Hu4D5-1) binds to HER2 with 80-fold lower 
affinity than Mu4D5 and does not inhibit HER2-overexpressing cells. Two positions in VL 
(E55Y and G66R) and five positions in VH domain (R71A, D73T, L78A, A93S and V102Y) 
were reverted to amino acids present in Mu4D5 to improve binding. These substitutions located 
in CDR anchor residues (positions 55VL, 93VH and 102VH) and framework residues (positions 
66VL, 71VH, 73VH and 78VH), which are known to critically affect the conformation of CDRs. 
HU4D5-8 binds 3-fold stronger than Mu4D5, and has anti-proliferative activity comparable to 
Mu4D5 (Carter et al., 1992; Kelley et al., 1992; Eigenbrot et al., 1992). Relative to Hu4D5-8, 
which retains seven mouse residues, the 4D5 framework used in library-S contains only one 
mouse residue (R66 in VL).  The 4D5 framework used in library-F contains four mouse residues 
(R66 in VL, and A71, T73 and A78 in VH). To highlight the amino acid differences between 
various 4D5 frameworks, a multiple sequence alignment is included in Figure 5.7. 
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Figure 5.7: Multiple sequence alignment of 4D5 framework sequences: (A) the variable light 
chain region and (B) the variable heavy chain region. The following sequences were included in 
the alignment: anti-HER2 murine 4D5 Fab (Mu4D5), Hu4D5-1 (fully humanized form of 
Mu4D5), Hu4D5-8 (humanized form of Mu4D5 and Herceptin Fab), Library-F (4D5 framework 
used in library-F) and Library-S (4D5 framework used in library-S). Hyphen indicates 
diversified positions in library-F and library-S. Symbols asterisk, colon, period and space 
indicate identical residues, conservative substitutions, semi-conservative substitutions and 
mismatches, respectively. Three VH substitutions (71, 73 and 78) in the FRM3 region are shown 
in bold letters. CDR residues are colored in red. Sequences were aligned using the Clustal 
Omega program. The Kabat scheme is used for numbering amino acids. CDRs were defined 
according to North et al., 2011. 
 
5.1.3 Library-S: Construction and Quality Control 
Library-S was constructed using an established M13 bacteriophage system that allows 
bivalent Fab display (Lee et al., 2004A). A Hu4D5-8 Fab-encoding phagemid whose CDRs have 
been replaced with NotI sites was used as a template to construct libraries. Kunkel mutagenesis 
was used to repair the NotI sites and replace CDR positions with fixed or degenerate codons 
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encoding the amino acid composition shown in Figure 5.6. Upon digestion of the non-mutated 
template DNA by NotI, library DNA from the mutagenesis reaction was electroporated into an E. 
coli strain suitable for high-efficiency transformation and phage production. To minimize biases 
in bacterial growth and phage production due to differences in CDRH3 lengths, we constructed 
library-S in 20 different reactions, each reaction representing a CDRH3 length, and rescued 20 
sub-libraries (SL1 - SL20) separately. 
To assess the quality of sub-libraries, we performed a NGS analysis of their naïve 
CDRH3 diversity. On average, we obtained ~1,000 filtered-reads per pool, and determined their 
overall sequence composition (Figure 5.8A). Except for SL13, SL15 and SL20, the proportion 
of incorrect sequences (sum of out-of-frame sequences, template sequences and sequences with 
stop codons) in the sub-libraries was less than 10%. The average proportion of incorrect 
sequences present in 20 sub-libraries was only 5.7%. Satisfied with the quality of sub-libraries, 
we combined equal number of phages from 20 sub-libraries to make library-S. To assess library-
S quality, we sequenced both the diversified CDRs in the library. We obtained 13,118 CDRL3 
and 13,712 CDRH3 sequences, and determined their overall sequence composition. The 
proportion of incorrect CDRL3 and CDRH3 sequences was only 1.8% and 3.4%, respectively. 
Since the library size was higher than the theoretical CDRL3 diversity, the proportion of unique 
CDRL3 sequences was only 40%. Also, for a few sub-libraries with short CDRH3 lengths, the 
library size was higher than the theoretical CDRH3 diversity, resulting in a decrease in the 
proportion of unique CDRH3 sequences to 81%. Considering the randomness in the pairing of 
CDRs L3 and H3, the actual proportion of unique Fabs would increase in the library. 
To assess library-S diversity in detail, we linked the two diversified CDRs together, 
sequenced the CDRL3-CDRH3 strip on a 200 bp chip, and obtained 188,529 sequences. 
Template retention in the library was only 2%, indicating that restriction enzyme digestion of the 
library mutagenesis reaction is an efficient strategy to reduce the amount of template sequences. 
Sequence analysis showed the presence of 94% unique sequences, and 91% sequences with a 
single copy in the library. Further, the proportion of the most frequent CDRH3 sequence in the 
library was only 0.02%, which indicated that there is no significant sequence-bias in the library. 
After electroporation of library DNA into E. coli, we estimated the size of the library to be 9.4 
billion Fabs by bacterial titrations. Having determined the proportion of correct and unique 
sequences by deep sequencing, we estimated that there are 8.5 billion unique Fabs in the library.  
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Figure 5.8: NGS analysis of the naïve library-S diversity. (A) Overall composition of CDRH3 
sequences in sub-libraries (SL) 1-20. (B) CDRL3 length distribution. (C) CDRH3 length 
distribution. Sequence logos showing the positional amino acid composition of (D) CDRL3 
sequences containing 9 residues, (E) JH4 CDRH3 sequences containing 15 residues and (F) JH6 
CDRH3 sequences containing 23 residues. (G) Total amino acid composition of the CDRL3 
central region. (H) Total amino acid composition of the CDRH3 DH segment for lengths 7-16. (I) 
Total amino acid composition of the CDRH3 DH segment for lengths 16-25. The expected amino 
acid composition (encoded by phosphoramidite trimers) is also included (filled circles). 
 
Next, we analyzed CDRL3 and CDRH3 sequences in terms of length distribution. 
Although CDRL3 length was fixed to 9 residues, we observed two different CDRL3 lengths in 
the population (Figure 5.8B). 20% of CDRL3 sequences had only 8 residues. One of the four 
diversified positions in the CDRL3 central region was found to be absent. A possible explanation 
for this deletion could be a DNA synthesis error that could have happened during the 
incorporation of phosphoramidite codons into oligonucleotides. Considering that the Hu4D5-8 
framework can accommodate CDRL3 lengths ranging from 8 to 12 residues (Persson et al., 
2013), we did not try to eliminate the CDRL3 sequences with 8 residues. With respect to 
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CDRH3, 19 loop lengths were included in the design: lengths 7-16 had a JH4 segment and 
lengths 16-25 had a JH6 segment. Since we mixed equal number of phages from 20 sub-libraries, 
we expected to obtain a flat CDRH3 length distribution. However, the analysis showed that JH4-
containing CDRH3 sequences (74%) were overrepresented relative to JH6-containing CDRH3 
sequences (26%) (Figure 5.8C).  
Next, we analyzed the amino acid composition of CDRL3 and CDRH3. Sequence logo 
analysis showed a clear difference in sequence conservation between CDR anchor residues and 
central variable positions. Also, sequence logos indicated that CDR diversification was uniform 
across variable positions and no major deviations were seen between the expected and observed 
amino acid compositions of anchor residues. Representative sequence logos are shown in 
Figures 5.8D, 5.8E and 5.8F. To obtain a more refined amino acid distribution, we analyzed the 
composition of 13 possible amino acids within the CDRL3 central region (Figure 5.8G), 13 
possible amino acids within the DH segment of JH4-containing CDRH3 sequences (Figure 
5.8H), and 9 possible amino acids within the DH segment of JH6-containing CDRH3 sequences 
(Figure 5.8I). These regions have the highest diversity in the library and are encoded by one of 
two codons X and Z with predefined proportions of 9 and 13 amino acids, respectively. While 
the frequency of most residues was close to frequencies predefined in codons X and Z, tyrosine 
was overrepresented and glycine was underrepresented compared to the design.  
5.1.4 Library-S Validation  
To verify library-S functionality, we conducted four rounds of solid-phase selections 
against two human cell-surface receptor ectodomains Jagged-1 and Jagged-2. Briefly, we 
immobilized recombinant target-Fc fusion proteins on Maxisorp plates, and incubated target-
coated wells with library-S deselected for binding to the Fc protein. Upon elimination of non-
specific phages by washing, we eluted bound phages and amplified them in E. coli overnight for 
subsequent rounds of panning. Random clone picking and Sanger sequencing of ten phagemids 
from round-3 and round-4 phage pools identified two sequence-unique clones for Jagged-1 and 
seven sequence-unique clones for Jagged-2. Phage-ELISA showed that all Jagged-1 and Jagged-
2 Fab clones bound to the target receptor but not to BSA and the Fc protein (Figure 5.9A). We 
then subcloned two Jagged-1 Fab clones and four Jagged-2 Fab clones into a Fab expression 
vector and expressed and purified Fabs from E. coli using Protein-L affinity chromatography. 
We observed high Fab expression rates (estimated average ~17.4 mg/L), suggesting that new
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Figure 5.9: Jagged-1 and Jagged-2 Fabs from library-S. (A) Sequence characteristics and 
phage-displayed Fab binding characteristics for two Jagged-1 Fabs and seven Jagged-2 Fabs 
isolated by Sanger sequencing. (B) Fab yield, affinity and specificity of purified Jagged-1 and 
Jagged-2 Fabs. Fab yield was estimated for 1 L bacterial culture. EC50 values and KD values for 
Fabs binding to their intended targets were determined by multi-point Fab-ELISA and bio-layer 
interferometry, respectively. Fab specificity was determined using single-point Fab-ELISA at 
100 nM Fab concentration. Phage-ELISA and specificity-ELISA ABS450 values are shown as 
heatmaps. In ELISA heatmaps, Notch-1/2/3 and Jagged-1/2 target proteins are indicated as N1, 
N2, N3, J1 and J2.  
 
CDRs and framework mutations are well accommodated by the Fab-4D5 framework. Next, we 
determined EC50 values for Fabs binding to Jagged-1 or Jagged-2 using Fab-ELISA. J1/S/1 
bound to Jagged-1 with an EC50 of 6 nM. J1/S/2 bound ~7-fold weaker than J1/S/1 (EC50 = 40 
nM). J2/S/1, J2/S/2 and J2/S/4 bound to Jagged-2 with an EC50 value of ~1 nM, and J2/S/5 had 
an EC50 value of 50 nM (Figure 5.9B). Next, we measured the kinetics of Fab binding using bio-
layer interferometry. Briefly, Fabs were immobilized on amine-reactive sensors and sensor tips 
were exposed to increasing concentrations of target receptors. Association and dissociation rates 
were assessed by a wavelength shift and kinetic data sets were fit using a 1:1 binding model. 
Both Jagged-1 Fabs had sub-nM KD values: 0.3 nM for J1/S/1 and 0.5 nM for J1/S/2. Among the 
four Jagged-2 Fabs, J2/S/4 was the highest-affinity binder (KD = 80 pM), and J2/S/5 was the 
Figure 5
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Jagged-1 J1/S/2 QQSLATPLT ARSEYGTAGYFDY 13
Jagged-2 J2/S/1 QQGEYTPLT ARGSYYVPAFDY 12
Jagged-2 J2/S/2 QQGSYSPLT ARGHYTTPDFDY 12
Jagged-2 J2/S/3 QQGSFGPLT ARGHYLFPDFDY 12
Jagged-2 J2/S/4 QQGTYLPLT ARGYYSYPGFDY 12
Jagged-2 J2/S/5 QQGGHSPLT ARPSYSYGSFDY 12
Jagged-2 J2/S/6 QQSSYSPLT ARGHYFRRGFDY 12
Jagged-2 J2/S/7 QQGSYSPLT ARGFFYYPAFDY 12
Target Clone Fab yield EC50 KD
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Jagged-1 J1/S/1 18.7 5.88 ± 2.34 0.28 ± 0.01
Jagged-1 J1/S/2 21.5 40.3 ± 2.69 0.48 ± 0.04
Jagged-2 J2/S/1 14.6 1.23 ± 0.17 0.17 ± 0.01
Jagged-2 J2/S/2 14.6 1.32 ± 0.19 0.69 ± 0.01
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lowest-affinity binder (KD = 3.8 nM). J2/S/1 and J2/S/2 possessed sub-nM KD values, 0.17 nM 
and 0.69 nM, respectively (Figure 5.9B). In total, all the six Fabs bound very strongly to their 
targets with EC50 values ranging from 1 nM to 50 nM, and KD values ranging from 80 pM to 3.8 
nM. Next, to assess Fab specificity, we tested the binding of Fabs to Notch and Jagged receptor 
ectodomains using Fab-ELISA. At 100 nM Fab concentration, Jagged-1 Fabs cross-reacted with 
Jagged-2, whereas Jagged-2 Fabs exhibited target-specific binding (Figure 5.9B). Kinetic 
analysis showed that Jagged-1 Fabs, J1/S/1 and J1/S/2, bound to Jagged-2 with KD values of 3.2 
± 0.1 nM and 7.2 ± 0.3 nM, respectively. Jagged-1 Fabs showed ~10-fold specificity over 
Jagged-2, and Jagged-2 Fabs showed >1000-fold specificity over Jagged-1. Together, these 
results highlighted the potential of library-S in generating Fabs with very high affinity and 
specificity against cell-surface receptors.  
5.1.5 Validation of the NGS-assisted Antibody Reconstruction Platform 
To demonstrate the feasibility of our Fab reconstruction approach, we used the Jagged-2 
selection output.  Like others before (Ravn et al., 2010; Venet et al., 2012), we observed a 
significant enrichment in target-specific CDRH3 lengths and sequences after the third round of 
selection (extended data, Figures 5.13C, 5.15C and 5.15F); therefore, we chose to use the round-
3 phage pool for CDRL3-CDRH3 strip sequencing. We generated and sequenced the CDR strip 
as illustrated in Figure 5.2, and ranked the CDRL3-CDRH3 sequences based on their relative 
frequencies. A list of enriched CDR-combinations (with frequencies >1%) is shown in Figure 
5.10A. The seven CDRL3-CDRH3 sequences identified by random clone picking and Sanger 
sequencing identically matched to seven CDR-combinations in the list. Next, we parsed the 
CDRL3 and CDRH3 regions, and analyzed them in terms of length distribution (Figure 5.10B). 
In agreement with Sanger sequencing results, a significant enrichment was observed for CDRL3 
length of 9 residues and CDRH3 length of 12 residues. Also, a minor enrichment was noted with 
two CDRH3 lengths (10 and 14 residues). We then extracted the sequences containing CDRH3 
length of 12 residues, and generated sequence logos for CDRL3 and CDRH3 regions (Figure 
5.10C). Enrichment of specific amino acids was observed in the diversified regions of both 
CDRs. Notably, Gly91 in CDRL3, and Gly95, Tyr97 and Pro100 in CDRH3. J2/S/5 had 
mismatches in two of these positions (Pro95 and Gly100) and bound weaker than other three Fab 
clones. Next, to assess the binding properties of clones corresponding to less frequent CDRH3 
lengths, we reconstructed three rare clones with CDRH3 lengths of 10 or 14 residues. J2/S/R1
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Figure 5.10: NGS-assisted reconstruction of rare Fab clones from the Jagged-2 selection. 
(A) Enriched sequences (> 1%) from the round-3 CDRL3-CDRH3 strip sequencing output. 
Seven Fabs isolated by Sanger sequencing are indicated. (B) CDRL3 and CDRH3 length 
distribution of the Jagged-2 selection output (round-3). (C) Sequence logos showing the 
positional amino acid composition of CDRL3 and CDRH3 sequences from the Jagged-2 
selection output. (D) Sequence characteristics and phage-displayed Fab binding characteristics 
for three Jagged-2 rare clones reconstructed from CDRL3-CDRH3 NGS information. (E) Fab 
yield, affinity and specificity of purified rare Fabs J2/S/R2 and J2/S/R3. EC50 and KD values 
were determined by multi-point Fab-ELISA and bio-layer interferometry, respectively. Fab 
specificity was determined using single-point Fab-ELISA at 100 nM Fab concentration. Phage-
ELISA and specificity-ELISA ABS450 values are shown as heatmaps.  
 
Rank CDRL3)CDRH3 Round.3.(%)
1 QQGEYTPLT-ARGSYYVPAFDY 25.41 J2/S/1
2 QQGSFGPLT-ARGHYLFPDFDY 18.18 J2/S/3
3 QQGSYSPLT-ARGHYTTPDFDY 4.65 J2/S/2
4 QQGYVSPLT-ARGHYYEPTFDY 3.84
5 QQGTYLPLT-ARGYYSYPGFDY 3.43 J2/S/4
6 QQGGHSPLT-ARPSYSYGSFDY 2.95 J2/S/5
7 QQGSYSPLT-ARGYYSYPGFDY 2.80
8 QQGWGYPLT-ARVASPYWGYDFDY 2.76
9 QQSSYSPLT-ARGHYFRRGFDY 2.45 J2/S/6
10 QQGSYSPLT-ARGFFYYPAFDY 2.05 J2/S/7
11 QQGSYSPLT-ARGRYTGAAFDY 1.92
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and J2/S/R2 had short CDRH3 lengths (10 residues). J2/S/R1 had a frequency of 0.4%, and 
showed strong binding in phage-ELISA. J2/S/R2 had a frequency of 0.03%, and showed 
moderate binding in phage-ELISA (Figure 5.10D). The purified Fab J2/S/R2 bound to Jagged-2 
with EC50 and KD values of 200 nM and 5.06 nM, respectively. J2/S/R2 also had strict specificity 
for Jagged-2. J2/S/R3 had a CDRH3 length of 14 residues, and had the highest frequency (2.8%) 
among rare clones. The EC50 of the purified Fab J2/S/R3 (2.23 nM) was similar to the EC50 
values of top clones. As expected, J2/S/R3 did not cross-react with other targets in Fab-ELISA 
(Figure 5.10E). Together, these results indicated that less frequent clones with low-nM affinity 
and high specificity could be reconstructed from phage selection outputs. 
5.1.6 Reconstruction of Rare Fab clones with Better Binding Properties 
In case of selections against Notch-2 and Notch-3, top clones isolated by Sanger 
sequencing had low affinity and/or specificity, therefore we used our Fab reconstruction 
approach to check whether rare clones with better binding properties can be recovered from 
selection outputs. For both targets, we subjected the round-3 phage pool to CDRL3-CDRH3 strip 
sequencing and analyzed the sequences in terms of relative abundance and length distribution. 
Sequence analysis, phage and Fab work for both the targets are summarized in Figure 5.11. For 
the Notch-2 selection, Sanger sequencing gave rise to three unique Fab clones. While N2/S/3 had 
the highest frequency (53.1%) in the round-3 phage pool, N2/S/1 and N2/S/2 had very low 
frequencies (~0.2%). N2/S/1 and N2/S/3 performed poorly in Fab-ELISA and kinetic analyses. 
Despite its low abundance, N2/S/2 bound to Notch-2 with a low-nM KD (5 nM). However, 
N2/S/3 cross-reacted with Notch-3 and Jagged-2 (Figure 5.11D). Sequence analysis indicated 
the enrichment of three types of Fab sequences for the Notch-2 selection: (I) sequences with 
CDRH3 lengths of eight residues (similar to N2/S/1); (II) sequences containing a leucine residue 
in the first diversified position of CDRH3 (similar to N2/S/2) and (III) sequences containing the 
FGG-motif in the N-terminus of CDRH3 (similar to N2/S/3). With CDRH3 length of eight 
residues, type-I sequences contain five fixed anchor residues and only three diversified positions. 
Since we have observed the enrichment of type-I sequences in many unsuccessful selections 
(data not shown), we did not reconstruct them. The combination of short CDRH3 length and 
very low CDRH3 diversity might have resulted in their non-specific behavior. Type-II and type-
III sequences were found in four different CDRH3 lengths (13, 14, 15 and 16 residues for type-
II, and 14, 15, 16 and 25 residues for type-III). We reconstructed the most-frequent Fab sequence
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Figure 5.11: Notch-2 and Notch-3 Fabs from Library-S. CDRL3 and CDRH3 length 
distributions of (A) Notch-2 and (B) Notch-3 selection outputs. (C) Sequence characteristics and 
phage-displayed Fab binding characteristics for Notch-2 Fabs (top panel) and Notch-3 Fabs 
(bottom panel). (D) Fab yield, affinity and specificity of Notch-2 Fabs (top panel) and Notch-3 
Fabs (bottom panel). In panels C and D, reconstructed rare clones are highlighted in gray. Fab 
specificity was determined at 1 µM Fab concentration. Phage-ELISA and specificity-ELISA 
ABS450 values are shown as heatmaps.                   
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N2/S/R5 QQRSVYPLT ARFGGHGSFTYAFDY 15 1.37
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from each enriched CDRH3 length for both types II and III, and tested them for binding to 
Notch-2 by phage-ELISA. Among the type-II Fabs, N2/S/R3 and N2/S/R4 showed higher 
ELISA output than N2/S/2, N2/S/R1 cross-reacted with the Fc protein, and N2/S/R2 did not bind 
to Notch-2. Among the type-III Fabs, N2/S/R5 showed higher ELISA output than N2/S/3, 
N2/S/R7 showed lower ELISA output than N2/S/3, and N2/S/R6 did not bind to Notch-2 
(Figure 5.11C). In total, four out of seven rare clones tested positive in phage-ELISA. We 
purified one of the four ELISA-positive clones (N2/S/R7) that had the longest CDRH3 length 
and assessed its affinity and specificity for Notch-2. N2/S/R7 had EC50 and KD values of 15.94 
nM and 7.68 nM, respectively. Similar to N2/S/2, N2/S/R7 cross-reacted with Notch-3 and 
Jagged-2 (Figure 5.11D). Even though N2/S/R7 had the lowest frequency among the type-III 
sequences (0.1%), it bound ~8-fold stronger than N2/S/3 that had the highest frequency (53.1%). 
For the Notch-3 selection, Sanger sequencing gave rise to five clones that matched with the 
description for type-I sequences. In phage-ELISA, two clones (N3/S/1 and N3/S/2) showed 
strong binding to Notch-3 whereas three clones (N3/S/3, N3/S/4 and N3/S/5) showed moderate 
to weak binding (Figure 5.11C). When phage-displayed Fabs were converted into soluble Fabs, 
N3/S/1 and N3/S/2 showed weak binding to Notch-3 in Fab-ELISA and kinetic analyses (Figure 
5.11D). CDRH3 length analysis confirmed the enrichment of type-I sequences in the Notch-3 
selection and in addition, showed a minor enrichment for sequences with 16 residues. We 
reconstructed the most-frequent Fab sequence (0.16%) from CDRH3 length of 16 residues, and 
assessed its affinity and specificity for Notch-3. N3/S/R1 had EC50 and KD values of 16.04 nM 
and 2.65 nM, respectively. In Fab-ELISA, N3/S/R1 cross-reacted with Notch-1 and Jagged-2 
(Figure 5.11D). For both Notch-2 and Notch-3 selections, rare clones reconstructed from NGS 
information bound better than top clones isolated by Sanger sequencing. Rare Fabs N2/S/R7 and 
N3/S/R1 both possessed low-nM KD values for their targets. However, both Fabs cross-reacted 
with two other Notch/Jagged receptors.  
5.1.7 Reconstruction of Rare Fab clones from Library-F Selections 
To demonstrate the feasibility of reconstructing Fabs with four diversified CDRs, we 
chose Jagged-2 as a target. We panned library-F against the Jagged-2 ectodomain, and subjected 
the round-3 phage pool to L3-H1-H2-H3 strip sequencing as illustrated in Figure 5.2.  We parsed 
the CDRL3 and CDRH3 regions, and analyzed them in terms of length distribution (Figure 
5.12A). A significant enrichment was observed for CDRL3 sequences with 8 residues (70.4%)
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Figure 5.12: Jagged-2 Fabs from library-F. (A) CDRL3 and CDRH3 length distribution of the 
Jagged-2 selection output (round-3). (B) Sequence characteristics and phage-displayed Fab 
binding characteristics of 9 top Fabs isolated by Sanger sequencing and 7 rare Fabs reconstructed 
from L3-H1-H2-H3 NGS information. (C) Fab yield, affinity and specificity of purified Fabs. 
Fab specificity was determined at 1 µM Fab concentration. Phage-ELISA and specificity-ELISA 
ABS450 values are shown as heatmaps. In panels B and C, reconstructed rare clones are 
highlighted in gray. 
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and CDRH3 sequences with 10 residues (56.8%). CDRH3 sequences with 7, 8 and 14 residues 
were present between 5-10%, and CDRH3 sequences with 11, 12, 15, 16, 17, 18 and 23 residues 
were present between 1-5%. Random clone picking and Sanger sequencing of 30 phagemids 
from round-3 and round-4 phage pools identified 9 sequence-unique Fab clones. These clones 
had CDRH3 lengths of 7, 8, 10, 14, 17 and 18 residues. We reconstructed 7 rare clones from five 
less-frequent CDRH3 lengths (11, 12, 15, 16, 18 and 23 residues). The frequencies of 
reconstructed rare clones ranged from 0.7% to 0.1%. Phage-ELISA indicated that 15 out of 16 
clones bound to Jagged-2 but not to the control proteins (Figure 5.12B). One rare clone 
(J2/F/R1) bound to BSA and the Fc protein in addition to Jagged-2. We converted 13 phage-
displayed Fabs into soluble Fabs encompassing different CDRL3 and CDRH3 lengths, and 
assessed their affinity and specificity using Fab-ELISA (Figure 5.12C). Among the seven top 
clones, five Fabs possessed low-nM EC50 values for Jagged-2. However, all five Fabs cross-
reacted with Jagged-1. J2/F/5 and J2/F/8 had low affinities for Jagged-2, nonetheless had high 
Fab expression rates in E. coli. It is worth noting that J2/F/5 had the highest frequency in the 
round-3 phage pool (45%). Among the six rare clones, five Fabs possessed low-nM EC50 values 
for Jagged-2. The rare clone J2/F/R7 with the lowest frequency (0.1%) had an EC50 of 24.62 nM. 
Strikingly, three out of six rare clones (J2/F/R4, J2/F/R6 and J2/F/R7) possessed strict specificity 
for Jagged-2. Together, these results indicated that rare clones could not only bind tighter than 
top clones but also could be more specific than top clones. 
5.1.8 Evolution Profiles of Top Clones and Rare Clones 
To monitor the evolution profiles of Fabs during phage display selections, we sequenced 
the CDRH3 region of Notch/Jagged selection outputs on a 100 bp Ion semiconductor chip, and 
followed the frequency of CDRH3 sequences in selection outputs over five subsequent rounds of 
selection. CDRH3 sequences corresponding to 24 ELISA-positive top clones and 24 ELISA-
positive rare clones were chosen for this analysis from both Fab libraries (S and F). The 
propagation behavior for 24 top sequences and 24 rare sequences are shown in Figures 5.13A 
and 5.13B. The average propagation behavior for 24 top sequences and 24 rare sequences are 
shown in Figures 5.13C and 5.13D. On average, top sequences showed significant enrichments 
in rounds- 3, 4 and 5 and reached 21.7% after five rounds. Rare sequences showed a minor 
enrichment in round-3 (1.4%) and depletion in rounds- 4 and 5. This confirmed that three 
selection rounds would be sufficient to isolate top clones and reconstruct rare clones from phage
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Figure 5.13: Propagation behavior of (A) 24 top CDRH3 sequences and (B) 24 rare CDRH3 
sequences. X-axis indicates rounds 1 to 5, and Y-axis indicates the frequency of Fab CDRH3 
sequences in selection outputs. Average propagation behavior of (C) 24 top CDRH3 sequences 
and (D) 24 rare CDRH3 sequences. 
 
selection outputs. Rounds- 4 and 5 increased the abundance of top clones at the expense of rare 
clones. In addition to highlighting the differences in evolution profiles between top and rare 
clones, this analysis clearly illustrated the need for NGS-based approaches to recover rare clones 
from selection outputs. 
5.1.9 Discussion 
In recent years, NGS technologies have revolutionized both fundamental and 
translational aspects of biological research. Sequencing of functional antibody repertoires and 
subsequent bioinformatic analyses have provided unprecedented insight into the mechanisms of 
B-cell development in humans and other species, and has transformed our understanding of 
immune responses to autoimmunity, vaccination, infection and cancer.  Sequencing of antibody 
repertoires is also used for identifying critical biomarkers and epitopes targeted by functional 
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antibody responses, for developing vaccines, immunomodulatory drugs and diagnostic tools, and 
for discovering antibodies (reviewed by Georgiou et al., 2014; Robinson, 2015; Lavinder et al., 
2015). NGS technologies have also been employed in several phage display platforms for 
analyzing natural and synthetic antibody fragment sequences, and for identifying and 
reconstructing scFv and Fab binders not found by conventional ELISA screens (reviewed by 
Naso et al., 2014; Glanville et al., 2015).  
In this work, we developed an NGS-assisted antibody discovery platform by integrating 
phage-displayed single-framework synthetic Fab libraries with Ion Torrent sequencing. The use 
of single-framework synthetic Fab libraries enabled seamless integration of antibody phage 
display with short-read DNA sequencing. With a defined single-framework, sequencing efforts 
were directed only towards the diversified CDR regions. Since NGS primers were designed to 
anneal to the framework regions, single-framework libraries also offered the advantage of having 
one set of primers during amplicon preparation. During sequence analysis, the use of a single-
framework eliminated complications associated with the occurrence of multiple frameworks and 
framework mutations present in natural antibody repertoires. To compensate for the reduction in 
variable domain diversity, the single-framework libraries were rationally engineered to include 
length, amino acid and conformational diversities within CDRs.  Using trinucleotide mutagenesis 
technology (Virnekas et al., 1994), two or four of the six CDR loops were diversified in a 
combinatorial fashion based on structural bioinformatics analysis of antigen-antibody structures. 
Besides contributing to library stability and function, precise engineering of CDR diversity 
enabled fast and accurate interpretation of NGS data sets. The new Fab library described in this 
work delivered promising Fabs against Jagged-1/2 and was moderately successful against Notch-
2/3. The highest-affinity Fab bound to Jagged-2 with a KD value of 80 ± 13 pM and showed 
>1000-fold specificity over Jagged-1.  
Between the two commonly used short-read DNA sequencing platforms, Illumina and 
Ion Torrent, we chose to use the latter. Ion Torrent sequencing can deliver up to 5.5 × 106 reads 
with 100-400 bp read lengths in a short span of time (5 hours) at low cost ($749 per run). MiSeq 
from Illumina can provide up to 25 × 106 reads with 2 × 300 bp read lengths (paired-end reads), 
however it takes up to 55 hours and $1750 for a sequencing run (reviewed by Glanville et al., 
2015). With low cost and fast turnaround times, Ion Torrent sequencing enabled routine analysis 
of phage display selection outputs. NGS information was used for (1) assessing the quality of 
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Fab libraries, (2) analyzing selection outputs in terms of sequence evolution, length and amino 
acid distribution, and (3) identifying and reconstructing low-frequency rare clones from selection 
outputs. 
Due to limitations in attainable read lengths, NGS of Fab libraries and selection outputs is 
usually restricted to CDRH3 (Ravn et al., 2010; D’Angelo et al., 2014). Since CDRH3 
sequencing alone is not sufficient for high-throughput reconstruction of Fabs, we developed a 
method for linking and sequencing all diversified CDRs in phage Fab pools without losing right 
CDR combinations. Our method determined the sequences of paired CDRs in selection outputs 
and paved the way for straightforward conversion of NGS information into Fab clones. The 
method is rapid and simple and can be adapted to any synthetic scaffold-based phage library. 
Previous studies have shown that single-framework synthetic Fab libraries allow facile 
reformatting of Fabs between different vector systems for affinity maturation, bacterial 
expression and IgG conversion (Miersch and Sidhu, 2012; Adams and Sidhu, 2014). In this 
work, we demonstrate an additional advantage of single-framework synthetic Fab libraries. The 
combination of single Fab framework and precise CDR diversity resulted in rapid and reliable 
reconstruction of Fabs from NGS information.  
Typically, to recover antigen-specific Fabs from phage selection pools, hundreds to 
thousands of colonies from selection outcomes are first interrogated by binding assays 
(phage/Fab ELISA) in 96/384 well plates, and then identities of ELISA-positive clones are 
determined by Sanger sequencing (Ravn et al., 2010). Due to phage propagation biases in E. coli, 
many binders present in earlier selection rounds do not get enriched and remain at very low 
frequencies in later selection rounds. Therefore, the conventional clone recovery method leads to 
the repeated identification of the same enriched clones from phage selection pools (Derda et al., 
2011; Saggy et al., 2012). NGS-based reconstruction of antibody clones can avoid the repeated 
identification of growth-advantaged, high frequency binders, and can identify and recover many 
unique clones that are present in low frequencies in phage pools (Ravn et al., 2013; Naso et al., 
2014; Spiliotopoulos et al., 2015; Lopez et al., 2017). As evidence of this, low-frequency rare 
Fabs (~0.1%) reconstructed in this work showed higher affinity and specificity than high-
frequency top Fabs isolated by Sanger sequencing. Reconstruction of rare Fab clones from less-
frequent CDRH3 lengths increased the possibility of recovering Fabs with new and better 
binding solutions. 
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Synthetic antibody technology is well known for high-throughput generation of 
antibodies. In this work, the following factors contributed to the high-throughput reconstruction 
and Fabs from selection outputs: (1) multiplexing of up to 20 selection outputs in one sequencing 
run; (2) semi-automated NGS data processing and analysis; (3) synthesis of CDR-encoding 
oligonucleotides in 96-well format; (4) optimized procedures for cloning CDR-encoding 
oligonucleotides into the Fab-encoding template phagemid; (5) replacement of Sanger 
sequencing with restriction digestion analysis for screening positive phagemid clones; (6) 
optimized procedures for sub-cloning ELISA-positive phage-Fab clones into Fab-expression 
vector in 96-well format and  (7) confirmation of Fab sub-cloning and expression by bio-layer 
interferometry in 96-well format. We isolated top Fab clones by Sanger sequencing and 
compared them with rare Fab clones for emphasizing the need for NGS-based reconstruction 
approaches in antibody phage display. This step is now excluded in routine phage display 
selections. Following three rounds of selection, the selection output is subjected to L3-H3 or L3-
H1-H2-H3 sequencing, promising clones are identified by NGS analysis, reconstructed and 
tested for binding. This approach eliminated the use of Sanger sequencing from antibody phage 
display (from phage selections to Fab KD determination) and resulted in a reliable and high-
throughput antibody discovery platform. 
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5.2 Systematic Generation of Synthetic Antibody Fragments with Optimal CDR Lengths 
for Notch-1 Recognition	
In section 5.1, we validated the functionality of library-S by generating high-affinity Fabs 
against Notch and Jagged receptors (Notch-2/3 and Jagged-1/2). The highest-affinity Fab bound 
to Jagged-2 with a KD value of 80 ± 13 pM and showed >1000-fold specificity over Jagged-1. 
Though Notch-2/3 Fabs had low-nM KD values, they showed cross-reactivity with other Notch 
and Jagged members. In this section, we describe the generation and validation of anti-Notch-1 
Fabs from two phage-displayed single-framework synthetic Fab libraries, library-S and library-F. 
Over the course of Fab generation, we also show that implementing NGS approaches, screening 
focused diversity libraries, fine-tuning the library diversity and making small changes to 
diversity designs can improve the success rate of single-framework synthetic Fab libraries.	
5.2.1 Notch-1 Fabs from Library-S	
Library-S contains four fixed CDRs and two diversified CDRs (CDRL3 and CDRH3) on 
an optimized Hu4D5-8 framework. Length diversity was included within CDRH3 and amino 
acid diversity was included within both the diversified CDRs (Figures 5.14A and 5.14B). To 
generate Notch-1 Fabs, we conducted solid-phase panning of library-S against the human Notch-
1 receptor extracellular domain. Briefly, we immobilized the recombinant Notch-1-Fc fusion 
protein on Maxisorp plates, and incubated target-coated wells with library-S deselected for 
binding to the Fc protein. Upon elimination of non-specific phages by washing, we eluted bound 
phages and amplified them in E. coli overnight for subsequent rounds of panning. Random clone 
picking and Sanger sequencing of 20 phagemids from the round-4 phage pool gave rise to two 
Fab clones (Figure 5.14C). Clones N1/S/1 and N1/S/2 had a CDRH3 length of 13 and 16 
residues, respectively. Phage-ELISA indicated that both the Fabs bound to Notch-1 but not to 
BSA and the Fc protein (data not shown). 
Since lengths of five other CDRs were fixed, we anticipated that CDRH3 length diversity 
would play a central role in library-S function. To obtain Notch-1 Fabs with different CDRH3 
lengths, we split library-S into four sub-libraries each containing a set of CDRH3 lengths, and 
panned them against Notch-1. After each selection round, we calculated the number of phages 
eluted from target-coated wells relative to BSA-coated wells. A positive enrichment in target-
specific phage number was only observed with two sub-libraries SL2 and SL3 (Figure 5.14D).
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Figure 5.14: Notch-1 Fabs from library-S. (A) Schematic representation of library-S CDR 
diversity. (B) CDR diversity designs for L3 and H3. Z denotes any of the following thirteen 
amino acids introduced at different proportions: Y (20%), S (20%), G (20%), T (6.5%), A 
(6.5%), P (6.5%), H (3.5%), R (3.5%), E (3.5%), F (2.5%), W (2.5%), V (2.5%) or L (2.5%). X 
denotes any of the following nine amino acids introduced at different proportions: Y (25%), S 
(20%), G (20%), A (10%), F (5%), W (5%), H (5%), P (5%) or V (5%). CDRH3 length is varied 
by altering the number of Z and X. (C) CDRL3 and CDRH3 sequences of two Notch-1 Fabs 
isolated from library-S. Fixed anchor residues are in black and diversified CDR positions are in 
red. (D) Left panel: panning of library-S sub-libraries (SL1 to SL4) against Notch-1. Heatmap 
showing the enrichment of Notch-1 binding phages after phage display selection rounds 4 and 5. 
Fold enrichment is the ratio of number of phages eluted from target-coated wells to number of 
phages eluted from BSA-coated wells. Right panel: CDRL3 and CDRH3 sequences of Fab 
N1/SL2/1 (isolated from SL2) and Fab N1/SL3/1 (isolated from SL3). (E) Pairwise sequence 
alignments between master- and sub-library Fab CDR sequences. Only diversified CDR 
positions within L3 and H3 were included for the alignment. Sequences were aligned in 
EMBOSS Needle using the Needleman-Wunsch algorithm. (F) Affinity and specificity of four 
Notch-1 Fabs isolated from library-S master- and sub-libraries. EC50 and KD values were 
determined using multi-point Fab-ELISA and bio-layer interferometry, respectively. Fab 
specificity was determined using single-point Fab-ELISA at 1 µM Fab concentration. ABS450 
values are shown as a heatmap.	
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Interestingly, SL2 and SL3 contained CDRH3 lengths of 13 and 16 amino acids, respectively, 
within their length set. Through random clone picking and Sanger sequencing, we isolated Fab 
clones N1/SL2/1 and N1/SL3/1 from SL2 and SL3 round-4 phage selection pools, respectively 
(Figure 5.14D). N1/SL2/1 and N1/S/1 had the same CDRH3 length of 13 residues. Their 
CDRL3 central segments were 25% similar and their CDRH3 diversity segments were 50% 
similar to each other. Both N1/SL2/1 and N1/S/1 contained the ETY-sequence at the N-terminus 
of CDRH3. N1/SL3/1 and N1/S/2 had the same CDRH3 length of 16 residues. Their CDRL3 
central segments were 33.3% similar and their CDRH3 diversity segments were 81.8% similar to 
each other. N1/SL3/1 contained SSS-sequence within its CDRL3, which was also found in 
N1/S/1 (Figure 5.14E). Phage-ELISA indicated that N1/SL2/1 and N1/SL3/1 bound to Notch-1 
but not to BSA and the Fc protein (data not shown). Random clone picking and Sanger 
sequencing of 20 phagemids from SL1 and SL4 round-4 selection pools gave rise to six Fab 
clones, however they bound to all test and control antigens in phage-ELISA (data not shown). 
To determine Fab affinity and specificity, we subcloned the four Notch-1 phage clones 
into a Fab expression vector and expressed and purified them from E. coli using Protein-L 
affinity chromatography. First, we determined EC50 values for Fabs binding to Notch-1 using 
Fab-ELISA. The EC50 values for N1/S/1 and N1/S/2 were 3.3 nM and 7.5 nM, respectively. With 
an EC50 of 49 nM, N1/SL2/1 bound 15-fold weaker than N1/S/1. The EC50 of N1/SL3/1 (12.7 
nM) was similar to that of N1/S/2 (Figure 5.14F). Second, we measured the kinetics of Fab 
binding using bio-layer interferometry. Briefly, Fabs were immobilized on amine-reactive 
sensors and sensor tips were exposed to increasing concentrations of Notch-1. Association and 
dissociation rates were assessed by a wavelength shift, and kinetic data sets were fit using a 1:1 
binding model. Consistent with Fab-ELISA, N1/S/1 was the highest-affinity binder (KD = 0.53 
nM). N1/SL2/1 bound to Notch-1 with a KD value of 3.2 nM. N1/S/2 and N1/SL3/1 possessed 
mid-nM KD values, 14 nM and 27.5 nM, respectively (Figure 5.14F). In both cases, the sub-
library Fabs showed weaker binding than the corresponding master-library Fabs. Third, to assess 
Fab specificity, we tested the binding of Fabs to Notch and Jagged receptor ectodomains using 
Fab-ELISA. At 1 µM Fab concentration, N1/S/1 and N1/SL3/1 cross-reacted with Notch-3, 
whereas N1/SL2/1 and N1/S/2 exhibited target-specific binding (Figure 5.14F). Kinetic analysis 
indicated that the highest-affinity Fab N1/S/1 bound to Notch-3 with a KD of 14.1 ± 0.53 nM. 
Interestingly, the specificity of N1/SL2/1 was better than its corresponding master-library Fab 
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N1/S/1, and the specificity of N1/S/2 was better than its corresponding sub-library Fab 
N1/SL3/1. 
5.2.2 Notch-1 Fabs from Library-F	
To obtain Notch-1 Fabs with both sub-nM affinity and high specificity, we decided to use 
library-F for selections. Library-F contains four diversified CDRs and two fixed CDRs on an 
optimized Hu4D5-8 framework. Length diversity was included within CDRs L3 and H3, and 
amino acid diversity was included within CDRs L3 and H3 and solvent-accessible positions of 
CDRs H1 and H2 (Persson et al., 2013) (Figures 5.15A and 5.15B). We anticipated that the 
additional diversity in library-F (length diversity in CDRL3 and amino acid diversity in CDRs 
H1/H2) would generate more potent and selective Fabs for Notch-1. 	
Solid-phase panning of library-F was conducted against the Notch-1 ectodomain. In an 
effort to identify Fabs with different CDRH3 lengths, we subjected the CDRH3 region of the 
phage selection outputs to Ion Torrent sequencing. Briefly, we amplified CDRH3 from the phage 
pools, performed emulsion amplification of the amplicon library on Ion sphere particles (ISPs), 
and sequenced the enriched ISPs on a 100 bp Ion semiconductor chip. First, we monitored the 
changes in CDRH3 length distribution over five subsequent rounds of selection (Figure 5.15C). 
With a clear enrichment in three short CDRH3 lengths (8, 9 and 10 residues), the length 
distribution changed significantly after three rounds. Also, four other CDRH3 lengths (14, 15, 17 
and 19 residues) stood out from the rest of the population with frequencies ranging between 2-
7%. Next, we ranked round-3 CDRH3 sequences based on their relative frequencies. 19 
sequences were present above 0.1%, and all of them had the above-mentioned CDRH3 lengths. 
While 15 out of 19 sequences had short CDRH3 lengths (Figure 5.15D), each of the other four 
CDRH3 lengths had one sequence above 0.1% (Figure 5.15E). The longest one in the list with 
19 residues turned out to be the anti-maltose binding protein CDRH3 sequence used in the 
template phagemid. Next, we decided to isolate the most-frequent Fab from each selected 
CDRH3 length, and followed the frequency of the six chosen Fab CDRH3 sequences over five 
subsequent rounds of selection (Figure 5.15F). The three short CDRH3 sequences showed a 
significant enrichment throughout the selection process. The three medium-sized CDRH3 
sequences not only showed a lower enrichment in round-3 but also showed depletion in the later 
rounds.  
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Figure 5.15: Panning library-F against Notch-1. (A) Schematic representation of library-F 
CDR diversity. (B) CDR diversity designs for L3, H1, H2 and H3. X denotes any of the 
following nine amino acids introduced at different proportions: Y (25%), S (20%), G (20%), A 
(10%), F (5%), W (5%), H (5%), P (5%) or V (5%). CDRL3 and CDRH3 lengths are varied by 
altering the number of X. (C) Changes in CDRH3 length distribution over five subsequent phage 
display rounds for the Notch-1 selection. The peak in rounds 1 and 2 (CDRH3 length of 19 
residues) is due to the presence of anti-MBP Fab CDRH3 sequence from the template phagemid. 
(D) CDRH3 sequences >0.1% in round-3 with short loop lengths (8, 9 and 10 amino acids). (E) 
CDRH3 sequences >0.1% in round-3 with loop lengths of 14, 15, 17 and 19 amino acids. In 
panels D and E, the most abundant sequence from each CDRH3 length is highlighted. (F) 
Propagation behavior of highlighted CDRH3 sequences over five rounds of selection.	
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As expected, random clone picking and Sanger sequencing of 20 clones from round-3 
and round-4 phage pools only recovered the three most-frequent clones with short CDRH3 
lengths (referred to as top clones). Therefore, we used our NGS-assisted Fab reconstruction 
method to recover the three less-frequent clones with medium CDRH3 lengths (referred to as 
rare clones). First, to identify the diversified CDR sequences (L3, H1 and H2) that paired with 
the CDRH3s of interest, we linked the diversified CDRs in the round-3 phage pool DNA next to 
each other by deleting the intervening framework regions, and sequenced all four diversified 
CDRs as a CDR strip (L3-H1-H2-H3) on a 400 bp Ion semiconductor chip. As the maximum 
read-length offered by Ion Torrent is only 400 bases, the framework deletion step was necessary 
to reduce the amplicon length from 1100 bases to 200 bases. Once the CDR-combinations were 
identified, we reconstructed the desired Fab clones by cloning CDR-encoding oligonucleotides 
into a Fab-4D5 encoding template phagemid by Kunkel mutagenesis. The diversified CDR 
sequences of all the six Fab clones are shown in Figure 5.16A.  
In phage-ELISA, all the six Fab clones tested positive for binding to Notch-1 (Figure 
5.16A). Compared to the top clones, ELISA signals were ~4-fold weaker for N1/F/R2, and ~10-
fold weaker for N1/F/R3. Next, we converted the six phage-Fab clones into soluble Fab proteins, 
and measured EC50 values for Fabs binding to Notch-1 using Fab-ELISA (Figure 5.16B). Except 
for N1/F/R3, the other five Fabs had an EC50 of ~4 nM. N1/F/R3 bound ~10-fold weaker than 
the other Fabs (EC50 = 37 nM). Next, we analyzed Fab-binding kinetics using bio-layer 
interferometry and Fab specificity using Fab-ELISA (Figure 5.16B). Even though the two top 
clones N1/F/1 and N1/F/2 exhibited sub-nM KD values for Notch-1, they also possessed mid-nM 
KD values for Notch-2, and low-nM values for Notch-3. N1/F/1 bound to Notch-1, Notch-2 and 
Notch-3 with KD values of 0.45 ± 0.05 nM, 40.68 ± 1.24 nM and 5.3 ± 0.22 nM, respectively. 
N1/F/1 affinity was 90-fold lower for Notch-2 and 12-fold lower for Notch-3. N1/F/2 bound to 
Notch-1, Notch-2 and Notch-3 with KD values of 0.72 ± 0.05 nM, 30.92 ± 0.96 nM and 4.31 ± 
0.17 nM, respectively. N1/F/2 affinity was 43-fold lower for Notch-2 and 6-fold lower for 
Notch-3. In brief, the specificity of N1/F/1 was two-fold better than N1/F/2. The third top clone 
N1/F/3 had a KD value of 1.88 nM for Notch-1, and cross-reacted with Notch-3 and Jagged-2 in 
Fab-ELISA. The three rare clones with medium CDRH3 lengths possessed very similar binding 
profiles. They bound to Notch-1 with low-nM KD values, and showed weak to moderate binding 
with Jagged-2 in Fab-ELISA. N1/F/R1 and N1/F/R2 bound to Notch-1 with KD values of 1.98 
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nM and 1.42 nM, respectively. In agreement with phage-ELISA and Fab-ELISA, N1/F/R3 was 
the lowest-affinity Notch-1 binder from library-F (KD = 6.6 nM). Kinetic analysis confirmed 
dose-dependent binding of N1/F/R2 with Jagged-2, and determined the KD value to be 71.72 ± 
2.18 nM.  
 Most notably, the rare clones recovered using NGS approaches had low-nM affinities for 
Notch-1, and were more specific than the top clones isolated by Sanger sequencing. In particular, 
N1/F/R2 was less frequent in the round-3 phage pool (~2%), did not show enrichment in round-4 
and round-5, and had weak phage-ELISA output, however the KD value for purified Fab 
N1/F/R2 was very similar to N1/F/3 and N1/F/R1 that were more frequent in phage pools. In 
addition, N1/F/R2 showed tighter binding to Jagged-2 than other clones. This example clearly 
illustrates the need for substituting ELISA-based screening with NGS-based strategies for 
identifying Fab leads from phage selection outputs. 
 
	
Figure 5.16: Notch-1 Fabs from library-F. (A) Sequence characteristics and phage-displayed 
Fab binding characteristics of 3 top Fabs isolated by Sanger sequencing and 3 rare Fabs 
reconstructed from L3-H1-H2-H3 NGS information. (B) Affinity and specificity of purified 
Notch-1 Fabs. Fab specificity was determined at 1 µM Fab concentration. Phage-ELISA and 
specificity-ELISA ABS450 values are shown as heatmaps. Rare clones are highlighted in gray. 
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5.2.3 Notch-1 Fabs from the Modified-F Long-CDR Library	
In addition to facilitating rare clone reconstruction, sequencing CDR-combinations in a 
selection output opens the possibility of studying how CDRs are paired between each other 
against a given target. Here, to check the influence of CDRL3 length diversity on CDRH3 length 
solutions for Notch-1, we monitored the pairing between CDRL3 lengths and CDRH3 lengths in 
the round-3 phage selection output. The analysis showed a clear indication for a preferential 
pairing of certain CDRL3 and CDRH3 lengths (Figure 5.17A). For example, CDRH3 length of 
8 amino acids most-frequently paired with CDRL3 lengths of 8 and 9 amino acids. Also, it 
appeared that the selection preferred to use the longest CDRL3 length to provide long CDRH3 
length solutions for Notch-1 recognition. Since Fabs with long CDRH3 sequences occurred at 
very low frequencies (copy number <3), we did not reconstruct these clones. In addition to 
slower amplification rates in E. coli, the poor enrichment of long CDR clones could result from 
the underrepresentation of long CDR sequences in the library. To confirm this, we amplified the 
CDRL3 and CDRH3 regions from the naïve library-F phage pool, and sequenced them on a 100 
bp Ion semiconductor chip. Length analysis confirmed the presence of a bias in the library 
towards short sequences in both the CDRs (Figure 5.17B).  Also, we noticed high retention of 
template CDRL3 (~24%) and CDRH3 (~13%) sequences in the library (bars corresponding to 
CDRL3 length of 9 residues and CDRH3 length of 19 residues in Figure 5.17B). 	
To isolate Notch-1 Fabs with long CDRs, we decided to modify the length bias in library-
F towards long CDRs, and use the modified library for selections. The modified-F library had the 
following design features: (1) CDRL3, CDRH1 and CDRH2 diversity designs were unaltered; 
(2) in addition to 17 JH4-CDRH3 lengths (7-23 residues) used in library-F, 10 JH6-CDRH3 
lengths (16-25 residues) used in library-S were included; (3) to bias the length diversity towards 
long CDR lengths, the amount of mutagenic oligonucleotides used in mutagenesis reactions were 
normalized according to their theoretical diversity; and (4) to prevent the expression of Fabs with 
unmutated template CDRs, the anti-maltose-binding protein diversified CDR sequences were 
replaced with TAA stop codons in the template phagemid. The modified-F library was 
constructed using a well-established M13 bacteriophage system that allows bivalent Fab display 
(Lee et al., 2004A). Kunkel mutagenesis was used to repair the stop codons in the Fab-4D5 
encoding template phagemid and replace CDR positions with fixed or degenerate codons 
encoding the designed amino acid composition. Following mutagenesis, the library DNA was
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Figure 5.17: Notch-1 Fabs from the modified-F long-CDR library. (A) Pairing between 
CDRL3 lengths and CDRH3 lengths in the Notch-1 selection output (round-3) from library-F 
selections. L3-H3 pairs were obtained from L3-H1-H2-H3 NGS information, and for each 
possible L3 length, H3 length distribution was generated. (B) CDRL3 and CDRH3 length 
distribution of the naïve library-F. (C) CDRL3 and CDRH3 length distribution of the modified-F 
library. (D) CDRL3 and CDRH3 length distribution of the Notch-1 selection output after four 
rounds of selection with the modified-F library. (E) Diversified CDR sequences and phage-
displayed Fab binding characteristics of 7 Notch-1 Fabs isolated from modified-F selections 
using Sanger sequencing. (F) CDRL3 length, CDRH3 length, affinity and specificity of Fabs 
N1/ModF/2 and N1/ModF/5. EC50 and KD values were determined by multi-point Fab-ELISA 
and bio-layer interferometry, respectively. Fab specificity was determined at 1 µM Fab 
concentration. Phage-ELISA and specificity-ELISA ABS450 values are shown as heatmaps.	
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electroporated into an E. coli strain suitable for high-efficiency transformation and phage 
production. NGS analysis of the CDRL3 and CDRH3 regions of the naïve modified-F library 
confirmed proper CDR diversification and the length bias towards long CDRs (Figure 5.17C). 
We panned the modified-F long-CDR library against Notch-1, and sequenced the CDRL3 
and CDRH3 regions from the round-4 phage selection output on a 100 bp Ion semiconductor 
chip. Length analysis indicated a significant enrichment in CDRL3 sequences of 12 residues and 
CDRH3 sequences of 18, 21 and 23 residues (Figure 5.17D). Random clone picking and Sanger 
sequencing of 20 phagemids recovered seven unique clones from the round-4 phage pool. Three 
clones tested positive for binding to Notch-1 in phage-ELISA (Figure 5.17E). Each ELISA-
positive clone had a different CDRH3 length, and also showed a high CDRH3 sequence 
enrichment in the round-4 phage pool (19.15% for N1/ModF/1, 25.96% for N1/ModF/2, and 
43.5% for N1/ModF/5). We chose to pursue with two clones that had longer CDRH3 lengths 
(N1/ModF/2 and N1/ModF/5). We converted the phage-Fab clones into soluble Fab proteins, and 
assayed them using Fab-ELISA (Figure 5.17F). Both the Fabs bound stronger to Notch-1 than 
all other library-S or library-F Fabs. The EC50 values for N1/ModF/2 and N1/ModF/5 were 1.7 
nM and 2.4 nM, respectively. Further, N1/ModF/2 showed strict specificity for Notch-1, whereas 
N1/ModF/5 showed dual specificity for Notch-1 and Notch-3. During kinetic studies, 
N1/ModF/2 exhibited the highest affinity for Notch-1 (KD = 0.15 nM). N1/ModF/2 possessed 
~17-fold higher affinity than the Notch-1 specific antibody anti-NRR1 reported previously (KD = 
2.5 nM) (Wu et al., 2010). With a sub-nM KD and strict specificity, N1/ModF/2 turned out to be 
the best Fab clone for Notch-1. N1/ModF/5 bound to Notch-1 and Notch-3 with KD values of 
0.83 nM and 7.1 nM, respectively.  
5.2.4 MERTK Fab from the Modified-F Long-CDR Library 
To assess the performance of modified-F against Notch-unrelated targets, we conducted 
solid-phase selections against four cell-surface receptor ectodomains (GP130, VEGFR-1, IL6Rα, 
and MERTK). After each selection round, we calculated the number of phages eluted from 
target-coated wells relative to BSA-coated wells (Figure 5.18A). A positive enrichment in 
target-specific phages was not observed for three selections. This could have been due to poor 
target behavior on Maxisorp plates, absence of right library diversity and/or biases in phage 
propagation during selection rounds. Further studies are required to draw conclusions about these 
selection results. A moderate enrichment was observed against MERTK, a target for which both
	 92	
	
Figure 5.18: Performance of the modified-F long-CDR library against Notch-unrelated 
targets. (A) Heatmap showing the enrichment of target-binding phages for four targets over five 
selection rounds. Enrichment values from the Notch-1 selection are given for comparison. Fold 
enrichment is the ratio of number of phages eluted from target-coated wells to number of phages 
eluted from BSA-coated wells. (B) CDR sequences, phage-displayed Fab and purified-Fab 
binding profiles of MERTK Fabs isolated from library-S, library-F and the modified-F library. 
Within CDR sequences, fixed positions are in black and diversified positions are in red. Phage-
ELISA and Fab-ELISA ABS450 values are shown as heatmaps.			
the other libraries (S and F) proved to be unsuccessful. Through random clone picking and 
Sanger sequencing, we isolated a MERTK Fab from the modified-F selection, which bound to 
MERTK with an EC50 of 4.86 ± 0.85 nM and a KD of 1.68 ± 0.22 nM. Interestingly, the clone 
contained the design features found only in modified-F, but not in library-S (CDRL3 length of 12 
residues and H1/H2 optimization) or library-F (CDRH3 length of 24 residues and JH6 usage) 
(Figure 5.18B). The results from MERTK selections indicated that small changes to diversity 
designs could increase the success rate of single-framework synthetic Fab libraries. Overall, the 
modified-F library might not be suitable against all kinds of targets, however could be used 
whenever there is a need for long CDR length solutions or upon failure with other libraries.  	
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5.2.5 Discussion 
Given that library-S delivered Fabs against Jagged-1/2 and Notch-2/3, we tested whether 
library-S could give rise to Fabs with high affinity and specificity against Notch-1. Library-S 
gave rise to a sub-nM bi-specific binder (N1/S/1) and a mid-nM mono-specific binder (N1/S/2). 
Next, we split library-S into four sub-libraries each containing a set of CDRH3 lengths, and 
panned them against Notch-1. Through sub-library screens, we expected to obtain Fabs with 
different CDRH3 lengths and Fabs with higher affinities compared to the master-library Fabs. 
Although results were contrary to our expectations, sub-library panning gave rise to a low-nM 
mono-specific binder (N1/SL2/1). Its corresponding master-library Fab showed six-fold higher 
affinity for Notch-1 (sub-nM KD), however also had a mid-nM KD for Notch-3. In going from 
library-S to library-F, we anticipated that the additional diversity in library-F (length diversity in 
CDRL3 and amino acid diversity in CDRs H1/H2) would generate more potent and selective 
Fabs for Notch-1. Through library-F selections, we isolated three top clones with short CDRH3 
lengths by Sanger sequencing, and reconstructed three rare clones with medium CDRH3 lengths 
from NGS information. The top clones possessed sub-nM to low-nM KD values for Notch-1 but 
also cross-reacted with two other receptors making them tri-specific binders. The rare clones 
possessed low-nM to mid-nM KD values for Notch-1, and cross-reacted with Jagged-2 making 
them bi-specific binders. 
Even though CDRH3 in library-S had higher length, amino acid and JH segment 
diversities than in library-F, library-S selections provided only two optimal CDRH3 length 
solutions for Notch-1. In library-F, the addition of length and conformational diversity to CDRs 
adjacent to CDRH3 increased the number of optimal CDRH3 length solutions for Notch-1. 
Further, CDRH3 length solutions allowed by library-F Fabs were distinct from library-S Fabs, 
indicating that length/conformational diversity in CDRs L3, H1 and H2 could also alter and 
determine the type of CDRH3 loop responsible for the interaction. Not only CDR lengths and 
amino acids, but also binding profiles of library-F Fabs were different from library-S Fabs, 
confirming previous observations that the increase in overall interface diversity fundamentally 
changes the nature of Fab-binding solutions rather than optimizing a common binding solution 
(Fellouse et al., 2007). 
Since CDR length diversity in library-F was biased towards short sequences, we designed 
and constructed the modified-F library with the length bias towards long CDRs. We used the 
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modified-F library to isolate two Notch-1 Fabs (N1/ModF/2 and N1/ModF/5) with long CDRL3 
and CDRH3 sequences. N1/ModF/2 exhibited the highest affinity for Notch-1 (KD = 0.15 nM) 
and showed strict specificity for Notch-1. N1/ModF/5 showed low-nM binding to Notch-1 and 
cross-reacted with Notch-3. Strikingly, the binding profiles of modified-F Fabs were very similar 
to library-S Fabs. Only mono-specific Fabs (Notch-1) and bi-specific Fabs (Notch-1 and Notch-
3) were isolated from both the libraries. N1/ModF/2 bound ~20-fold stronger than the best 
library-S-based mono-specific Fab N1/SL2/1. With a slightly weaker affinity for Notch-1 and 
two-fold higher affinity for Notch-3, N1/ModF/5 performed poorly than the library-S-based bi-
specific Fab N1/S/1. While long CDR lengths contributed to the specificity of modified-F Fabs, 
we speculate that the additional amino acid diversity contributed to the specificity of library-S 
Fabs.  
In this work, both single-framework synthetic Fab libraries (S and F) yielded sub-nM to 
mid-nM Notch-1 binders with different specificity profiles. However, to obtain high-affinity 
Notch-1 specific Fabs, screening the master library alone was not sufficient. In the case of 
library-S, screening sub-libraries identified a low-nM Notch-1 specific binder. In the case of 
library-F, fine-tuning the library towards long CDR lengths gave rise to a sub-nM Notch-1 
specific binder. In addition to delivering Notch-1 Fabs, our work highlighted the importance of 
sampling a focused diversity within an antibody library. The master library only has sparse 
coverage of a large diversity space, due to limitations in attainable library size. Its sub-libraries 
provide a dense coverage of a smaller diversity space. If the master library is a lead discovery 
library, then its sub-libraries are targeted discovery libraries. Our work shows that random or 
rational focusing of a smaller diversity using targeted discovery libraries offer new and better 
binding solutions. In contrast, affinity maturation libraries offer optimization of an existing 
binding solution and are constructed by random or rational diversification of an existing antibody 
(Marvin and Lowman, 2015).  
Previous studies have shown that NGS has three main applications in antibody phage 
display: library quality control, analysis of selection outputs, and reconstruction of rare clones 
(Ravn et al., 2010; Zhang et al., 2011; Mahon et al., 2013; D’Angelo et al., 2014; Glanville et 
al., 2015; Yang et al., 2017). In this work, NGS proved to be useful for all three applications. 
Most notably, we used NGS information for identifying and reconstructing rare clones with less-
frequent CDRH3 lengths, for studying the pairing between CDRL3 and CDRH3 lengths in the 
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selection output, and for fine-tuning the library length diversity. These advances in the use of 
NGS information gave rise to Fab clones with better binding properties. We used CDRH3 length 
as a parameter for designing and screening libraries and for isolating Fabs from selection 
outputs. This approach proved to be successful for obtaining Fabs with different and superior 
binding profiles.  
In summary, we used the synthetic antibody technology for generating potent and 
selective Fabs against the extracellular domain of Notch-1. Twelve Fabs with ten different 
CDRH3 lengths were identified from single-framework synthetic Fab libraries using phage 
display. Upon testing, Fabs showed high affinity for Notch receptors (sub-nM to mid-nM KD 
values) and exhibited different binding profiles (mono- or bi- or tri-specific). Most likely, these 
Fabs recognize different epitopes on Notch-1 and could be used for modulating the Notch 
signaling pathway using different mechanisms of action. Two Fabs exhibited strict specificity for 
Notch-1 with clinically relevant KD values. In contrast to gene knockout approaches, γ-secretase 
inhibitors and pan-Notch antibodies (Espinoza and Miele, 2013; Takebe et al., 2014), our mono-
specific Fabs will permit more precise control of Notch-1 inhibition for both research and 
therapeutic applications. Over the course of Fab generation, we also showed that implementing 
NGS approaches, screening focused diversity libraries, fine-tuning the library diversity and 
making small changes to diversity designs can improve the success rate of single-framework 
synthetic Fab libraries. These findings have valuable implications for antibody library design, 
antibody phage display and combinatorial antibody engineering.  	 		
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5.3. Generation and Validation of Anti-EGFR Fabs from Naïve and Structure-Guided 
Synthetic Antibody Libraries 
In this section, we used EGFR as a model protein to test whether structural information 
on discontinuous protein interfaces could be used for semi-rationally designing synthetic Fab 
libraries that are biased towards interacting with a specific site on the receptor. First, we describe 
the design and construction of a structure-guided Fab library that was biased towards interacting 
with EGFR domain-II. The structure-guided Fab library was constructed by grafting the EGFR 
domain-II dimerization arm into CDRH3 and by diversifying key positions within ungrafted 
CDRs. Next, we describe the isolation, affinity maturation, characterization and epitope-mapping 
of anti-EGFR Fabs from the structure-guided and naïve synthetic Fab libraries.  Screening the 
structure-guided Fab library against EGFR gave rise to a Fab named DL06, which was affinity-
matured to Fab DL06-SR02. For comparison, Library-F was used to generate an anti-EGFR Fab 
named Fab-H whose binding overlapped with the Fab-DL06. Both Fabs possessed low-nM KD 
values for recombinant and cell-surface EGFR and inhibited EGF-mediated EGFR activation. 
Epitopes of both Fabs mapped to EGFR domains I-II and did not overlap with binding sites of 
any clinically relevant anti-EGFR antibodies. 
5.3.1 Design and Construction of the EGFR Domain II Structure-Guided Fab Library  
EGFR contains a 4-domain (I to IV, distal to membrane proximal) modular extracellular 
ligand-binding domain, a single trans-membrane domain, and intracellular tyrosine kinase and 
regulatory domains. In the absence of a ligand, the EGFR monomer exists in a dynamic 
equilibrium between an auto-inhibited conformation, where domains II and IV form an 
intramolecular interaction, and an extended conformation, where domain II is exposed for 
dimerization. Upon ligand binding to domains I and III,	 the equilibrium shifts toward the 
extended conformation, which promotes receptor dimerization and subsequent activation of 
downstream signaling pathways (Ogiso et al., 2002; Garrett et al., 2002; Burgess et al., 2003; 
Ferguson, 2008; Bessman et al., 2014) (Figure 5.19A). In the ligand-bound extended dimer 
conformation of EGFR, the homo-dimer interface is composed of multiple discontinuous 
contacts. All dimer contacts observed in the crystal structures are mediated by domain II.  
Domain II is divided into 8 disulfide-bonded modules, in which modules 2, 5 and 6 interact with 
corresponding modules in the neighboring receptor. An antiparallel β-hairpin loop that projects 
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out from module 5, referred to as the dimerization arm (residues 242-259), makes extensive 
contacts with the dimerization arm of the neighboring receptor burying a surface area of 855 Å2. 
In addition to mediating loop-loop interactions, the dimerization arm reaches across the interface 
to contact domains I and III of the neighboring receptor. Studies have shown that the 
dimerization arm is necessary but not sufficient EGFR dimerization. Two other smaller 
interaction sites contribute to the dimer interface, one is at the C-terminus of the dimerization 
arm (module 6) and the other is close to the N-terminus of domain II (module 2). The total 
surface area buried in the dimer interface is 1125 Å2 on each receptor (Garrett et al., 2002; 
Burgess et al., 2003; Ferguson, 2008). Many reports suggest that the dimer interface extends into 
domain IV, and domain IV contributes directly to stabilization of the EGFR dimer (Schlessinger, 
2002 and Ferguson, 2008). 
Based on these observations, we created a structure-guided Fab library by grafting the 
EGFR domain II dimerization loop into CDRH3 of the Hu4D5-8 Fab framework (Fellouse et al., 
2007) and by diversifying solvent-accessible residues within CDRL3, CDRH1 and CDRH2 
(Figure 5.19B). We hypothesized that the dimerization loop in CDRH3 would direct Fabs in the 
library towards binding domain II of EGFR, and that other CDRs would optimize this interaction 
by making additional contributions to binding affinity and specificity. To generate the structure-
guided Fab library, we first replaced the CDRH3 apex region of the anti-maltose-binding protein 
(MBP) Fab phagemid with the 28-residue β-hairpin dimerization loop (C240-C267). The domain 
II graft was flanked by one NNC codon at each terminus to allow for sequence optimization at 
graft junctions. CDRH3 anchor residues at the N- and C-termini were not modified. Next, we 
diversified the solvent-accessible residues within CDRs L3, H1 and H2 of the Hu4D5-8 Fab 
framework using Kunkel mutagenesis. Diversity designs of these CDRs resembled the design of 
library-F, a highly validated synthetic Fab library (Persson et al., 2013). The domain II structure-
guided Fab library contained two fixed CDRs (L1 and L2), three diversified CDRs (L3, H1 and 
H2) and one CDR containing the EGFR dimerization loop with a theoretical diversity of ~1014. 
Following phagemid mutagenesis, the reaction product was transformed into SS320 E. coli cells 
for phage library production, giving a final library diversity of ~ 5 X 109. To monitor the quality 
of the library, we verified graft inclusion and CDR diversification by sequencing 20 phagemids 
isolated from the library. All phagemids analyzed contained the domain II graft in CDRH3 and 
varying length and sequence diversity in CDRL3, CDRH1 and CDRH2 (data not shown).   
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Figure 5.19: Design of EGFR domain II structure-directed Fab library. (A) Structural view 
of EGF-induced EGFR dimerization. Unliganded EGFR monomer in the tethered conformation 
(PDB 1NQL) and EGF-bound EGFR dimer in the extended conformation (PDB 1IVO) are 
shown in cartoon representation. In the absence of a ligand, EGFR predominantly exists in a 
tethered conformation in which domains II and IV interact and impede ligand binding. Upon 
EGF binding to domains I and III, EGFR adopts an extended conformation in which domain II is 
exposed for promoting receptor dimerization. The domain II dimer interface is composed of 
multiple discontinuous contacts, and a β-hairpin loop in domain II (colored in magenta/black), 
referred to as the dimerization arm has been shown to be crucial for dimerization. (B) CDR 
diversity designs of library-F and EGFR domain II structure-directed library. Library-F contains 
two fixed CDRs (L1 and L2) and four diversified CDRs (L3, H1, H2 and H3). Length diversity 
is included within CDRL3 and CDRH3. X denotes a mixture of nine amino acids (Y, S, G, A, F, 
W, H, P or V). The design of EGFR domain II structure-guided library is the same as library-F 
except for CDRH3. CDRH3 of the structure-directed library contains a 28-residue graft 
corresponding to the EGFR domain II dimerization loop (residues 240-267). B denotes the 
mixture of amino acids encoded by the NNC codon. The dimerization loop residues in CDRH3 
are colored in blue, and the diversified CDR residues in CDRs L3, H1 and H2 are colored in red. 
 
5.3.2 Isolation of EGFR Specific Fabs From Structure-Guided and Naïve Fab libraries  
We used the EGFR domain II structure-guided Fab library to conduct in vitro solid-phase 
phage display selections against the recombinant human EGFR ectodomain (EGFR-ECD). 
Enrichment in target-specific phages was observed after six rounds of selection. Random clone- 
picking and sequencing analysis of 20 phagemids revealed three unique clones, all containing the 
dimerization loop graft in CDRH3. Fab-ELISA showed that one clone, named DL06, had the 
	 99	
highest affinity for EGFR-ECD (IC50 ~200 nM, data not shown). To improve the affinity of 
DL06, we constructed a DL06-based affinity maturation library by soft-randomizing the 
dimerization loop in CDRH3, and used the library for solid-phase selections against EGFR-ECD 
(see section 4.7). After four rounds, we isolated a Fab named DL06-SR02, which bound to 
EGFR-ECD with an IC50 of ~30 nM (data not shown).	 Sequencing revealed that DL06-SR02 
contained three mutations in the CDRH3 dimerization loop, and one spurious substitution in 
CDRH1 relative to the parent Fab DL06 (Figure 5.20A). For brevity, DL06-SR02 is referred to 
as DL06 throughout this report. 
To compare whether a naïve Fab library without any grafted motifs is capable of yielding 
Fabs that recognize domain-II of EGFR, we used library-F to conduct solid-phase selections 
against EGFR-ECD. Though the domain II structure-guided library and library-F contain the 
same diversity within CDRs L3, H1, and H2, library-F contains much more diversity within 
CDRH3 (~1017), whereas the motif-grafted library contains a fixed dimerization loop within 
CDRH3 flanked by one random residue at each end. The theoretical and actual diversities of 
library-F were calculated to be ~1028 and ~1010, respectively (Persson et al., 2013). We isolated 
several EGFR-specific clones from library-F after three rounds of selection, however we chose to 
pursue one Fab, named FabH (Figure 5.20A), as competitive Fab-ELISA assays revealed that 
DL06 and FabH competed with each other for binding EGFR-ECD. Competitive Fab-ELISA 
was performed using Fabs in both non-biotinylated and site-specifically biotinylated formats 
(BT-Fab). Pre-incubation of EGFR-ECD with saturating concentrations of DL06 inhibited the 
binding of BT-FabH to EGFR-ECD. As a positive control, binding of the BT-DL06 analog was 
also inhibited in the presence of DL06 (Figure 5.20B). These results were reproduced in the 
opposite configuration in which saturating concentrations of FabH was used to pre-block EGFR-
ECD, resulting in potent inhibition of both BT-DL06 and the BT-FabH analog positive control 
(Figure 5.20C).  
5.3.3 Characterization DL06 and FabH Interactions With EGFR  
To assess the specificity of DL06 and FabH, we performed a Fab-ELISA against 
immobilized Fc-tagged EGFR and other ErbB family member ectodomains. At a concentration 
of 50 nM, both Fabs bound specifically to EGFR with no observable binding to other ErbB 
family members or the Fc protein (Figure 5.20D).  
 
	 100	
 
 
	
Figure 5.20: Isolation and characterization of Fab-DL06 and Fab-H. (A) CDRL3, CDRH1, 
CDRH2 and CDRH3 sequences of anti-MBP Fab (template), DL06, DL06-SR02 and Fab-H. 
Amino acid mutations in DL06-SR02 relative to DL06 are in bold letters. (B) Influence of DL06 
on BT-DL06 (positive control) and BT-FabH binding to EGFR-ECD assessed by competitive 
Fab-ELISA (C) Influence of FabH on BT-DL06 and BT-FabH (positive control) binding to 
EGFR-ECD assessed by competitive Fab-ELISA. In panels B and C, Fab-ELISA was performed 
using HRP-conjugated streptavidin. (D) Specificity of Fab-DL06 and Fab-H towards ErbB 
family members assessed by single-point Fab-ELISA at 50 nM Fab concentration. (E) Effect of 
CDR perturbations in DL06. Diversified CDR sequences in DL06 were back mutated to anti-
MBP template Fab sequences, and purified DL06 CDR mutants were tested for binding to 
EGFR-ECD by single-point Fab-ELISA at 200 nM Fab concentration. In panels D and E, Fab-
ELISA was performed using an HRP-conjugated anti-FLAG secondary antibody. 	
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Figure 5.21: Binding kinetic analysis of anti-EGFR Fabs. Bio-layer interferometry was used 
for analyzing the binding of EGFR-ECD to sensor-immobilized DL06 (A) and FabH (B). 
Association and dissociation were monitored using serial two-fold dilutions of EGFR-ECD, 
starting from 1480 nM EGFR-ECD for DL06 and 200 nM EGFR-ECD for FabH. Data points 
were globally fit to 1:1 binding model. (C) Binding parameters obtained for Fab-EGFR 
interactions.	
 
To confirm that the CDRH3 EGFR domain II graft in DL06 contributes to Fab binding 
and to measure relative contributions of other diversified CDRs towards Fab-EGFR interactions, 
we back-mutated sequences of each diversified CDR in DL06 to the corresponding anti-MBP 
Fab CDR and evaluated the binding of these Fabs to EGFR. A Fab-ELISA assay conducted on 
EGFR-ECD using 200 nM DL06 or the various CDR variants revealed that binding was 
substantially diminished by changing CDRs L3, H2, or H3 to anti-MBP Fab CDRs, whereas 
reversion of CDRH1 to anti-MBP Fab CDRH1 resulted in only a ~ 45% loss of binding (Figure 
5.20E). This demonstrated that the CDRH3 graft was required for Fab binding, and also 
indicated that other diversified CDRs made critical contributions to Fab-EGFR interactions.  
To measure kinetics of DL06 and FabH binding to EGFR-ECD, we used bio-layer 
interferometry. Fabs were immobilized on amine-reactive sensors and exposed to increasing 
concentrations of EGFR-ECD. Association and dissociation rates were assessed by a wavelength 
shift and kinetic data sets were globally fit using a 1:1 binding model (Figures 5.21A and 
5.21B). The kinetic parameters for Fab-EGFR interactions are summarized in Figure 5.21C.
	 102	
																							 	
Figure 5.22: Analysis of anti-EGFR Fabs binding to cell-surface EGFR. (A) Binding of 
DL06 and FabH to untransfected 293F cells and 293F cells-expressing WT EGFR was assessed 
by flow cytometry using a PE-conjugated anti-FLAG secondary antibody. (B) Determination of 
EC50 values for DL06 and FabH binding to 293F cells-expressing WT EGFR and A431 cells 
endogenously expressing EGFR. Binding was assessed by flow cytometry using a PE-conjugated 
anti-FLAG secondary antibody. The frequency of PE-positive cells was determined for a range 
of Fab concentrations, and data points were fit to one-site specific binding model.  	
 
DL06 and FabH bound to EGFR-ECD with KD values of 6.8 ± 0.1 nM and 1.4 ± 0.01 nM, 
respectively. DL06 bound ~5-fold weaker than FabH, with the main difference being that DL06 
had a slower KON.  
To check whether DL06 and FabH bind to cell-surface EGFR, we used flow cytometry.  
We overexpressed a full-length EGFR construct fused to GFP at its C-terminus (EGFR-GFP) 
(Carter and Sorkin, 1998) in HEK293F cells, and assessed flag-tagged Fab binding to HEK293F 
and EGFR-expressing HEK293F cells using a PE-conjugated mouse anti-FLAG antibody. At a 
concentration of 100 nM, >95% of EGFR-expressing cells were PE-positive, indicating that 
DL06 and FabH bound to cell-surface EGFR, and no significant binding was observed with 
untransfected HEK293F cells (Figure 5.22A). To measure EC50 values for Fabs binding to cell-
surface EGFR, we incubated various concentrations of DL06 and FabH with EGFR-expressing 
HEK293F and A431 epidermoid carcinoma cells, and plotted the frequency of PE-positive cells 
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versus Fab concentration (Figure 5.22B). Both Fabs exhibited saturation behavior and low-nM 
EC50 values for cell-surface EGFR. DL06 bound to 293F-EGFR and A431 cells with EC50 values 
of 8.15 ± 0.4 nM and 12.12 ± 1.5 nM, respectively. FabH bound to 293F-EGFR and A431 cells 
with EC50 values of 0.57 ± 0.02 nM and 1.49 ± 0.2 nM, respectively. FabH bound 14-fold 
stronger to 293F-EGFR and 8-fold stronger to A431 cells than DL06. 
5.3.4 Mapping DL06 and FabH Interaction Domains on EGFR 
To confirm that DL06 and FabH did not bind to previously characterized epitopes in 
EGFR domain III, we tested the influence of two monoclonal antibodies (mAbs), cetuximab 
(CTX) and panitumumab (PMB), on DL06 and FabH binding to EGFR. CTX and PMB bind 
exclusively to EGFR domain III. Their epitopes substantially overlap with each other, and 
partially overlap with the EGF-binding site in EGFR domain III (Voigt et al., 2012). Pre-
incubation of EGFR-ECD or cell-surface EGFR with saturating concentrations of CTX did not 
affect the binding of DL06 and FabH to EGFR (Figures 5.23A and 5.23B), indicating that 
epitopes of CTX and DL06 and FabH are distinct from each other. Pre-incubation of EGFR-ECD 
or cell-surface EGFR with saturating concentrations of PMB partially blocked DL06 and FabH 
binding to EGFR (Figures 5.23C and 5.23D), suggesting that epitopes of PMB and DL06 and 
FabH could partially overlap with each other. To confirm this, we used phage-ELISA to test 
whether phage-displayed EGFR domain III (Tundidor et al., 2014) could bind to immobilized 
DL06 and FabH. No binding was observed between Fabs and EGFR domain III, indicating that 
domain III alone was not sufficient for EGFR-Fab interactions. As a positive control, EGFR 
domain III bound to CTX and PMB in a dose-dependent manner (Figure 5.23E). The partial 
blockage of DL06 and FabH binding by PMB may be caused by steric interactions between Fabs 
and PMB binding sites, and/or an allosteric influence of PMB on Fab-binding sites. 
To conduct domain-level epitope mapping of DL06 and FabH, we generated EGFR-GFP 
truncation constructs encoding individual domains or their combinations, and tested the binding 
of DL06, FabH and control mAbs (CTX and PMB) to EGFR-GFP truncations expressed on 
HEK293F cells. GFP-fluorescence was used to monitor EGFR expression and PE-conjugated 
secondary antibody was used to monitor Fabs or mAbs binding to cells. Binding of Fabs and 
mAbs to EGFR truncations is summarized as a comparative heat-map in Figure 5.24. We 
expected that CTX and PMB could be used as positive controls for all domain-III containing 
constructs. However, both CTX and PMB did not bind to D3, D2-D3, and D1-D2-D3, indicating
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Figure 5.23: Influence of anti-EGFR mAbs on anti-EGFR Fabs binding to EGFR. (A) 
Influence of CTX on DL06 and FabH binding to EGFR-ECD. (B) Influence of CTX on DL06 
and FabH binding to cell-surface EGFR. (C) Influence of PMB on DL06 and FabH binding to 
EGFR-ECD. (D) Influence of PMB on DL06 and FabH binding to cell-surface EGFR. Influence 
of mAbs (CTX and PMB) on binding of Fabs (DL06 and FabH) to EGFR-ECD was assessed by 
competitive Fab-ELISA using an HRP-conjugated anti-FLAG secondary antibody. Influence of 
mAbs (CTX and PMB) on binding of Fabs (DL06 and FabH) to cell-surface EGFR was assessed 
by flow cytometry using a PE-conjugated anti-FLAG secondary antibody. (E) Analysis of 
phage-displayed EGFR domain III binding to immobilized BSA, CTX, PMB, DL06 and FabH 
by phage-ELISA using an HRP-conjugated anti M13 (phage coat protein) secondary antibody. 
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Figure 5.24: Domain-level epitope mapping of anti-EGFR Fabs. (A) Schematic of domain 
organization for the WT EGFR-GFP construct. (B) Heatmap showing the binding of anti-EGFR 
Fabs (DL06 and FabH) and mAbs (CTX and PMB) to WT EGFR and EGFR truncations 
expressed on 293F cells. Binding was assessed by flow cytometry using a PE-conjugated anti-
FLAG secondary antibody for DL06 and FabH, and a PE-conjugated anti-human IgG secondary 
antibody for CTX and PMB. A heatmap was constructed from PE-positive cell signals to 
visualize and compare relative Fab/mAb binding to EGFR and mutant-transfected 293F cells by 
subtracting signals from untransfected cells and normalizing to maximal WT-EGFR signals.   
 
that some truncations had unstable domain breakpoints for proper folding or expression. Both 
CTX and PMB bound to D3-D4 and D2-D3-D4, indicating that N-terminus truncations were 
tolerated by EGFR. DL06 and FabH interacted with three truncation constructs (D1, D1-D2, and 
D1-D2-D3), however the binding was less than that observed with WT-EGFR. DL06 and FabH 
interacted most strongly with the D1-D2 construct. Deletion of D1 or D1-D2 from EGFR 
(constructs D2-D3-D4 and D3-D4) completely abolished DL06 and FabH binding. In contrast, 
CTX and PMB interacted with D2-D3-D4 and D3-D4. Together, this indicated that epitopes for 
DL06 and FabH were localized within domains I and II. DL06 bound ~2-fold tighter to D1 than 
FabH, whereas FabH bound ~2-fold tighter to D1-D2 than DL06, suggesting that both Fabs 
targeted different epitopes within domains I and II. While CTX and PMB did not bind to D1-D2-
D3, Fabs exhibited weaker binding to this construct relative to D1-D2. This could have resulted 
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from the changes in overall structural orientations or conformations in domains I to III upon 
deleting domain IV. Fabs and mAbs did not bind to D2 and D4 constructs, but no conclusions 
were drawn because of the absence of a positive control for binding. 
To confirm the importance of EGFR domain II in Fab-EGFR interactions, we assayed 
DL06, FabH, and PMB binding to the EGFR-vIII glioblastoma mutant expressed on HEK293 
cells using flow cytometry. In EGFR-vIII, EGFR amino acids 6-274 are replaced by a glycine, 
which leads to the deletion of domain-I and 75% of domain-II, including the dimerization loop 
(Gan et al., 2009). As expected, both DL06 and FabH did not bind to EGFR-vIII, whereas PMB 
bound to EGFR-vIII (Figure 5.25A). To test the importance of EGFR dimerization loop on 
DL06 and FabH binding, we assayed DL06, FabH, and PMB binding to two dimerization loop 
mutants (D28-EGFR and DM-EGFR) expressed on HEK293 cells using flow cytometry. D28-
EGFR contains a deletion of 28 amino acids corresponding to the dimerization loop (ΔC240-
C267), and DM-EGFR has two point mutations (Y251A and R285S) in domain II. Both 
constructs have been shown to prevent EGFR homo-dimerization (Ogiso et al., 2002 and 
Dawson et al., 2005). The EC50 values for DL06 and FabH binding to D28-EGFR and DM-
EGFR were only ~3-fold weaker relative to WT-EGFR. PMB showed a ~2-fold decrease in 
binding to D28-EGFR, and exhibited similar EC50 values for binding to WT-EGFR and DM-
EGFR (Figure 5.25B). These results were surprising for DL06, since we believed that the 
dimerization loop graft in CDRH3 would target binding to the dimerization loop of EGFR, and 
thus, deletion of the dimerization loop in EGFR was expected to have a much greater effect on 
Fab binding. 
5.3.5 DL06 and FabH Inhibit EGF-Mediated EGFR Activation  
To check the influence of EGF on DL06 and FabH binding to cell-surface EGFR, we 
incubated EGFR-expressing HEK293F cells with EGF for 15 minutes, and measured EC50 
values for DL06 and FabH binding to EGF-treated cells using flow cytometry (Figures 5.26A 
and 5.26B). At 10 nM EGF concentration, DL06 and FabH had EC50 values of 127.05 ± 12.62 
nM and 2.86 ± 0.15 nM, respectively. In comparison with EC50 values for EGF-untreated cells, 
DL06 showed a ~16-fold reduction in binding, and FabH showed a ~5-fold reduction in binding. 
At 30 nM EGF concentration, DL06 titrations did not show saturation therefore EC50 was not 
calculated. With an EC50 of 11.25 ± 0.12 nM, FabH showed ~18-fold reduction in binding 
	 107	
relative to EGF-untreated cells. The results indicated that EGF had a stronger effect on DL06 
than FabH binding to cell-surface EGFR. Given that DL06 showed partial binding to EGFR 
domain I, the strong EGF effect suggested that DL06 could partially overlap with the EGF-
binding site in domain I. EGF-induced reduction in Fab binding could also have resulted from 
the change in EGFR conformation. 
 
																						 	
Figure 5.25: Effect of EGFR domain II mutations on binding of anti-EGFR Fabs to cell-
surface EGFR. (A) Analysis of DL06, FabH and PMB binding to WT EGFR and vIII EGFR by 
flow cytometry. Binding of DL06 and FabH to 293F cells and WT- or vIII-expressing 293F cells 
was assessed using a PE-conjugated anti-FLAG secondary antibody. Binding of PMB to 293F 
cells and WT- or vIII-expressing 293F cells was assessed using a PE-conjugated anti-human IgG 
secondary antibody. (B) EC50 values for DL06, FabH and PMB binding to WT EGFR, D28 
EGFR and DM EGFR. EGFR constructs were expressed on HEK293F cells, and binding was 
assessed by flow cytometry using PE-conjugated antibodies mentioned in panel A. The 
frequency of PE-positive cells was determined for a range of Fab and PMB concentrations, and 
data points were fit to one-site specific binding model. EC50 values are summarized in panel B.   
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Figure 5.26: Fabs inhibit EGF-mediated EGFR activation. (A) Influence of EGF on DL06 
binding to EGFR expressed on HEK293F cells. (B) Influence of EGF on FabH binding to EGFR 
expressed on HEK293F cells. Binding of Fabs to cell-surface EGFR in the presence and absence 
of EGF was assessed by flow cytometry using a PE-conjugated anti-FLAG secondary antibody. 
The frequency of PE-positive cells was determined for a range of Fab concentrations, and data 
points were fit to one-site specific binding model. (C) Western blots showing the inhibition of 
EGF-induced EGFR phosphorylation by DL06 and FabH in A431 and MDA-MB-231 cells. 
Western analysis was conducted using rabbit polyclonal EGFR and EGFR pTyr1173 primary 
antibodies and HRP-conjugated anti-rabbit secondary antibodies.  	
To evaluate consequences of DL06 and FabH binding on EGF-induced EGFR activation, 
we used two EGFR over-expressing cell lines: A431 epidermoid carcinoma cells and MDA-MB-
231 breast cancer cells. Serum-starved cells were incubated with various Fab concentrations for 
60 minutes, and then stimulated with 50ng/mL EGF for 15 minutes. Western analysis was 
performed to detect EGFR phosphorylation at Tyr1173 and total EGFR. Western blots showed 
the dose-dependent inhibition of EGF-induced EGFR activation by DL06 and FabH (Figure 
5.26C). Saturating levels of DL06 and FabH inhibited >95% of EGFR phosphorylation without 
altering the total EGFR content. Even though DL06 exhibited lower affinities for recombinant 
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EGFR and cell-surface EGFR, and experienced a higher EGF-induced reduction in binding to 
cell-surface EGFR, DL06 showed ~5-fold higher inhibition of EGFR activation than FabH, 
suggesting that small differences in Fab epitopes could lead to Fabs with different mechanisms 
of action. 
5.3.6 Discussion 
Structures of protein complexes provide a wealth of information for designing antibodies 
that mimic and disrupt protein interactions. The combination of synthetic antibody libraries and 
combinatorial phage display enables precise control of sequences that mediate interactions 
between antibodies and target proteins and provides an unprecedented opportunity for 
engineering antibody properties by directed evolution. The purpose of this work was to test 
whether structural information on discontinuous protein interfaces could be used for semi-
rationally designing synthetic Fab libraries that are biased towards interacting with a desired site 
on the target receptor. Our work builds on previous studies showing the ability of antibodies to 
accept discrete motifs and small domains as grafts within their CDRs.  
We used structural information on the EGFR homo-dimerization interaction (Garrett et 
al., 2002; Burgess et al., 2003) to design a structure-guided Fab library that was biased towards 
interacting with domain II of EGFR. To construct this Fab library, we grafted the EGFR domain 
II dimerization arm into CDRH3. This graft alone was not capable of interacting with EGFR-
ECD. Since EGFR homo-dimerization involves multiple discontinuous regions that cover a large 
surface area (1125 Å2), it is not practical to graft an entire EGFR homo-dimerization interaction 
into a CDR. Antibody interactions however can cover a surface area of 2071 ± 456 Å2 using 
several CDRs (Ramaraj et al., 2012), and thus we diversified additional CDRs (L3, H1 and H2) 
in the Fab framework. We hypothesized that by grafting a receptor interaction motif into 
CDRH3, combined with diversification of additional CDRs, we could isolate Fabs with 
specificity for the native interaction domain in the target receptor. By targeting EGFR domain II 
by design, the aim was to obtain lead antibodies that would block receptor activation and 
dimerization, but whose mechanism of action would be distinct from the existing therapeutic 
antibodies. We further sought to compare the grafting strategy with selections using a functional 
naïve synthetic Fab library. 
Solid-phase phage display screens led to the isolation of EGFR-specific Fabs DL06 and 
FabH from structure-guided and naïve synthetic Fab libraries, respectively. Six selection rounds 
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were required to isolate DL06 from the structure-guided library. Further, the affinity of DL06 
was lower than FabH isolated from the naïve synthetic Fab library. These results suggested that 
high-affinity binding clones are relatively rare in the structure-guided library. Affinity maturation 
was required to improve the affinity of DL06, whereas FabH isolated from Library-F was of 
suitably high affinity. Both Fabs possessed low-nM affinities for EGFR-ECD and cell-surface 
EGFR. DL06 isolated from the structure-guided library required the domain II dimerization loop 
graft in CDRH3 for EGFR binding, but additionally required each of the remaining CDRs (L3, 
H2, and to a lesser degree- H1).  
Domain-level epitope mapping indicated that epitopes for DL06 and FabH span across 
multiple extracellular domains of EGFR. Among the EGFR truncation constructs, DL06 and 
FabH interacted most strongly with the D1-D2 construct. In addition to making a direct 
interaction with Fabs, domain I may also be involved in proper positioning of domain II for Fab 
binding. Glioblastoma mutations in the domain I-domain II interface have been shown to directly 
influence the domain II conformation (Bessman et al., 2014). Domains III and IV may contain 
partial Fab epitopes or may be involved in proper orientation of the EGFR conformation required 
for Fab binding. DL06 and FabH competed with each other for binding to EGFR-ECD, 
confirming substantial overlap of their epitopes during domain mapping. Fab/EGF competition 
studies indicated that Fab epitopes are conformation dependent and are lost upon EGF binding to 
EGFR. Despite the fact that Fabs interacted with D1-D2, deletion of the EGFR domain II 
dimerization loop did not show significant changes in Fab binding. Relative to WT EGFR, Fabs 
only showed a 3-fold decrease in binding to D28 EGFR. This limited loss in binding indicates 
that there are difficulties in precisely controlling the targeting epitopes of Fabs when using 
grafting strategies for mimicking discontinuous protein-protein interactions. The ungrafted CDRs 
may play a more dominant role in directing binding interactions than the grafted CDR, and 
perhaps a limited diversification strategy could be effective in ungrafted CDRs for obtaining Fab 
clones that bind to a specific motif on a receptor. 
The binding of an inhibitor to the domain II dimerization arm of EGFR has not yet been 
described, however such an agent would clearly be a potent inhibitor of ligand-induced 
dimerization of EGFR. It is possible that the lack of such an inhibitor may result from the 
relatively limited selection procedures that have been used to generate the current repertoire of 
inhibitory antibodies. Anti-EGFR antibodies in the clinic target domain III of EGFR, which is 
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likely due to its preferred tethered conformation used to generate antibodies. This is in contrast to 
ErbB2, which exists predominantly in the extended conformation, where antibodies in the clinic 
target domains II (pertuzumab) and IV (trastuzumab) (Fauvel and Yasri, 2014). Immunizing 
mice with NR6 fibroblasts expressing the EGFR vIII mutant (Δ6-273) generated EGFR domain 
II antibodies (Mab806 and Mab7A7) that are currently under clinical development (Gan et al., 
2012). These antibodies bind to a linear epitope in domain II (residues 287-302), which is 
located at the C-terminus of the dimerization loop. Mab806 binds to EGFR-vIII and 
overexpressed WT-EGFR in the extended monomer conformation (Garrett et al., 2009). Studies 
have shown that domain III and domain II EGFR antibodies possess different mechanisms of 
action. At the receptor level, domain III antibodies prevent ligand binding to EGFR and sterically 
inhibit the formation of the extended monomer conformation whereas domain II antibodies 
prevent EGFR homo- or hetero-dimerization (Schmitz and Ferguson, 2009; Gan et al., 2012). 
Phase-I clinical trials with Mab806 showed excellent targeting of tumor sites without any 
significant toxicity (Scott et al., 2007), thus it will be interesting to explore the activity of DL06 
and FabH antibodies against EGFR-overexpressing cancer cells and mouse models. 
Our studies clearly distinguished the epitopes of DL06 and FabH from all other 
antibodies targeting EGFR. Cetuximab, panitumumab and nimotuzumab bind exclusively to 
domain III (Schmitz and Ferguson, 2009), whereas domain III alone was not sufficient for DL06 
and FabH interactions. Further, the presence of cetuximab did not affect the binding of DL06 and 
FabH to EGFR. Mab806 binds to a linear epitope in domain II and binds stronger to EGFR-vIII 
than to WT-EGFR (Garrett et al., 2009), whereas DL06 and FabH bind to a complex epitope 
spanning multiple EGFR domains and do not bind to EGFR-vIII. The continued development of 
anti-EGFR antibodies has been driven by the observation that targeting novel epitopes can 
provide potential clinical benefits. First, targeting an epitope distinct from that of a primary 
therapy can circumvent resistance mutations that render first line therapies ineffective (Montagut 
et al., 2012). Second, combinations of non-competitive antibodies can offer additional potency 
outside of immune-effector functions of antibodies by enhancing receptor inactivation (Klapper 
et al., 1997) or by promoting receptor internalization (Friedman et al., 2005) and are proving 
clinically useful (Yamashita-Kashima et al., 2011; Ko et al., 2015). DL06 and FabH could prove 
beneficial using both the mechanisms, as they target unique epitopes that are different from 
previously validated epitopes on EGFR.  
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Despite the apparent overlap of DL06 and FabH epitopes, we observed clear differences 
in their in vitro binding and cell-based activity. During binding kinetic analysis, DL06 displayed 
an 18-fold slower KON and a 3-fold slower KOFF than FabH, suggesting that DL06 and FabH 
could use different binding mechanisms to interact with EGFR. Even though DL06 exhibited 
lower affinities for recombinant EGFR and cell-surface EGFR, DL06 showed ~5-fold higher 
inhibition of EGFR phosphorylation than FabH. Fab/EGF competition studies indicated that EGF 
had a stronger effect on DL06 than FabH binding to cell-surface EGFR. These results suggest 
that DL06 and FabH could use different mechanisms of action to prevent EGFR activation. 
Although it was possible to obtain similar Fabs from both libraries, in light of noted differences 
it is difficult to conclude that one approach offers a stark advantage over the other. Rather, we 
conclude that both approaches may offer alternatives to conventional antibody discovery 
techniques.  
In summary, we generated and validated two anti-EGFR Fabs from structure-guided and 
naïve synthetic Fab libraries. Both Fabs possessed low-nM KD values for recombinant and cell-
surface EGFR, recognized new epitopes on EGFR, and inhibited EGF-mediated EGFR 
activation. Though we are not the first to obtain anti-EGFR antibodies from wholly synthetic 
sources (Schaefer et al., 2011), our work reconfirms the potential of single-framework synthetic 
Fab libraries in generating novel antibody leads for clinical development. Synthetic libraries, 
whether based upon naïve or structure-directed diversity, proved advantageous over conventional 
immunization techniques by allowing access to valid untargeted epitopes on a clinically-relevant 
drug target. Further, our work highlights the utility of structure-guided synthetic libraries and the 
versatility of naïve synthetic libraries in obtaining specific, potent and novel antibodies.  
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6. CONCLUSIONS AND FUTURE DIRECTIONS 
 
Synthetic antibody technology has been successful in generating antibodies against a 
wide variety of antigens with desirable biophysical, biochemical, cell biological, 
pharmacological and clinical properties. As of July 2016, 13 synthetic antibody-based drugs (12 
IgGs and one IgG-drug conjugate) have been undergoing phase II clinical studies and three 
synthetic antibodies (IgGs) have been undergoing phase III clinical studies. These 16 synthetic 
antibodies were derived from phage-displayed synthetic Fab or scFv libraries (Frenzel et al., 
2016). 
Due to the limitations in the quality of the phage-displayed antibody library (Ponsel et al., 
2011; Zhai et al., 2011), the immobilized target (Koide et al., 2009; Miersch and Sidhu, 2012) 
and the phagemid/phage/host system (Derda et al., 2011; Saggy et al., 2012), phage display 
screening of antibody libraries against immobilized targets does not give rise to antibody 
fragments in all selection experiments. Further, antibody fragments discovered from a successful 
selection may not possess favorable production, biological and pharmacological characteristics 
for drug development (Beck et al., 2010; Ponsel et al., 2011; Nixon et al., 2014). Therefore, 
special strategies are required for increasing the success rate of phage display selections and for 
obtaining useful antibodies with desirable properties. In this thesis, we have implemented various 
strategies for generating high-quality Fabs against Notch, Jagged and EGF receptors.  
We designed, constructed and validated a new phage-displayed single-framework 
synthetic Fab library, named library-S. The library was built on a modified Hu4D5 framework 
that contained three point mutations in the FRM3 region to accommodate the new CDRH2 loop. 
Four CDRs were fixed to preserve the most-frequent canonical CDR conformation preferred by 
the chosen Fab framework. Length, amino acid, and conformational diversity were engineered 
within CDRL3 and CDRH3 using custom-designed tri-nucleotide mixes. During CDR 
diversification, template retention was substantially reduced by restriction enzyme digestion of 
the phagemid library. The quality of the phage library was assessed in terms of overall sequence 
composition, length, and amino acid distributions. The library contained ~8.5 billion unique Fabs 
and >95% of the library correctly encoded both the diversified CDR sequences. The library was 
shown to be functional by conducting solid-phase selections against Notch and Jagged receptors. 
Further studies are required to characterize the effects of new CDRs and framework substitutions 
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on the biophysical properties of the modified Hu4D5-8 framework, and to fully explore the 
potential of the library against different classes of targets. 
In recent years, NGS technologies have been employed in several phage display 
platforms for analyzing natural and synthetic antibody fragment sequences, and for identifying 
and reconstructing scFv and Fab binders not found by conventional ELISA screens (Naso et al., 
2014; Glanville et al., 2015). In this work, we developed an NGS-assisted antibody discovery 
platform by integrating phage-displayed single-framework synthetic Fab libraries with Ion 
Torrent sequencing. Due to limitations in attainable read lengths, NGS analysis of Fab libraries 
and selection outputs is usually restricted to CDRH3. Since CDRH3 information alone is not 
sufficient for high-throughput reconstruction of Fabs, we developed a method for linking and 
sequencing all diversified CDRs in phage Fab pools without losing right CDR combinations. Our 
method determined the complete fingerprint of selection outputs and paved the way for reliable 
and straightforward conversion of NGS information into Fab clones. The method is rapid and 
simple and can be adapted to any synthetic scaffold-based phage library. We used our NGS-
assisted Fab reconstruction method to recover low-frequency rare clones from phage selection 
outputs. While previous studies chose rare clones for rescue based on their relative frequencies in 
sequencing outputs (Ravn et al., 2010; D’Angelo et al., 2014), we chose rare clones for 
reconstruction from less-frequent CDRH3 lengths. In some cases, reconstructed rare clones 
(frequency ~0.1%) showed higher affinity and better specificity than high-frequency top clones 
isolated by Sanger sequencing, highlighting the significance of NGS-based approaches in 
synthetic antibody discovery.  
In this work, NGS information was useful for (1) assessing the quality of Fab libraries, 
(2) analyzing selection outputs in terms of sequence evolution, length and amino acid 
distribution, and (3) identifying and reconstructing low-frequency rare clones from selection 
outputs. Most notably, we used NGS information for identifying and reconstructing rare clones 
with less-frequent CDRH3 lengths, for studying the pairing between CDRL3 and CDRH3 
lengths in the selection output, and for fine-tuning the library length diversity. These advances in 
the use of NGS information gave rise to Fab clones with better binding properties. We used 
CDRH3 length as a parameter for designing and screening libraries and for isolating Fabs from 
selection outputs. This approach proved to be successful for obtaining Fabs with different and 
superior binding profiles. 
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In this work, we reconstructed rare Fab clones in the phagemid vector and sub-cloned the 
ELISA-positive clones into the Fab expression vector. In future, desired CDR combinations can 
be reconstructed directly in suitable Fab/scFv/IgG expression vectors, and tested for binding to 
relevant antigens using bio-layer interferometry in a high-throughput format. The NGS approach 
described in this work can be used for identifying and reconstructing Fabs from biopanning 
experiments where isolating target-specific Fabs is more difficult than from solid-phase 
selections (Tomic et al., 2015). NGS analysis can be used for comparing CDR sequences from 
negative and positive selections, and enriched CDR combinations in target phage pools can be 
used for reconstruction. In this work, we obtained only ~10,000 sequences per selection round 
due to multiplexing of numerous selection outputs in one chip. This number was sufficient to 
interrogate the selection output and isolate a few low-frequency rare clones from the selection 
output. Advances in depth and length of NGS reads will help to obtain more diverse Fab clones 
and to reconstruct ultra-low frequency Fabs from earlier rounds of selection. This NGS-assisted 
approach can also be used for screening Fabs against an array of antigens pooled in different 
configurations, and subsequently deconvoluting the resulting selection outputs to deduce Fab 
sequences specific for each pooled antigen (Larman et al., 2012). NGS information can also be 
used for mapping binding energy landscapes, designing affinity maturation libraries, and 
improving biophysical properties of antibodies, especially when crystal structures of antigen-
antibody complexes are also available for analysis (Whitehead et al., 2012; Koenig et al., 2015; 
Koenig et al., 2017).    
While generating Notch-1 binders from single-framework synthetic Fab libraries, we 
realized the potential of screening focused diversity libraries in obtaining Fabs with both high 
affinity and high specificity. In the case of library-S, screening sub-libraries identified a low-nM 
Notch-1 specific binder. In the case of library-F, fine-tuning the library towards long CDR 
lengths gave rise to a sub-nM Notch-1 specific binder. Our work showed that screening focused 
diversity libraries could provide new and better binding solutions in comparison with Fabs 
obtained from the master library. Sub-libraries and long-CDR libraries can be used in high-
throughput selection campaigns for generating new and better binding solutions against a large 
panel of antigens. In particular, the long-CDR library can be useful for generating antagonists 
against enzymes in which the druggable active sites are buried deeply inside the protein (Nam et 
al., 2016). Interestingly, the long-CDR library (Modified-F) gave rise to a low-nM binder against 
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MERTK, a target for which both the other libraries (S and F) proved to be unsuccessful. The 
anti-MERTK Fab contained design features found only in modified-F, but not in library-S 
(CDRL3 length of 12 residues and H1/H2 optimization) or library-F (CDRH3 length of 24 
residues and JH6 usage). This indicated that small changes to diversity designs could increase the 
success rate of single-framework synthetic Fab libraries.  
The new synthetic Fab library, library-S, constructed in this work delivered promising 
Fabs against Jagged-1, Jagged-2 and Notch-1 and was moderately successful against Notch-2 
and Notch-3. The highest-affinity Fab, named J2/S/4, bound to Jagged-2 with a KD value of 80 ± 
13 pM and showed >1000-fold specificity over Jagged-1. J2/S/4 possessed ~3-fold higher 
affinity than the Jagged-2 specific synthetic antibody anti-JAG2.b33 reported previously (KD = 
210 pM) (Lafkas et al., 2015). Library-F, constructed and validated by the Sidhu lab (Persson et 
al., 2013), delivered numerous high affinity Fabs against Jagged-2 and Notch-1. The new 
modified-F long-CDR library gave rise to the highest affinity Notch-1 binder.  The Fab clone, 
named N1/ModF/2, bound to Notch-1 with a KD value of 0.15 ± 0.01 nM and exhibited strict 
specificity for Notch-1. N1/ModF/2 possessed ~17-fold higher affinity than the Notch-1 specific 
synthetic antibody anti-NRR1 reported previously (KD = 2.5 nM) (Wu et al., 2010). We 
generated Jagged-2 Fabs with 12 different CDRH3 lengths and Notch-1 Fabs with 10 different 
CDRH3 lengths. Since these Fabs exhibited different binding profiles, we speculate that these 
Fabs recognize different epitopes on Jagged-2 and Notch-1 and could be used for modulating the 
Notch signaling pathway using different mechanisms of action. In contrast to γ-secretase 
inhibitors and Notch monoclonal antibodies that suffer from treatment-related side effects due to 
pan-Notch inhibition (Espinoza and Miele, 2013; Takebe et al., 2014), our mono-specific Notch-
1 and Jagged-2 Fabs possessing clinically relevant KD values will permit a more precise 
modulation of Notch signaling pathway for both research and therapeutic applications. 
Previous studies have shown that linear peptides, discrete motifs or small domains can be 
grafted into CDRs to design antibodies with desired binding properties (Simon et al., 2005; 
Perchiacca et al., 2012; Zhang et al., 2014; Liu et al., 2015B). A few studies have combined 
motif grafting with combinatorial approaches to improve the binding properties of grafted 
antibodies (Barbas et al., 1993; Koerber et al., 2013; Lee et al., 2015). In this motif-grafting 
project, we used structural information on the EGFR homo-dimerization interaction to design a 
single-framework synthetic Fab library that was biased towards interacting with domain II of 
	 117	
EGFR. The structure-guided Fab library was constructed by grafting the EGFR domain-II 
dimerization arm into CDRH3 and by diversifying key positions within ungrafted CDRs. 
Screening the structure-guided Fab library against EGFR-ECD gave rise to a Fab named DL06. 
For comparison, Library-F was used to generate an anti-EGFR Fab named Fab-H whose binding 
overlapped with the Fab-DL06. Both Fabs possessed low-nM KD values for recombinant and 
cell-surface EGFR and inhibited EGF-mediated EGFR activation. Epitopes of both Fabs mapped 
to EGFR domains I-II and did not overlap with binding sites of any clinically-relevant anti-
EGFR antibodies.  
The motif-grafting approach described in this work can be used as a general strategy for 
semi-rationally designing phage-displayed synthetic Fab libraries that are biased towards 
interacting with disease-relevant discontinuous protein-protein interfaces. If structural 
information about the antigen is available, this strategy can be extended to target difficult or 
buried epitopes on other receptors. The EGFR domain II structure-guided Fab library constructed 
in this project can be used for generating Fabs against other ErbB receptors, and for conducting 
biopanning experiments against cell-surface EGFR. The EGFR domain truncations and 
dimerization loop mutants constructed in this project can be used as targets in biopanning 
experiments for generating Fabs against specific EGFR domains, motifs or conformations. Both 
anti-EGFR Fabs developed in this project possess low-nM KD values, recognize new epitopes on 
EGFR, and inhibit EGF-induced EGFR activation, thus they are good candidates for structural 
studies and cell biological studies. Since DL06 and FabH exhibited differences in their in vitro 
binding kinetics despite targeting similar epitopes, and considering that DL06 contains an ultra-
long CDRH3 with 38 residues, it will be interesting to compare the binding thermodynamics and 
binding mechanisms of DL06 and FabH. In combination with cetuximab, DL06 and FabH can be 
used for engineering dual-domain-targeting antibodies against EGFR. Currently, other members 
of the laboratory are developing positron emission tomography-based methods for detecting 
EGFR overexpression in vivo using DL06/FabH-derived imaging probes.  
In total, this PhD project resulted in novel methods for discovering synthetic antibodies, 
three functional Fab libraries and numerous high-quality Fabs against Notch, Jagged and EGF 
receptors. We showed that implementing NGS approaches, screening focused diversity libraries, 
fine-tuning the CDR length diversity, making changes to CDR diversity designs and using 
structure-guided motif-grafting approaches can improve the success rate of single-framework 
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synthetic Fab libraries. These findings have valuable implications for antibody library design, 
antibody phage display and combinatorial antibody engineering. The NGS-guided antibody 
discovery platform and Fab libraries developed in this work may result in reliable and 
sustainable isolation of Fabs for multiple disease-relevant antigens. Further, Fabs discovered in 
this work can serve as lead molecules for developing novel Notch/Jagged/EGFR-targeted 
therapeutics such as mono/bi-specific antibodies, T-cell redirecting antibodies, antibody-drug 
conjugates, antibody-radionuclide conjugates and chimeric antigen receptor T cells.   
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8. APPENDICES 
 
Appendix 1: Library-F phagemid  
	
		
The pHP-153 phagemid encoding the anti-MBP Fab is referred to as the library-F phagemid. It 
was used as a template phagemid for constructing library-F and the EGFR domain II structure-
guided Fab library. It was also used for deriving template phagemids for constructing library-S 
and the modified-F library. The phagemid contains origins of replication for single-stranded 
DNA (f1 origin) and double-stranded DNA (pBR322 origin), and a selection marker (AmpR) 
that confers resistance to carbenicillin. An alkaline phosphatase-A (Pho-A) promoter drives the 
bicistronic expression of light and heavy chain fragments. The light chain contains the VL 
domain, the CL domain and a C-terminus FLAG tag. The heavy chain contains the VH domain, 
the CH1 domain, a hinge region and the truncated pIII protein. The N-terminus secretion signals 
direct the light and heavy chains to the bacterial periplasm where they associate to form Fabs.  		
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Appendix 2: Fab expression plasmid 		
		
The pCW-LIC plasmid was used for expressing and purifying Fabs from E. coli. To simplify the 
sub-cloning of Fabs from the phagemid vector into the pCW-LIC plasmid, we modified the 
multiple cloning site of the pCW-LIC plasmid. After modification, the multiple cloning site 
contains a light chain secretion signal (pelB), eight amino acids from the VL domain (VL start), 
SacI and XhoI restriction sites, and a hexa-histidine tag. To sub-clone Fabs, Fab sequences were 
amplified from phagemids by PCR, and ligated into the SacI/XhoI-digested pCW-LIC vector 
using Gibson assembly. An IPTG-inducible Tac-promoter drives the bicistronic expression of 
light and heavy chain Fab fragments. The light chain contains the VL domain, the CL domain and 
a C-terminus FLAG tag. The heavy chain contains the VH domain, the CH1 domain, and a C-
terminus hexa-histidine tag. The N-terminus secretion signals direct the light and heavy chains to 
the bacterial periplasm where they associate to form Fabs. The plasmid contains origins of 
replication for single-stranded DNA (f1 origin) and double-stranded DNA (pBR322 origin), and 
a selection marker (AmpR) that confers resistance to carbenicillin. 		
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Appendix 3: List of oligonucleotides used for library-S CDR diversification 
S-L3-09: TTCGCAACTTATTACTGTCAGCAAZZZZCCTCTGACGTTCGGACAGGGTACC  
S-H3-JH4-07: CCGTCTATTATTGTGCTCGCZBTTCGACTACTGGGGTCAAGGAAC 
S-H3-JH4-08: CCGTCTATTATTGTGCTCGCZZBTTCGACTACTGGGGTCAAGGAAC 
S-H3-JH4-09: CCGTCTATTATTGTGCTCGCZZZBTTCGACTACTGGGGTCAAGGAAC 
S-H3-JH4-10: CCGTCTATTATTGTGCTCGCZZZZBTTCGACTACTGGGGTCAAGGAAC 
S-H3-JH4-11: CCGTCTATTATTGTGCTCGCZZZZZBTTCGACTACTGG GGTCAAGGAAC 
S-H3-JH4-12: CCGTCTATTATTGTGCTCGCZZZZZZBTTCGACTACTGG GGTCAAGGAAC 
S-H3-JH4-13: CCGTCTATTATTGTGCTCGCZZZZZZZBTTCGACTACTGG GGTCAAGGAAC 
S-H3-JH4-14: CCGTCTATTATTGTGCTCGCZZZZZZZZBTTCGACTACTGG GGTCAAGGAAC 
S-H3-JH4-15: CCGTCTATTATTGTGCTCGCZZZZZZZZZBTTCGACTACTGGGGTCAAGGAAC 
S-H3-JH4-16: CCGTCTATTATTGTGCTCGCZZZZZZZZZZBTTCGACTACTGGGGTCAAGGAAC 
S-H3-JH6-16: CCGTCTATTATTGTGCTCGCXXXXXXXTACTACTACTACTTTGACTACTGGGGTCAAGGAACCCT 
S-H3-JH6-17: CCGTCTATTATTGTGCTCGCXXXXXXXXTACTACTACJOGACUTGGGGTCAAGGAACCCT 
S-H3-JH6-18: CCGTCTATTATTGTGCTCGCXXXXXXXXXTACTACTACJOGACUTGGGGTCAAGGAACCCT 
S-H3-JH6-19: CCGTCTATTATTGTGCTCGCXXXXXXXXXTACTACTACTACJOGACUTGGGGTCAAGGAACCCT 
S-H3-JH6-20: CCGTCTATTATTGTGCTCGCXXXXXXXXXXTACTACTACTACJOGACGTTTGGGGTCAAGGAACCCT 
S-H3-JH6-21: CCGTCTATTATTGTGCTCGCXXXXXXXXXXXTACTACTACTACJOGACGTTTGGGGTCAAGGAACCCT 
S-H3-JH6-22: CCGTCTATTATTGTGCTCGCXXXXXXXXXXXXTACTACTACTACJOGACGTTTGGGGTCAAGGAACCCT 
S-H3-JH6-23: CCGTCTATTATTGTGCTCGCXXXXXXXXXXXXXTACTACTACTACGGAOGACGTTTGGGGTCAAGGAACCCT 
S-H3-JH6-24: CCGTCTATTATTGTGCTCGCXXXXXXXXXXXXXXTACTACTACTACGGAOGACGTTTGGGGTCAAGGAACCCT 
S-H3-JH6-25: CCGTCTATTATTGTGCTCGCXXXXXXXXXXXXXXXTACTACTACTACGGAATGGACGTTTGGGGTCAAGGAACCCT 
21 mutagenic oligonucleotides were used for library-S diversification. Diversified positions 
within mutagenic oligonucleotides are colored in red. Codon Z denotes any of the following 
thirteen amino acids introduced at different proportions: Y (20%), S (20%), G (20%), T (6.5%), 
A (6.5%), P (6.5%), H (3.5%), R (3.5%), E (3.5%), F (2.5%), W (2.5%), V (2.5%) or L (2.5%). 
Codon B encodes for four amino acids A, G, D or Y at 25% each. Codon X denotes any of the 
following nine amino acids introduced at different proportions: Y (25%), S (20%), G (20%), A 
(10%), F (5%), W (5%), H (5%), P (5%) or V (5%). Codon J encodes for two amino acids G or 
Y at 50% each. Codon O encodes for two amino acids M or F at 50% each. Codon U encodes for 
two amino acids V or Y at 50% each.  											
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Appendix 4: List of oligonucleotides used for diversifying CDRs in the modified-F library 
F-L3-08: GCAACTTATTACTGTCAGCAAXXXSTACGTTCGGACAGGG  
F-L3-09: GCAACTTATTACTGTCAGCAAXXXXSTACGTTCGGACAGGG  
F-L3-10: GCAACTTATTACTGTCAGCAAXXXXXSTACGTTCGGACAGGG  
F-L3-11: GCAACTTATTACTGTCAGCAAXXXXXXSTACGTTCGGACAGGG  
F-L3-12: GCAACTTATTACTGTCAGCAAXXXXXXXSTACGTTCGGACAGGG  
F-H1-13: GCAGCTTCTGGCTTCAACKWWWWQCACTGGGTGCGTCAG 
F-H2-10: GCCTGGAATGGGTTGCAWATTWNWWRWACTWTATGCCGATAGCGTC 
F-H3-JH4-07: CGTCTATTATTGTGCTCGCXEFTTCGACTACTGGGGTCAAG 
F-H3-JH4-08: CGTCTATTATTGTGCTCGCXXEFTTCGACTACTGGGGTCAAG 
F-H3-JH4-09: CGTCTATTATTGTGCTCGCXXXEFTTCGACTACTGGGGTCAAG 
F-H3-JH4-10: CGTCTATTATTGTGCTCGCXXXXEFTTCGACTACTGGGGTCAAG 
F-H3-JH4-11: CGTCTATTATTGTGCTCGCXXXXXEFTTCGACTACTGGGGTCAAG 
F-H3-JH4-12: CGTCTATTATTGTGCTCGCXXXXXXEFTTCGACTACTGGGGTCAAG 
F-H3-JH4-13: CGTCTATTATTGTGCTCGCXXXXXXXEFTTCGACTACTGGGGTCAAG 
F-H3-JH4-14: CGTCTATTATTGTGCTCGCXXXXXXXXEFTTCGACTACTGGGGTCAAG 
F-H3-JH4-15: CGTCTATTATTGTGCTCGCXXXXXXXXXEFTTCGACTACTGGGGTCAAG 
F-H3-JH4-16: CGTCTATTATTGTGCTCGCXXXXXXXXXXEFTTCGACTACTGGGGTCAAG 
F-H3-JH4-17: CGTCTATTATTGTGCTCGCXXXXXXXXXXXEFTTCGACTACTGGGGTCAAG 
F-H3-JH4-18: CGTCTATTATTGTGCTCGCXXXXXXXXXXXXEFTTCGACTACTGGGGTCAAG 
F-H3-JH4-19: CGTCTATTATTGTGCTCGCXXXXXXXXXXXXXEFTTCGACTACTGGGGTCAAG 
F-H3-JH4-20: CGTCTATTATTGTGCTCGCXXXXXXXXXXXXXXEFTTCGACTACTGGGGTCAAG 
F-H3-JH4-21: CGTCTATTATTGTGCTCGCXXXXXXXXXXXXXXXEFTTCGACTACTGGGGTCAAG 
F-H3-JH4-22: CGTCTATTATTGTGCTCGCXXXXXXXXXXXXXXXXEFTTCGACTACTGGGGTCAAG 
F-H3-JH4-23: CGTCTATTATTGTGCTCGCXXXXXXXXXXXXXXXXXEFTTCGACTACTGGGGTCAAG 
S-H3-JH6-16: CCGTCTATTATTGTGCTCGCXXXXXXXTACTACTACTACTTTGACTACTGGGGTCAAGGAACCCT 
S-H3-JH6-17: CCGTCTATTATTGTGCTCGCXXXXXXXXTACTACTACJOGACUTGGGGTCAAGGAACCCT 
S-H3-JH6-18: CCGTCTATTATTGTGCTCGCXXXXXXXXXTACTACTACJOGACUTGGGGTCAAGGAACCCT 
S-H3-JH6-19: CCGTCTATTATTGTGCTCGCXXXXXXXXXTACTACTACTACJOGACUTGGGGTCAAGGAACCCT 
S-H3-JH6-20: CCGTCTATTATTGTGCTCGCXXXXXXXXXXTACTACTACTACJOGACGTTTGGGGTCAAGGAACCCT 
S-H3-JH6-21: CCGTCTATTATTGTGCTCGCXXXXXXXXXXXTACTACTACTACJOGACGTTTGGGGTCAAGGAACCCT 
S-H3-JH6-22: CCGTCTATTATTGTGCTCGCXXXXXXXXXXXXTACTACTACTACJOGACGTTTGGGGTCAAGGAACCCT 
S-H3-JH6-23: CCGTCTATTATTGTGCTCGCXXXXXXXXXXXXXTACTACTACTACGGAOGACGTTTGGGGTCAAGGAACCCT 
S-H3-JH6-24: CCGTCTATTATTGTGCTCGCXXXXXXXXXXXXXXTACTACTACTACGGAOGACGTTTGGGGTCAAGGAACCCT 
S-H3-JH6-25: CCGTCTATTATTGTGCTCGCXXXXXXXXXXXXXXXTACTACTACTACGGAATGGACGTTTGGGGTCAAGGAACCCT 
34 mutagenic oligonucleotides were used for diversifying CDRs in the modified-F library. 
Diversified positions within mutagenic oligonucleotides are colored in red. Codon X denotes any 
of the following nine amino acids introduced at different proportions: Y (25%), S (20%), G 
(20%), A (10%), F (5%), W (5%), H (5%), P (5%) or V (5%). Codon S encodes for two amino 
acids P or L at 50% each. Codon T encodes for two amino acids I or F at 50% each. Codon K 
encodes for two amino acids I or L at 50% each. Codon W encodes for two amino acids Y or S at 
50% each. Codon Q encodes for two amino acids I or M at 50% each. Codon N encodes for two 
amino acids P or S at 50% each. Codon R encodes for two amino acids G or S at 50% each. 
Codon E encodes for two amino acids A or G at 50% each. Codon F encodes for four amino 
acids F, L, I or M at 25% each. Codon J encodes for two amino acids G or Y at 50% each. Codon 
O encodes for two amino acids M or F at 50% each. Codon U encodes for two amino acids V or 
Y at 50% each. 
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Appendix 5: List of oligonucleotides used for diversifying CDRs in the EGFR domain II 
structure-guided Fab library  
F-L3-08: GCAACTTATTACTGTCAGCAAXXXSTACGTTCGGACAGGG  
F-L3-09: GCAACTTATTACTGTCAGCAAXXXXSTACGTTCGGACAGGG  
F-L3-10: GCAACTTATTACTGTCAGCAAXXXXXSTACGTTCGGACAGGG  
F-L3-11: GCAACTTATTACTGTCAGCAAXXXXXXSTACGTTCGGACAGGG  
F-L3-12: GCAACTTATTACTGTCAGCAAXXXXXXXSTACGTTCGGACAGGG  
F-H1-13: GCAGCTTCTGGCTTCAACKWWWWQCACTGGGTGCGTCAG 
F-H2-10: GCCTGGAATGGGTTGCAWATTWNWWRWACTWTATGCCGATAGCGTC 
EGFR-H3-38: TATTGTGCTCGCACTDTGTCCCCCCCTGATGCTGTACAACCCCACTACTTACCAAATGGACGTCAACCCCGAAGGTA 
AATACTCTTTTGGTGCTACTTGTDTGGGCTATGGACTAC 
Eight mutagenic oligonucleotides were used for diversifying CDRs in the EGFR domain II 
structure-guided Fab library. Diversified positions within mutagenic oligonucleotides are colored 
in red. Codon X denotes any of the following nine amino acids introduced at different 
proportions: Y (25%), S (20%), G (20%), A (10%), F (5%), W (5%), H (5%), P (5%) or V (5%). 
Codon S encodes for two amino acids P or L at 50% each. Codon T encodes for two amino acids 
I or F at 50% each. Codon K encodes for two amino acids I or L at 50% each. Codon W encodes 
for two amino acids Y or S at 50% each. Codon Q encodes for two amino acids I or M at 50% 
each. Codon N encodes for two amino acids P or S at 50% each. Codon R encodes for two amino 
acids G or S at 50% each. Codon D denotes the mixture of 15 amino acids encoded by the NNC 
codon. 
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Appendix 6: List of oligonucleotides used for NGS sample preparation  
L3-Fwd: CCATCTCATCCCTGCGTGTCTCCGACTCAGAACCATCCGCCCGGAAGACTTCGCAACTTA 
L3-Rev: CCTCTCTATGGGCAGTCGGTGATATCTCCACCTTGGTACCCTG 
H1-Fwd: CCATCTCATCCCTGCGTGTCTCCGACTCAGAACCATCCGCCGTTTGTCCTGTGCAGCTTC 
H1-Rev: CCTCTCTATGGGCAGTCGGTGATCCCTTACCCGGGGCCTGACG 
H2-Fwd: CCATCTCATCCCTGCGTGTCTCCGACTCAGAACCATCCGCCCCCGGGTAAGGGCCTGGAA 
H2-Rev: CCTCTCTATGGGCAGTCGGTGATCTTATAGTGAAACGGCCCTTGACGCT 
H3-Fwd: CCATCTCATCCCTGCGTGTCTCCGACTCAGAACCATCCGCAGGACACTGCCGTCTATTAT 
H3-Rev: CCTCTCTATGGGCAGTCGGTGATACGGTGACTAGTGTACCTTG 
L3-H3 Seq: ACGTTCGGACAGGGTTATTATTGTGCTCGC 
L3-H1 Seq: ACGTTCGGACAGGGTGCTTCTGGCTTCAAC 
H1-H2 Seq: CACTGGGTGCGTCAGCTGGAATGGGTTGCA 
H2-H3 Seq: TATGCCGATAGCGTCTATTATTGTGCTCGC 
Oligonucleotides used for NGS amplicon preparation contained the following features: forward 
primers contained adaptor (blue), key (green), barcode (red) and antibody framework (black) 
regions, and reverse primers contained truncated P1 (orange) and antibody framework (black) 
regions. Adaptor and truncated P1 sequences were included in the primers for facilitating 
emulsion PCR following amplicon preparation. To amplify a CDR of interest from phage pools, 
for example CDRH3, H3-Fwd and H3-Rev primers were used in the PCR reaction. To generate 
the L3-H3 CDR strip from phage pools, one oligonucleotide (L3-H3 Seq) was used in the 
Kunkel mutagenesis reaction. To generate the L3-H1-H2-H3 CDR strip from phage pools, three 
oligonucleotides (L3-H1 Seq, H1-H2 Seq and H2-H3 Seq) were used in the Kunkel mutagenesis 
reaction. To amplify L3-H3 or L3-H1-H2-H3 CDR strips, L3-Fwd and H3-Rev primers were 
used in the PCR reaction. 
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Appendix 7: Contribution of Other Researchers to the PhD Project 
Dr. Sachdev Sidhu at the University of Toronto provided library-F phage and library-F 
mutagenic oligonucleotides. Dr. Helena Persson (Sidhu Lab) designed and constructed library-F 
(Persson et al., 2013).  
Wayne Hill: Sanger sequencing and Ion Torrent Sequencing  
Daniel Hogan and Dr. Kris Barreto: Assistance with next-generation sequencing data analysis 
Dr. Timothy Strozen: Modification of the pCW-LIC Fab expression plasmid 
Dr. Landon Pastushok: Optimization of conditions for sub-cloning Fabs from the phagemid 
vector into the pCW-LIC Fab expression vector 
The motif-grafting project described in Section 5.3 is a collaborative work between the Geyer lab 
at the University of Saskatchewan and the Sidhu lab at the University of Toronto. Dr. Geyer 
conceived the project, designed and constructed the EGFR domain II structure-guided library, 
and isolated the lead antibody fragment named DL06. Out of 8 figures in Section 5.3 (Figures 
5.19 to 5.26), Dr. Shane Miersch (Sidhu Lab) generated data for Figures 5.20, 5.23A, 5.23C and 
5.26C. 
Lindsay Pelzer: Maintenance of HEK293F and A431 cell lines 
Ashley Sutherland: Assistance with Adobe Illustrator 
 
